0001558370-24-010956.txt : 20240806 0001558370-24-010956.hdr.sgml : 20240806 20240806080033 ACCESSION NUMBER: 0001558370-24-010956 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240806 DATE AS OF CHANGE: 20240806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 241177160 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 10-Q 1 hrmy-20240630x10q.htm 10-Q
http://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMember0001802665--12-31Q2falsehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#RelatedPartyMemberhttp://fasb.org/us-gaap/2024#RelatedPartyMember00http://fasb.org/us-gaap/2024#RelatedPartyMemberhttp://fasb.org/us-gaap/2024#RelatedPartyMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent0001802665hrmy:October2023ShareRepurchaseProgramMember2024-06-300001802665hrmy:October2023ShareRepurchaseProgramMember2024-01-012024-06-300001802665hrmy:October2023ShareRepurchaseProgramMember2024-01-012024-03-310001802665hrmy:October2023ShareRepurchaseProgramMember2023-01-012023-06-300001802665hrmy:October2023ShareRepurchaseProgramMember2023-01-012023-03-310001802665us-gaap:CommonStockMember2024-04-012024-06-300001802665us-gaap:CommonStockMember2023-04-012023-06-300001802665us-gaap:CommonStockMember2023-01-012023-06-300001802665us-gaap:RetainedEarningsMember2024-06-300001802665us-gaap:AdditionalPaidInCapitalMember2024-06-300001802665us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001802665us-gaap:RetainedEarningsMember2024-03-310001802665us-gaap:AdditionalPaidInCapitalMember2024-03-310001802665us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100018026652024-03-310001802665us-gaap:RetainedEarningsMember2023-12-310001802665us-gaap:AdditionalPaidInCapitalMember2023-12-310001802665us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001802665us-gaap:RetainedEarningsMember2023-06-300001802665us-gaap:AdditionalPaidInCapitalMember2023-06-300001802665us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001802665us-gaap:RetainedEarningsMember2023-03-310001802665us-gaap:AdditionalPaidInCapitalMember2023-03-310001802665us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100018026652023-03-310001802665us-gaap:RetainedEarningsMember2022-12-310001802665us-gaap:AdditionalPaidInCapitalMember2022-12-310001802665us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001802665us-gaap:CommonStockMember2024-06-300001802665us-gaap:CommonStockMember2024-03-310001802665us-gaap:CommonStockMember2023-12-310001802665us-gaap:CommonStockMember2023-06-300001802665us-gaap:CommonStockMember2023-03-310001802665us-gaap:CommonStockMember2022-12-310001802665us-gaap:StockAppreciationRightsSARSMember2024-01-012024-06-300001802665srt:MinimumMember2023-01-012023-12-310001802665srt:MaximumMember2023-01-012023-12-310001802665us-gaap:RestrictedStockUnitsRSUMember2023-12-310001802665us-gaap:RestrictedStockUnitsRSUMemberhrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember2024-01-012024-06-300001802665us-gaap:RestrictedStockUnitsRSUMemberhrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember2023-01-012023-12-310001802665us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001802665country:UShrmy:WAKIXMember2022-02-012022-02-280001802665hrmy:TermLoanMember2024-01-012024-06-300001802665us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001802665us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300001802665us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001802665us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300001802665us-gaap:RetainedEarningsMember2024-04-012024-06-300001802665us-gaap:RetainedEarningsMember2024-01-012024-06-300001802665us-gaap:RetainedEarningsMember2023-04-012023-06-300001802665us-gaap:RetainedEarningsMember2023-01-012023-06-300001802665hrmy:IncrementalTermLoanMember2023-09-300001802665hrmy:FiveYearSeniorSecuredTermLoanMember2023-07-310001802665srt:MinimumMember2024-06-300001802665srt:MaximumMember2024-06-300001802665us-gaap:RelatedPartyMember2024-04-012024-06-300001802665us-gaap:RelatedPartyMember2024-01-012024-06-300001802665us-gaap:RelatedPartyMember2023-04-012023-06-300001802665us-gaap:RelatedPartyMember2023-01-012023-06-300001802665hrmy:WAKIXMember2022-03-310001802665hrmy:CataplexyMemberhrmy:NdaForWakixMember2020-10-310001802665hrmy:DaytimeSleepinessMemberhrmy:WAKIXMember2019-08-310001802665hrmy:DaytimeSleepinessMemberhrmy:WAKIXMember2024-06-300001802665hrmy:CataplexyMemberhrmy:NdaForWakixMember2024-06-300001802665hrmy:WAKIXMember2024-06-300001802665us-gaap:RestrictedStockUnitsRSUMember2024-06-300001802665us-gaap:EmployeeStockOptionMember2024-06-300001802665hrmy:FiveYearSeniorSecuredTermLoanMember2023-07-012023-07-310001802665hrmy:RepaymentOfDebtDueOnMaturityDateMemberhrmy:TermLoanMember2024-01-012024-06-300001802665hrmy:RepaymentOfDebtCommencingOnDecember312023Memberhrmy:TermLoanMember2024-01-012024-06-300001802665hrmy:RepaymentOfDebtBeginningOnDecember312025Memberhrmy:TermLoanMember2024-01-012024-06-300001802665hrmy:TermLoanMember2024-06-300001802665srt:MinimumMemberhrmy:TermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-012024-06-300001802665srt:MinimumMemberhrmy:TermLoanMemberus-gaap:BaseRateMember2024-01-012024-06-300001802665srt:MaximumMemberhrmy:TermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-012024-06-300001802665srt:MaximumMemberhrmy:TermLoanMemberus-gaap:BaseRateMember2024-01-012024-06-300001802665hrmy:BioprojetMemberhrmy:SalesBasedTrademarkAndTieredRoyaltiesMember2024-04-012024-06-300001802665hrmy:BioprojetMemberhrmy:SalesBasedTrademarkAndTieredRoyaltiesMember2024-01-012024-06-300001802665hrmy:BioprojetMemberhrmy:SalesBasedTrademarkAndTieredRoyaltiesMember2023-04-012023-06-300001802665hrmy:BioprojetMemberhrmy:SalesBasedTrademarkAndTieredRoyaltiesMember2023-01-012023-06-300001802665hrmy:PANTHERxSpecialtyPharmacyLLCMemberus-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001802665hrmy:PANTHERxSpecialtyPharmacyLLCMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001802665hrmy:CaremarkLLCMemberus-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001802665hrmy:CaremarkLLCMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001802665hrmy:AccredoHealthGroupIncMemberus-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001802665hrmy:AccredoHealthGroupIncMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001802665hrmy:PANTHERxSpecialtyPharmacyLLCMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001802665hrmy:CaremarkLLCMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001802665hrmy:AccredoHealthGroupIncMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001802665hrmy:PANTHERxSpecialtyPharmacyLLCMemberus-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001802665hrmy:CaremarkLLCMemberus-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001802665hrmy:AccredoHealthGroupIncMemberus-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001802665hrmy:IncentiveAwardPlanTwoThousandTwentyMember2024-06-300001802665hrmy:EmployeeStockPurchasePlanMember2021-04-3000018026652023-06-3000018026652022-12-310001802665hrmy:LongTermCommercialPaperMember2023-12-310001802665hrmy:LongTermUsGovernmentSecuritiesMember2024-06-300001802665hrmy:ShortTermUsGovernmentSecuritiesMember2023-12-310001802665us-gaap:ShortTermInvestmentsMember2024-06-300001802665hrmy:ShortTermCorporateDebtSecuritiesMember2024-06-300001802665hrmy:ShortTermCommercialPaperMember2024-06-300001802665hrmy:LongTermInvestmentsMember2024-06-300001802665hrmy:LongTermCorporateDebtSecuritiesMember2024-06-300001802665us-gaap:ShortTermInvestmentsMember2023-12-310001802665hrmy:ShortTermCorporateDebtSecuritiesMember2023-12-310001802665hrmy:ShortTermCommercialPaperMember2023-12-310001802665hrmy:LongTermUsGovernmentSecuritiesMember2023-12-310001802665hrmy:LongTermInvestmentsMember2023-12-310001802665hrmy:LongTermCorporateDebtSecuritiesMember2023-12-310001802665us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-06-300001802665us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-06-300001802665us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2024-06-300001802665us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2024-06-300001802665us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-06-300001802665us-gaap:FairValueInputsLevel2Member2024-06-300001802665us-gaap:FairValueInputsLevel1Member2024-06-300001802665us-gaap:CorporateDebtSecuritiesMember2024-06-300001802665us-gaap:CommercialPaperMember2024-06-300001802665us-gaap:CashAndCashEquivalentsMember2024-06-300001802665us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001802665us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001802665us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310001802665us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2023-12-310001802665us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2023-12-310001802665us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001802665us-gaap:FairValueInputsLevel2Member2023-12-310001802665us-gaap:FairValueInputsLevel1Member2023-12-310001802665us-gaap:CorporateDebtSecuritiesMember2023-12-310001802665us-gaap:CommercialPaperMember2023-12-310001802665us-gaap:CashAndCashEquivalentsMember2023-12-3100018026652023-10-012023-10-310001802665hrmy:Hbs102Memberhrmy:AllCountriesExcludingChinaMemberhrmy:AssetPurchaseAgreementWithConsynanceTherapeuticsMember2021-08-012021-08-310001802665us-gaap:SellingAndMarketingExpenseMember2024-04-012024-06-300001802665us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001802665us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001802665us-gaap:SellingAndMarketingExpenseMember2024-01-012024-06-300001802665us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001802665us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001802665us-gaap:SellingAndMarketingExpenseMember2023-04-012023-06-300001802665us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001802665us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001802665us-gaap:SellingAndMarketingExpenseMember2023-01-012023-06-300001802665us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001802665us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001802665us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001802665us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000018026652023-04-012023-06-300001802665us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001802665hrmy:BioprojetMemberhrmy:SalesBasedTrademarkAndTieredRoyaltiesMember2024-06-300001802665hrmy:BioprojetMemberhrmy:SalesBasedTrademarkAndTieredRoyaltiesMember2023-12-310001802665hrmy:October2023ShareRepurchaseProgramMember2023-10-310001802665us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001802665us-gaap:CommonStockMember2024-01-012024-06-300001802665hrmy:IncentiveAwardPlanTwoThousandTwentyMember2024-01-012024-06-300001802665hrmy:EmployeeStockPurchasePlanMember2021-04-302021-04-3000018026652023-12-312023-12-310001802665us-gaap:StockAppreciationRightsSARSMember2023-12-310001802665us-gaap:StockAppreciationRightsSARSMember2024-06-3000018026652023-01-012023-12-310001802665hrmy:EmployeeStockPurchasePlanMember2024-04-012024-06-300001802665hrmy:EmployeeStockPurchasePlanMember2024-01-012024-06-300001802665hrmy:EmployeeStockPurchasePlanMember2023-04-012023-06-300001802665hrmy:EmployeeStockPurchasePlanMember2023-01-012023-06-3000018026652018-06-012018-06-300001802665hrmy:ThreeCustomersMemberus-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001802665hrmy:ThreeCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001802665hrmy:ThreeCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001802665hrmy:ThreeCustomersMemberus-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001802665srt:MinimumMember2024-01-012024-06-300001802665srt:MaximumMember2024-01-012024-06-300001802665hrmy:BioprojetMemberhrmy:WAKIXMember2019-08-012019-08-310001802665hrmy:BioprojetMemberhrmy:PitolisantsMember2022-07-012022-07-310001802665hrmy:BioprojetMemberhrmy:Orexin2ReceptorAgonistOx2rMember2024-04-012024-04-300001802665hrmy:BioprojetMemberhrmy:Orexin2ReceptorAgonistOx2rMember2024-01-012024-06-300001802665hrmy:Hbs102Memberhrmy:AllCountriesExcludingChinaMemberhrmy:AssetPurchaseAgreementWithConsynanceTherapeuticsMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-03-012023-03-310001802665hrmy:BioprojetMemberhrmy:WAKIXMember2021-01-012021-01-310001802665hrmy:CataplexyMemberhrmy:NdaForWakixMember2020-10-012020-10-310001802665hrmy:BioprojetMemberhrmy:WAKIXMember2020-10-012020-10-310001802665hrmy:BioprojetMember2019-11-012019-11-300001802665hrmy:DaytimeSleepinessMemberhrmy:WAKIXMember2019-08-012019-08-310001802665hrmy:BioprojetMember2019-08-012019-08-310001802665hrmy:BioprojetMemberhrmy:WAKIXMember2019-08-310001802665hrmy:BioprojetMemberhrmy:PitolisantsMember2019-02-280001802665hrmy:BioprojetMemberhrmy:Orexin2ReceptorAgonistOx2rMember2024-04-300001802665hrmy:BioprojetMemberhrmy:PitolisantsMember2022-07-310001802665hrmy:BioprojetMemberhrmy:WAKIXMembercountry:UShrmy:UponAchievementOfAggregateNetSalesMember2022-03-012022-03-310001802665hrmy:WAKIXMember2022-03-012022-03-310001802665hrmy:BioprojetMember2019-08-310001802665hrmy:Hbs102Memberhrmy:AllCountriesExcludingChinaMemberhrmy:AssetPurchaseAgreementWithConsynanceTherapeuticsMember2021-08-310001802665hrmy:EpygenixAcquisitionMember2024-04-012024-06-300001802665hrmy:EpygenixAcquisitionMember2024-01-012024-06-300001802665hrmy:TermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-012024-06-300001802665hrmy:EpygenixAcquisitionMember2024-04-302024-04-300001802665hrmy:ZynerbaAcquisitionMember2023-10-012023-10-310001802665hrmy:BioprojetMembercountry:US2022-03-012022-03-3100018026652023-01-012023-06-300001802665hrmy:EpygenixAcquisitionMember2024-04-3000018026652024-06-3000018026652023-12-3100018026652024-04-012024-06-3000018026652024-08-0200018026652024-01-012024-06-30utr:sqfthrmy:segmentxbrli:sharesiso4217:USDiso4217:USDxbrli:shareshrmy:Righthrmy:Votehrmy:Institutionxbrli:purehrmy:producthrmy:customer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to

Commission File Number: 001-39450

HARMONY BIOSCIENCES HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

82-2279923

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA

19462

(Address of principal executive offices)

(Zip Code)

(484) 539-9800

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading
Symbol(s)

    

Name of each exchange
on which registered

Common Stock, par value $0.00001 value per share

 

HRMY

 

The Nasdaq Stock Market LLC
(Nasdaq Global Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes      No   

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes    No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes     No  

As of August 2, 2024, there were 56,834,745 shares of the registrant’s common stock, par value $0.00001 value per share, outstanding.

TABLE OF CONTENTS

Page

Part I. Financial Information

3

Item 1. Financial Statements

3

Condensed Consolidated Balance Sheets (Unaudited)

3

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

4

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

5

Condensed Consolidated Statements of Cash Flows (Unaudited)

6

Notes to Condensed Consolidated Financial Statements (Unaudited)

7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

23

Item 3. Quantitative and Qualitative Disclosures About Market Risk

37

Item 4. Controls and Procedures

38

Part II. Other Information

38

Item 1. Legal Proceedings

38

Item 1A. Risk Factors

40

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

40

Item 3. Defaults upon Senior Securities

40

Item 4. Mine Safety Disclosures

40

Item 5. Other Information

40

Item 6. Exhibits

41

Signatures

42

2

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

    

June 30, 

    

December 31, 

    

2024

    

2023

ASSETS

 

  

 

  

CURRENT ASSETS:

 

  

 

  

Cash and cash equivalents

$

317,296

$

311,660

Investments, short-term

29,614

41,800

Trade receivables, net

 

83,157

 

74,140

Inventory, net

 

5,643

 

5,363

Prepaid expenses

 

16,127

 

12,570

Other current assets

 

6,507

 

5,537

Total current assets

 

458,344

 

451,070

NONCURRENT ASSETS:

 

  

 

  

Property and equipment, net

 

754

 

371

Restricted cash

 

270

 

270

Investments, long-term

87,178

72,169

Intangible assets, net

 

125,186

 

137,108

Deferred tax asset

180,186

144,162

Other noncurrent assets

 

6,465

 

6,298

Total noncurrent assets

 

400,039

 

360,378

TOTAL ASSETS

$

858,383

$

811,448

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

  

 

  

CURRENT LIABILITIES:

 

  

 

  

Trade payables

$

22,683

$

17,730

Accrued compensation

 

9,641

 

23,747

Accrued expenses

 

91,644

 

99,494

Current portion of long-term debt

15,000

15,000

Other current liabilities

 

7,614

 

7,810

Total current liabilities

 

146,582

 

163,781

NONCURRENT LIABILITIES:

 

  

 

  

Long-term debt, net

 

171,422

 

178,566

Other noncurrent liabilities

 

1,796

 

2,109

Total noncurrent liabilities

 

173,218

 

180,675

TOTAL LIABILITIES

 

319,800

 

344,456

COMMITMENTS AND CONTINGENCIES (Note 13)

 

  

 

  

STOCKHOLDERS’ EQUITY:

 

  

 

  

Common stock—$0.00001 par value; 500,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively; 56,833,771 and 56,769,081 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively

 

1

 

1

Additional paid in capital

 

632,168

 

610,266

Accumulated other comprehensive (loss) income

(234)

2

Accumulated deficit

 

(93,352)

 

(143,277)

TOTAL STOCKHOLDERS’ EQUITY

 

538,583

 

466,992

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

858,383

$

811,448

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements

3

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(In thousands, except share and per share data)

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2024

    

2023

    

2024

    

2023

Net product revenue

$

172,814

$

134,216

$

327,429

$

253,342

Cost of product sold

 

32,144

 

25,008

 

59,628

 

45,788

Gross profit

 

140,670

 

109,208

 

267,801

 

207,554

Operating expenses:

 

  

 

  

 

  

 

  

Research and development

 

63,583

 

14,969

 

85,772

 

28,258

Sales and marketing

 

28,507

 

24,528

 

55,740

 

47,100

General and administrative

 

27,224

 

22,809

 

52,900

 

44,871

Total operating expenses

 

119,314

 

62,306

 

194,412

 

120,229

Operating income

 

21,356

 

46,902

 

73,389

 

87,325

Other (expense) income, net

 

37

 

(31)

 

(104)

 

(29)

Interest expense

(4,404)

(6,218)

(8,939)

 

(11,949)

Interest income

 

4,705

 

3,442

 

9,133

 

6,528

Income before income taxes

 

21,694

 

44,095

 

73,479

 

81,875

Income tax expense

 

(10,103)

 

(9,795)

 

(23,554)

 

(18,090)

Net income

$

11,591

$

34,300

$

49,925

$

63,785

Unrealized (loss) income on investments

 

(63)

 

(491)

 

(236)

 

(371)

Comprehensive income

$

11,528

$

33,809

$

49,689

$

63,414

EARNINGS PER SHARE:

 

  

 

  

 

  

 

  

Basic

$

0.20

$

0.57

$

0.88

$

1.07

Diluted

$

0.20

$

0.56

$

0.87

$

1.05

Weighted average number of shares of common stock - basic

 

56,802,357

 

59,974,123

 

56,786,873

 

59,853,808

Weighted average number of shares of common stock - diluted

 

57,541,696

 

60,743,953

 

57,571,570

 

60,997,410

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements

4

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share and per share data)

Accumulated

Additional

other

Total

Common Stock

paid-in

comprehensive

Accumulated

stockholders’

   

Shares

   

Amount

   

capital

   

(loss) income

   

deficit

   

equity

Balance as of December 31, 2023

 

56,769,081

$

1

$

610,266

$

2

$

(143,277)

$

466,992

Net income

 

 

 

 

49,925

 

49,925

Unrealized loss on investments

(236)

(236)

Exercise of options and restricted stock units

 

64,690

 

 

420

 

 

420

Stock-based compensation

 

 

 

21,482

 

 

21,482

Balance as of June 30, 2024

 

56,833,771

$

1

$

632,168

$

(234)

$

(93,352)

$

538,583

Accumulated

Additional

other

Total

Common Stock

paid-in

comprehensive

Accumulated

stockholders’

   

Shares

   

Amount

   

capital

   

(loss) income

   

deficit

   

equity

Balance as of March 31, 2024

56,791,214

$

1

$

620,507

$

(171)

$

(104,943)

$

515,394

Net income

 

 

 

 

11,591

 

11,591

Unrealized loss on investments

(63)

(63)

Exercise of options

 

42,557

 

 

573

 

 

573

Stock-based compensation

 

 

 

11,088

 

 

11,088

Balance as of June 30, 2024

 

56,833,771

$

1

$

632,168

$

(234)

$

(93,352)

$

538,583

    

    

  

    

  

Accumulated

    

  

    

  

Additional

other

Total

Common Stock

paid-in

comprehensive

Accumulated

stockholders’

    

Shares

    

Amount

    

capital

(loss) income

    

deficit

    

equity

Balance as of December 31, 2022

 

59,615,731

$

1

$

675,118

$

(151)

$

(272,130)

$

402,838

Net income

 

 

 

 

63,785

 

63,785

Unrealized loss on investments

(371)

(371)

Exercise of stock options

 

383,927

 

 

4,069

 

 

4,069

Stock-based compensation

 

 

 

14,851

 

 

14,851

Balance as of June 30, 2023

 

59,999,658

$

1

$

694,038

$

(522)

$

(208,345)

$

485,172

    

    

  

    

  

Accumulated

    

  

    

  

Additional

other

Total

Common Stock

paid-in

comprehensive

Accumulated

stockholders’

    

Shares

    

Amount

    

capital

(loss) income

    

deficit

    

equity

Balance as of March 31, 2023

 

59,954,618

$

1

$

685,716

$

(31)

$

(242,645)

$

443,041

Net income

 

 

 

 

34,300

 

34,300

Unrealized loss on investments

(491)

(491)

Exercise of options

 

45,040

 

 

674

 

 

674

Stock-based compensation

 

 

 

7,648

 

 

7,648

Balance as of June 30, 2023

 

59,999,658

$

1

$

694,038

$

(522)

$

(208,345)

$

485,172

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements

5

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, except share and per share data)

    

Six Months Ended June 30, 

    

2024

    

2023

CASH FLOWS FROM OPERATING ACTIVITIES

 

  

 

  

Net income

$

49,925

$

63,785

Adjustments to reconcile net income to net cash used in operating activities:

 

 

  

Depreciation

 

254

 

206

Intangible amortization

 

11,922

 

11,922

Acquired in-process research & development (IPR&D) expense

42,595

Stock-based and employee stock purchase compensation expense

 

21,482

 

14,851

Stock appreciation rights market adjustment

 

(85)

 

(497)

Debt issuance costs amortization

 

356

 

840

Deferred taxes

(17,756)

(7,635)

Amortization of premiums and accretion of discounts on Investment securities

(1,220)

(1,312)

Other non-cash expenses

1,126

799

Change in operating assets and liabilities:

 

 

  

Trade receivables

 

(9,017)

 

(9,072)

Inventory

 

(280)

 

(557)

Prepaid expenses and other assets

 

(4,004)

 

2,227

Trade payables

 

3,555

 

2,777

Other liabilities

 

(25,095)

 

1,288

Net cash provided by operating activities

 

73,758

 

79,622

CASH FLOWS FROM INVESTING ACTIVITIES:

 

  

 

  

Purchase of investment securities

(46,317)

(72,847)

Proceeds from maturities and sales of investment securities

44,481

63,491

Purchase of property and equipment

 

(637)

 

(205)

Acquisition of Epygenix Therapeutics, Inc., net of cash acquired

 

(33,069)

 

Payment of license fee

 

(25,500)

 

Net cash used in investing activities

 

(61,042)

 

(9,561)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

  

 

  

Principal repayment of long term debt

(7,500)

(1,000)

Payments of employee withholding taxes related to stock-based awards

(269)

(514)

Proceeds from exercised options

 

689

 

4,584

Net cash (used in) provided by financing activities

 

(7,080)

 

3,070

NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

 

5,636

 

73,131

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—Beginning of period

 

311,930

 

244,534

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—End of period

$

317,566

$

317,665

Supplemental Disclosure of Cash Flow Information:

 

  

 

  

Cash paid during the year for interest

$

8,944

$

10,691

Cash paid during the year for taxes

42,093

19,890

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements

6

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

The Company

Harmony Biosciences Holdings, Inc., and its consolidated subsidiaries (the “Company”), was founded in July 2017 as Harmony Biosciences II, LLC, a Delaware limited liability company. The Company converted to a Delaware corporation named Harmony Biosciences II, Inc. in September 2017 and, in February 2020, the Company changed its name to Harmony Biosciences Holdings, Inc. The Company’s operations are conducted in its wholly owned subsidiaries, Harmony Biosciences, LLC (“Harmony”), and Harmony Biosciences Management, Inc. The Company is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders as well as patients living with other neurological diseases who have unmet medical needs. The Company is headquartered in Plymouth Meeting, Pennsylvania.

On October 10, 2023, the Company completed a tender offer to acquire all of the outstanding shares of common stock of Zynerba Pharmaceuticals, Inc. (together with its subsidiary, Zynerba Pharmaceutical Pty, Ltd., “Zynerba”). Zynerba is a clinical-stage pharmaceutical company focused on innovative pharmaceutically produced transdermal cannabidiol therapies for orphan neurobehavioral disorders, including Fragile X Syndrome. As of July 1, 2024, Zynerba was renamed and is known as Harmony Biosciences Management, Inc.

On April 30, 2024, the Company acquired all of the issued and outstanding capital stock of Epygenix Therapeutics, Inc., a Wyoming corporation (“Epygenix”). As a result, the Company now has an exclusive license relating to the use of clemizole, initially for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.

2. LIQUIDITY AND CAPITAL RESOURCES

The unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $93,352 and $143,277, as of June 30, 2024, and December 31, 2023, respectively. As of June 30, 2024, the Company had cash, cash equivalents and investments of $434,088.

The Company believes that its existing cash, cash equivalents and investments on hand as of June 30, 2024, as well as additional cash generated from operating and financing activities will meet its operational liquidity needs and fund its planned investing activities for the next twelve months from the date of issuance of these unaudited condensed consolidated financial statements.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated balance sheet as of June 30, 2024, the unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2024, and 2023, and the unaudited condensed consolidated statements of operations and comprehensive income and the unaudited condensed consolidated statements of shareholders’ equity for the three and six months ended June 30, 2024, and 2023, are unaudited. The

7

balance sheet as of December 31, 2023, was derived from audited financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2024, and the results of its operations and its cash flows for the three and six months ended June 30, 2024, and 2023. The unaudited condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Reclassifications

Certain prior period amounts within the unaudited condensed consolidated statements of operations and comprehensive income have been reclassified to conform to current period presentation. In particular, interest expense and interest income were previously classified together as interest expense, net and are now separately classified as interest expense and interest income, respectively. The reclassification of these items had no impact on net income, earnings per share or accumulated deficit in current or prior periods.

Significant Risks and Uncertainties

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, clinical trial results of the Company’s product candidates; the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products, if approved; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates.

The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company’s research and development efforts will result in successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes.

Operating Segments

The Company holds all its tangible assets, conducts its operations, and generates its revenue in the United States. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.

8

Fair Value of Financial Instruments

The Company’s unaudited condensed consolidated financial statements include cash, cash equivalents, restricted cash, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value.

It is the Company’s policy to measure non-financial assets and liabilities at fair value on a nonrecurring basis. These non-financial assets and liabilities are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes.

The Company measures certain assets and liabilities at fair value based on the fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

Money market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of June 30, 2024, or December 31, 2023.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents and restricted cash consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds and debt securities that approximate fair value. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.

    

As of

    

June 30, 

    

December 31, 

2024

2023

Cash and cash equivalents

$

317,296

$

311,660

Restricted cash

 

270

 

270

Total cash, cash equivalents, and restricted cash shown in the statements of cash flows

$

317,566

$

311,930

Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program.

Investments

The Company’s investments consist of debt securities that are classified as available-for-sale. Short-term and long-term investments are carried at fair value and unrealized gains and losses are recorded as a

9

component of accumulated comprehensive income in stockholders’ equity. Interest income earned on cash and investment balances, accretion of the discount on investments in debt securities, amortization of premiums and realized gains and losses, if any, are recorded in interest income on the unaudited condensed consolidated statement of operations and comprehensive income. Realized gains and losses that result from the sale of investments are determined on a specific identification basis.

At each reporting period, the Company reviews any unrealized losses position to determine if the decline in the fair value of the underlying investments is a result of credit losses or other factors. If the assessment indicates that a credit loss exists, any impairment is recognized as an allowance for credit losses in our consolidated statement of operations.

Concentrations of Risk

Substantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of June 30, 2024, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 41% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 35% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 24% of gross accounts receivable. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 39% of gross accounts receivable, CVS Caremark, which accounted for 32% of gross accounts receivable; and Pantherx, which accounted for 29% of gross accounts receivable.

For the six months ended June 30, 2024, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 40% of gross product revenue; Accredo accounted for 33% of gross product revenue; and Pantherx accounted for 27% of gross product revenue. For the six months ended June 30, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 35% of gross product revenue; Pantherx accounted for 33% of gross product revenue; and Accredo accounted for 32% of gross product revenue.

The Company depends on a single supplier for its product and a single supplier for its active pharmaceutical ingredient.

Share Repurchases

The Company accounts for share repurchases as constructive retirements, whereby it reduces common stock and additional paid-in capital by the amount of the original issuance, with any excess purchase price recorded as a reduction to retained earnings. Under this method, issued and outstanding shares of common stock are reduced by the amount of shares of common stock repurchased, and no treasury stock is recognized on the condensed consolidated financial statements.

10

Business Combinations

Business combinations and asset acquisitions are accounted for in accordance with FASB ASC 805 Business Combinations. Refer to Note 4, Acquisitions, for a more detailed discussion of the Company’s acquisitions of Zynerba and Epygenix.

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This ASU is effective for annual reporting periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 is required to be applied retrospectively to all prior periods presented in the financial statements. The Company has one reportable segment and is currently evaluating the impact that ASU 2023-07 will have on its condensed consolidated financial statements.

In December 2023, the FASB issued Accounting Standards Update (“ASU”) No 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 expands disclosures in the rate reconciliation and requires disclosure of income taxes paid by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its condensed consolidated financial statements.

4. ACQUISITIONS

Acquisition of Zynerba

In October 2023, the Company completed a tender offer to purchase the outstanding common stock of Zynerba (“Zynerba Common Stock”) for (i) $1.1059 per share of Zynerba Common Stock (the “Common Cash Amount”), the aggregate amount of which was $60,000 and was paid at closing, plus (ii) one contingent value right (each, a “CVR”) per share of Zynerba Common Stock (the “Common CVR Amount”), which represents the right to receive up to approximately $2.5444 per share of Zynerba Common Stock, subject to the achievement of certain clinical, regulatory and sales-based milestones. The Common CVR Amounts are to be paid in cash, subject to any applicable withholding of taxes and without interest. The aggregate amount of consideration to acquire Zynerba Common Stock was $60,000, excluding transaction related fees of $2,645 and was paid by the Company using cash on hand.

The Zynerba Acquisition was accounted for as an asset acquisition under ASC Topic 805, Business Combinations, because substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable IPR&D asset, ZYN002, Zynerba’s lead asset. ZYN002 is the first and only pharmaceutically manufactured, synthetic cannabidiol, devoid of THC, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system and is currently in Phase III clinical trial for the potential treatment of Fragile X Syndrome. The Company recognized the acquired assets and assumed liabilities based on the consideration paid, including transaction costs, on a relative fair value basis, and after first allocating the preliminary excess of the fair value of net assets acquired over the purchase price consideration to certain qualifying assets, principally, the IPR&D asset.

Acquisition of Epygenix

On April 30, 2024, the Company acquired all of the issued and outstanding capital stock of Epygenix pursuant to the terms of a stock purchase agreement. In connection with the closing of the transaction, the Company paid the former stockholders of Epygenix up front consideration of $35,000 less a working capital

11

adjustment. In addition, the Company will be obligated to pay up to $130,000 upon the achievement of development and regulatory milestones and up to $515,000 upon the achievement of certain sales-based milestones, in each case to Epygenix’s former stockholders. As a result, the Company now has an exclusive license relating to the use of clemizole, initially for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.

The total purchase consideration for Epygenix was as follows:

Cash consideration paid to selling shareholders and to settle restricted stock units ("RSUs")

$

32,686

Transaction costs

450

Total purchase consideration

$

33,136

The acquisition of Epygenix was accounted for as an asset acquisition under ASC Topic 805, Business Combinations. The Company did not acquire any outputs and there was not an acquired substantive process in place to create outputs. The Company recognized the acquired assets and assumed liabilities based on the consideration paid, including transaction costs, on a relative fair value basis, and after first allocating the preliminary excess of the fair value of net assets acquired over the purchase price consideration to certain qualifying assets, principally, the IPR&D asset. In accordance with the accounting for asset acquisitions, an entity that acquires IPR&D assets in an asset acquisition follows the guidance in ASC Topic 730, Research and Development, which requires that both tangible and intangible identifiable research and development assets with no alternative future use be allocated a portion of the consideration transferred and recorded as research and development expense at the acquisition date. As a result, the Company recorded a charge of $17,095 related to acquired in-process research and development expense during the three and six months ended June 30, 2024.

The following table shows the allocation of the purchase consideration based on the relative fair value of assets acquired and liabilities assumed by the Company, after reducing the excess fair value of the IPR&D asset as described above:

Assets acquired

Acquired in-process research and development

$

17,095

Deferred tax asset

18,268

Other assets

590

Total assets acquired

$

35,953

Total liabilities assumed

$

2,817

Net assets acquired

$

33,136

5. INVESTMENTS

The carrying value and amortized cost of the Company’s available-for-sale debt securities, summarized by type of security, consisted of the following:

June 30, 2024

Amortized

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

Short-term:

Commercial paper

$

16,175

1

(5)

$

16,171

Corporate debt securities

13,443

4

(4)

13,443

Total short-term investments

$

29,618

5

(9)

$

29,614

12

Long-term:

Corporate debt securities

59,793

37

(87)

59,743

U.S. government securities

27,615

(180)

27,435

Total long-term investments

$

87,408

37

(267)

$

87,178

December 31, 2023

Amortized

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

Short-term:

Commercial paper

$

23,832

36

(3)

$

23,865

Corporate debt securities

15,968

28

15,996

U.S. government securities

1,940

(1)

1,939

Total short-term investments

$

41,740

64

(4)

$

41,800

Long-term:

Commercial paper

$

744

$

744

Corporate debt securities

42,688

81

(28)

42,741

U.S. government securities

28,795

7

(118)

28,684

Total long-term investments

$

72,227

88

(146)

$

72,169

The Company classifies investments with an original maturity of less than one year as current and investments with an original maturity date of greater than one year as noncurrent on its unaudited condensed consolidated balance sheet. The investments classified as noncurrent have original maturity dates ranging from 1-2 years. The Company did not have any available-for-sale debt security investments in a continuous unrealized loss position of greater than 12 months as of June 30, 2024, and December 31, 2023, respectively.

6. FAIR VALUE MEASUREMENTS

Money market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of June 30, 2024, or December 31, 2023.

The Company’s assets measured at fair value consisted of the following:

June 30, 2024

December 31, 2023

Total

Level 1

Level 2

Total

Level 1

Level 2

Assets

Cash equivalents

$

270,989

270,989

$

244,569

243,685

884

Commercial paper

16,171

16,171

24,609

24,609

Corporate debt securities

73,186

73,186

58,737

58,737

U.S. government securities

27,435

27,435

30,623

30,623

Total

$

387,781

270,989

116,792

$

358,538

243,685

114,853

13

7. INVENTORY

Inventory, net consisted of the following:

    

As of

    

June 30, 

    

December 31, 

2024

2023

Raw materials

$

1,135

$

1,060

Work in process

 

1,744

 

2,020

Finished goods

 

2,764

 

2,283

Total inventory, net

$

5,643

$

5,363

8. INTANGIBLE ASSETS

In August 2019, the Company received FDA approval of WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (“EDS”) in adult patients with narcolepsy. This event triggered a milestone payment of $75,000 under the provisions of the 2017 LCA (defined below) which the Company capitalized as an intangible asset. The Company determined a useful life of 10 years for such intangible asset, and, as of June 30, 2024, the remaining useful life was 5.3 years.

In October 2020, the Company received FDA approval for the New Drug Application (“NDA”) for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. This event triggered a milestone payment of $100,000 under the provisions of the 2017 LCA which the Company capitalized as an intangible asset and paid in January of 2021. The Company determined a useful life of 9 years for such intangible asset, and, as of June 30, 2024, the remaining useful life was 5.3 years.

In February 2022, the Company attained $500,000 in life-to-date aggregate net sales of WAKIX in the United States. This event triggered a final $40,000 payment under the provisions of the 2017 LCA which the Company capitalized as an intangible asset and paid in March of 2022. The Company determined a useful life of 7.6 years for such intangible asset, and, as of June 30, 2024, the remaining useful life was 5.3 years.

Amortization expense was $5,961 for each of the three months ended June 30, 2024, and 2023, respectively, and $11,922 for each of the six months ended June 30, 2024, and 2023, respectively, and is recorded in general and administrative on the unaudited condensed consolidated statements of operations and comprehensive income.

The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:

Years ending December 31, 

    

2024 (excluding the six months ended June 30, 2024)

$

11,923

2025

 

23,845

2026

 

23,845

2027

 

23,845

2028

 

23,845

Thereafter

17,883

Total

$

125,186

14

The gross carrying amount and net book value of the intangible asset is as follows:

    

As of

    

June 30, 

    

December 31, 

2024

2023

Gross Carrying Amount

$

215,000

$

215,000

Accumulated Amortization

 

(89,814)

 

(77,892)

Net Book Value

$

125,186

$

137,108

9. LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS

License Agreements

In July 2017, Harmony entered into a License Agreement (the “2017 LCA”) with Bioprojet Société Civile de Recherche (“Bioprojet”) whereby Harmony acquired the exclusive right to commercialize the pharmaceutical compound pitolisant for the treatment, and/or prevention, of narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, and Parkinson’s disease as well as any other indications unanimously agreed by the parties in the United States and its territories. A milestone payment of $50,000 was due upon acceptance by the FDA of pitolisant’s NDA, which was achieved in February 2019 and was expensed within research and development for the year ended December 31, 2019. A milestone payment of $77,000, which included a $2,000 fee that is described below, was due upon FDA approval of WAKIX (pitolisant) for treatment of EDS in adult patients with narcolepsy, which was achieved in August 2019. The $2,000 payment and $75,000 milestone payment were paid in August and November 2019, respectively. In addition, a milestone payment of $102,000, which included a $2,000 fee was due upon the FDA approval of the NDA for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. The $2,000 payment was paid in October 2020 and a $100,000 milestone payment was paid in January 2021. A final $40,000 milestone payment was paid to Bioprojet in March 2022 upon WAKIX attaining $500,000 in aggregate net sales in the United States. The 2017 LCA also requires a fixed trademark royalty and a tiered royalty based on net sales, which is payable to Bioprojet on a quarterly basis. The Company incurred $30,199 and $22,542 for the three months ended June 30, 2024, and 2023, respectively, and $54,937 and $41,602 for the six months ended June 30, 2024, and 2023, respectively, for sales-based, trademark and tiered royalties recognized as cost of product sold. As of June 30, 2024, and December 31, 2023, the Company had accrued $30,199 and $40,419, respectively, for sales-based, trademark and tiered royalties.  

In July 2022, Harmony entered into a License and Commercialization Agreement (the “2022 LCA”) with Bioprojet whereby Harmony obtained exclusive rights to manufacture, use and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon agreement of both parties. Harmony paid an initial, non-refundable $30,000 licensing fee in October 2022 and additional payments of up to $155,000 are potentially due under the 2022 LCA upon the achievement of certain future development and sales-based milestones. In addition, there are other payments due upon achievement of development milestones for new indications and formulations as agreed upon by both parties. The 2022 LCA also requires a fixed trademark royalty and a tiered royalty based on net sales upon commercialization, which will be payable to Bioprojet on a quarterly basis.

In April 2024, the Company announced that it entered into a sublicense agreement with Bioprojet for an orexin-2 receptor agonist (OX2R) (the “Licensed Compound”) to be evaluated for the treatment of narcolepsy and other potential indications (the “Sublicense”). Under the Sublicense, the Company obtained the exclusive right to develop, manufacture and commercialize the Licensed Compound in the United States and Latin American territories (the “Licensed Territories”), which are rights that Bioprojet originally licensed from Teijin Pharma, the innovator of the Licensed Compound. The Licensed Compound is currently in pre-clinical development with a Clinical Trial Application currently anticipated in mid-2025. Under the Sublicense, the Company paid Bioprojet an upfront license fee of $25,500, which the Company recognized as an IPR&D charge recorded in research and development within the unaudited condensed consolidated statements of operations and comprehensive income for the three and six months ended June 30, 2024, and will also be obligated to pay up to $127,500 upon achievement of development and regulatory milestones and up to $240,000 upon

15

achievement of sales-based milestones, as well as royalty rates in the mid-teens on any sales of product using the Licensed Compound in the Licensed Territories.

Agreement Related to Intellectual Property

In August 2021, the Company entered into an asset purchase agreement with ConSynance Therapeutics, Inc. (the “APA”) to acquire HBS-102 (formerly referred to as “CSTI-100”), a potential first-in-class molecule with a novel mechanism of action. Under the terms of the APA, the Company acquired full development and commercialization rights globally, with the exception of Greater China, for $3,500. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identified asset. In March 2023, the Company achieved a preclinical milestone, which triggered a $750 payment under the provisions of the APA, which the Company recognized as an IPR&D charge recorded in research and development within the unaudited condensed consolidated statement of operations and comprehensive income for the six months ended June 30, 2023. There are additional payments due under the APA upon the achievement of certain milestones including $1,000 for preclinical milestones, $19,000 for development milestones, $44,000 for regulatory milestones and $110,000 for sales milestones.

10. ACCRUED EXPENSES

Accrued expenses consist of the following:

    

As of

    

June 30, 

    

December 31, 

2024

2023

Royalties due to Bioprojet

$

30,199

$

40,419

Rebates and other sales deductions

 

43,570

 

38,842

Interest

2,993

3,354

Sales and marketing

 

3,343

 

2,354

Research and development

 

7,201

 

9,835

Professional fees, consulting, and other services

 

2,053

 

2,195

Other expenses

 

2,285

 

2,495

$

91,644

$

99,494

11. DEBT

Term Loan A Credit Agreement

In July 2023, the Company entered into a Credit Agreement (the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as “Administrative Agent”, and certain lenders. The TLA Credit Agreement provides for a five-year senior secured term loan (the “TLA Term Loan”) in an aggregate principal amount of $185,000.

In September 2023, the Company entered into the First Incremental Amendment (the “First Incremental Amendment”) with the Administrative Agent and Bank of America, N.A., as incremental lender. The First Incremental Amendment provides for an incremental senior secured term loan (the “Incremental Term Loan”) in an aggregate principal amount of $15,000. The First Incremental Amendment amends the TLA Credit Agreement and provides that the Incremental Term Loan will have identical terms as the TLA Term Loan.

The repayment schedule for both the TLA Term Loan and the Incremental Term Loan (together, the “Term Loans”) consists of quarterly $3,750 principal payments, which commence on December 31, 2023, increasing to quarterly $5,000 principal payments beginning on December 31, 2025, with a $115,000 payment due on the maturity date of July 26, 2028. The Term Loans bear interest at a per annum rate equal to, at the Company’s option, (i) a base rate plus a specified margin ranging from 2.50% to 3.00%, based on the

16

Company’s senior secured net leverage ratio (as defined in the TLA Credit Agreement) or (ii) Term SOFR plus a credit spread adjustment of 0.10% plus a specified margin ranging from 3.50% to 4.00%, based on the Company’s senior secured net leverage ratio.

The net cash received related to the Term Loans as a result of the transactions, less debt issuance costs of $2,997, was $197,003. The debt issuance costs related to the Term Loans will be amortized as additional interest expense over the loan term of the TLA Credit Agreement. The fair value of the Term Loans as of June 30, 2024, was $187,863.

Long-term debt, net consists of the following:

    

June 30, 

    

December 31, 

2024

2023

Principal amount

$

188,750

$

196,250

Unamortized debt discount associated with debt financing costs

 

(2,328)

 

(2,684)

Total debt, net

186,422

193,566

Less current portion

(15,000)

(15,000)

Long-term debt, net

$

171,422

$

178,566

Future minimum payments relating to total debt, net as of June 30, 2024, for the periods indicated below consists of the following:

Years ending December 31, 

2024 (excluding the six months ended June 30, 2024)

$

7,500

2025

 

16,250

2026

 

20,000

2027

 

20,000

2028

 

125,000

Thereafter

Total

$

188,750

Interest expense related to the Company’s long-term debt, net, is included in interest expense within the unaudited condensed consolidated statements of operations and comprehensive income and consists of the following:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

2024

    

2023

2024

    

2023

Interest on principal balance

$

4,228

$

5,794

$

8,583

$

11,109

Amortization of deferred financing costs

 

176

 

424

 

356

 

840

Total term loan interest expense

$

4,404

$

6,218

$

8,939

$

11,949

12. LEASES

In June 2018, the Company entered into an operating lease for approximately fifteen thousand square feet of office space in Plymouth Meeting, PA, which expires in May 2024. The Company subsequently entered into two separate operating leases for additional office space in Plymouth Meeting, PA, which include approximately thirteen thousand square feet and seven thousand square feet of additional office space, respectively, and expire in May 2024. In March 2024, the Company amended its existing operating leases for office space in Plymouth Meeting to extend their terms through June 2025. The terms of the lease payments provide for rental payments on a monthly basis and on a graduated scale. The Company also leases a fleet of automobiles that are used by its sales representatives and are classified as operating leases.

17

Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future lease payments using our incremental borrowing rate. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Our leases have remaining lease terms of less than 1 year to 3 years, some of which may include the option to extend or terminate the leases.

The Company recorded operating lease costs of $622 and $444 for the three months ended June 30, 2024, and 2023, respectively and $1,131 and $822 for the six months ended June 30, 2024, and 2023, respectively.

As of June 30, 2024, the weighted-average remaining lease term for operating leases was 1.7 years and the weighted-average discount rate for operating leases was 7.56%.

Supplemental balance sheet information related to operating leases was as follows:

Leases

Classification

June 30, 2024

  

December 31, 2023

Assets

Operating lease right-of-use assets

Other noncurrent assets

$

2,508

$

2,344

Liabilities

Operating lease liability, current portion

Other current liabilities

$

1,786

$

1,437

Operating lease liability, long-term

Other long-term liabilities

854

1,082

Total operating lease liabilities

$

2,640

$

2,519

Supplemental cash flow information related to operating leases was as follows:

June 30, 2024

June 30, 2023

Operating cash flows from operating leases

$

1,075

$

922

Right of use assets obtained in exchange for operating lease obligations

$

1,254

$

615

Future payments under noncancelable operating leases with initial terms of one year or more as of June 30, 2024, consisted of the following:

Years ending December 31, 

    

2024 (excluding the six months ended June 30, 2024)

$

1,047

2025

 

1,250

2026

 

495

2027

 

12

2028

 

Thereafter

 

Total lease payments

2,804

Less: imputed interest

(164)

Total lease liabilities

$

2,640

13. COMMITMENTS AND CONTINGENCIES

Litigation

From time to time, the Company is subject to claims and suits arising in the ordinary course of business. The Company accrues such liabilities when they are known, if they are deemed probable and can be reasonably estimated. As of June 30, 2024, there were no material claims or suits outstanding.

18

14. STOCKHOLDERS’ EQUITY

Common Stock

The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the Company’s stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive any dividends declared by the Company’s board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. The Company’s common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.

Share Repurchase Program

In October 2023, the Company’s Board of Directors approved a share repurchase program (the “October 2023 Repurchase Program”) providing for the repurchase of shares of common stock in an aggregate amount of up to $200,000, excluding commissions and transaction fees. The October 2023 Repurchase Program may be suspended, terminated, or modified at any time for any reason. During the three and six months ended June 30, 2024, and 2023, no shares of common stock were repurchased and cancelled by the Company. As of June 30, 2024, the remaining amount of common stock authorized for repurchases was $150,000.

15. STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION

2020 Stock Incentive Plan

In August 2020, the Company adopted, and its stockholders approved, the 2020 Incentive Award Plan (the “2020 Plan”), in order to facilitate the grant of cash and equity incentives to directors, employees (including the Company’s named executive officers) and consultants of the Company and its subsidiaries. The 2020 Plan provides for the grant of stock options, including incentive stock options (“ISOs”) and non-qualified stock options (“NSOs”), SARs, restricted stock, dividend equivalents, restricted stock units (“RSUs”) and other stock or cash-based awards.

Stock options and stock appreciation rights under the 2020 Plan have a 10-year contractual term and vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). RSUs vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). As of June 30, 2024, there were 7,654,586 shares of common stock available for issuance under the 2020 Plan. The number of shares that may be issued under the 2020 Plan automatically increases on January 1 of each year in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors.

2017 Stock Incentive Plan

In August 2017, the Company adopted an equity incentive plan (the “2017 Plan”). Under the 2017 Plan, directors, officers, employees, consultants, and advisors of the Company can be paid incentive compensation measured by the value of the Company’s shares of common stock through grants of stock options, stock appreciation rights (“SARs”), or restricted stock. Following the adoption of the 2020 Plan, no further grants have been, or will be, made under the 2017 Plan. However, the 2017 Plan will continue to govern the terms and conditions of outstanding awards granted under it.

19

Stock Options

The following table summarizes stock option activity for the six months ended June 30, 2024:

    

    

    

Weighted-

    

Weighted-

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

    

Awards

    

Price

    

Term

    

Value ($000's)

Awards outstanding—December 31, 2023

 

6,316,422

$

32.47

7.17

Awards issued

 

1,307,396

$

30.51

  

Awards exercised

 

(46,996)

$

8.97

  

Awards forfeited

 

(27,791)

$

37.14

  

Awards outstanding—June 30, 2024

 

7,549,031

$

32.26

7.20

$

27,893

Awards exercisable—June 30, 2024

3,772,766

$

30.50

6.30

$

21,050

Stock Appreciation Rights

The following table summarizes SARs activity for the six months ended June 30, 2024:

    

    

    

Weighted-

    

Weighted-

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

    

Awards

    

Price

    

Term

    

Value ($000's)

Awards outstanding—December 31, 2023

 

43,208

$

9.38

5.32

Awards issued

 

$

  

Awards exercised

 

$

  

Awards forfeited

 

$

  

  

Awards outstanding—June 30, 2024

 

43,208

$

9.38

4.83

$

887

Awards exercisable—June 30, 2024

39,556

$

8.98

4.72

$

827

Restricted Stock Units

The following table summarizes RSU activity for the six months ended June 30, 2024:

    

    

Weighted-

Average

Number of

Grant Date

    

Awards

    

Fair Value

Awards outstanding—December 31, 2023

 

330,000

$

31.53

Awards issued

 

464,600

$

30.62

Awards vested

 

(15,000)

$

29.03

Awards forfeited

 

(3,250)

$

30.69

Awards outstanding—June 30, 2024

 

776,350

$

31.03

Value of Stock Options and SARs

The Company values options and SARs using the Black-Scholes option-pricing model. The Company lacks sufficient historical company-specific volatility information. Therefore, the Company estimates expected stock volatility based on historical volatility of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. For SARs, the expected term is based

20

upon the weighting of certain future events. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for the time periods approximately equal to the expected term of the award. An expected dividend yield of 0% is based on the fact that the Company has never paid cash dividends and does not expect to do so in the foreseeable future.

The assumptions used to value the awards are summarized in the following table.

As of

    

June 30, 

    

December 31, 

    

2024

    

2023

Dividend yield

 

0.00

%  

0.00

%

Expected volatility

 

69.84 - 72.98

%  

74.87 - 80.78

%

Risk-free interest rate

 

4.06 - 4.65

%  

3.42 - 4.62

%

Lack of marketability discount

 

0.00

%  

0.00

%

Expected term (years)

 

2.04 - 6.11

 

2.26 - 10.77

Value of RSUs

The fair value of RSUs is equal to the value of the Company’s common stock on the grant date.

The weighted average per share fair value of awards issued under the 2017 Plan and 2020 Plan was $21.24 and $20.64 on June 30, 2024, and December 31, 2023, respectively.

Stock-Based Compensation Expense

Stock-based compensation expense for the three and six months ended June 30, 2024, and 2023, was recorded in the unaudited condensed consolidated statements of operations and comprehensive income in the following line items:

    

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2024

    

2023

    

2024

    

2023

Research and development expense

$

1,683

$

956

$

3,054

$

1,932

Sales and marketing expense

 

2,100

 

1,146

 

4,094

 

2,219

General and administrative expense

 

7,180

 

5,691

 

14,249

 

10,203

$

10,963

$

7,793

$

21,397

$

14,354

Stock-based compensation expense related to options and RSUs issued under the 2017 Plan and 2020 Plan is included in stockholder’s equity, and a liability for SARs is included in other non-current liabilities, in the Company’s unaudited condensed consolidated balance sheet. As of June 30, 2024, the total unrecognized stock-based compensation expense was $68,926 and $19,749 for stock options and RSUs, respectively. This amount will be recognized in the Company’s consolidated statement of operations over a weighted average period of 2.6 years.

Employee Stock Purchase Plan

The 2020 Employee Stock Purchase Plan (“ESPP”) was adopted by the Company’s Board of Directors on April 30, 2021. The ESPP permits eligible employees to purchase shares of the Company’s common stock at a 15% discount from the lesser of the fair market value per share of the Company’s common stock on the first day of the offering period or the fair market value of the Company’s common stock on the purchase date. Funds are collected from employees through after-tax payroll deductions. The total number of shares reserved for issuance under the ESPP was initially 629,805, which automatically increases on January 1 of each year in an amount equal to the lesser of (i) 1.0% of the shares of the Company’s common stock outstanding on

21

December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors. It is intended that the ESPP meet the requirements for an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. There were 10,707 and 14,043 shares issued under the ESPP for each of the three and six months ended June 30, 2024, and 2023, respectively. The discount on the ESPP was $78 and $103 for the three months ended June 30, 2024, and 2023, respectively, and $158 and $208 for the six months ended June 30, 2024, and 2023, respectively, and is recorded within stock-based compensation expense.

16. EARNINGS PER SHARE

Basic earnings per share is calculated by dividing net income by the weighted average number of shares of common stock outstanding. Diluted net income per share of common is computed under the treasury stock method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income, the potential dilutive effects of stock options, stock appreciation rights and restricted stock units.

The following table sets forth the computation of basic and diluted net income per share:

    

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

    

2024

    

2023

Numerator

 

  

 

  

  

 

  

Net income

$

11,591

$

34,300

$

49,925

$

63,785

Denominator

 

  

 

  

 

  

 

  

Net income per share of common stock - basic

$

0.20

$

0.57

$

0.88

$

1.07

Net income per share of common stock- diluted

$

0.20

$

0.56

$

0.87

$

1.05

Weighted average number of shares of common stock - basic

 

56,802,357

 

59,974,123

 

56,786,873

 

59,853,808

Weighted average number of shares of common stock - diluted

 

57,541,696

 

60,743,953

 

57,571,570

 

60,997,410

Securities outstanding that were included in the computation above, utilizing the treasury stock method are as follows:

    

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

    

2024

    

2023

Stock options, SARs, and RSUs to purchase common stock

739,339

769,830

784,697

1,143,602

Potential shares of common stock issuable that were excluded from the computation of diluted weighted-average shares outstanding excluded from the numerator, are as follows:

    

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

    

2024

    

2023

Stock options, SARs, and RSUs to purchase common stock

 

7,629,250

 

5,520,235

7,583,892

 

5,146,464

22

17. INCOME TAXES

A reconciliation between the statutory federal income tax rate and the Company’s effective income tax rate for the three and six months ended June 30, 2024, and 2023 is as follows:

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

2024

    

2023

Federal income tax rate

21.0

%  

21.0

%

21.0

%  

21.0

%

Stock-based compensation

(0.7)

(0.5)

(0.2)

(1.5)

State taxes

11.2

4.0

7.4

5.1

Credits

(2.6)

(2.9)

(1.6)

(2.9)

Nondeductible IPR&D

16.5

4.9

Valuation allowance

0.6

0.3

Other

0.6

0.6

0.3

0.4

Total

46.6

%  

22.2

%

32.1

%  

22.1

%

18. RELATED-PARTY TRANSACTIONS

The Company was party to a management agreement for professional services provided by a related party, Paragon Biosciences, LLC (“Paragon”). Paragon is an entity that shares common ownership with the Company. In addition, the Chairman of the Company’s board of directors is the Founder, Chairman and CEO of Paragon. The Company is also party to a right of use agreement with Paragon whereby it has access to and the right to use certain office space leased by Paragon in Chicago, IL. The Company incurred $72 and $74 for the three months ended June 30, 2024, and 2023, respectively, and incurred $145 and $145 for the six months ended June 30, 2024, and 2023, respectively, in expenses to Paragon, which are included in general and administrative in the unaudited condensed consolidated statements of operations and comprehensive loss. As of June 30, 2024, and December 31, 2023, there were no amounts due to or due from related parties included in the unaudited condensed consolidated balance sheets.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, products, prospective products, product approvals, research and development costs, anticipated timing and likelihood of success of clinical trials, expected timing of the release of clinical trial data, the plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, statements about:

our commercialization efforts and strategy for WAKIX;
the rate and degree of market acceptance and clinical utility of pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved;

23

our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications;
our ongoing and planned clinical trials;
our ability to expand the scope of our license agreements with Bioprojet Société Civile de Recherche (Bioprojet);
the availability of favorable insurance coverage and reimbursement for WAKIX;
the timing of, and our ability to obtain, regulatory approvals for pitolisant for other indications as well as any other product candidates;
our estimates regarding expenses, future revenue, capital requirements and additional financing needs;
our ability to identify, acquire and integrate additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;
our commercialization, marketing and manufacturing capabilities and strategy;
significant competition in our industry;
our intellectual property position;
loss or retirement of key members of management;
failure to successfully execute our growth strategy, including any delays in our planned future growth;
our failure to maintain effective internal controls; and
the impact of government laws and regulations.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”, or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under the section in our most recent Annual Report on Form 10-K entitled “Item 1A. Risk Factors” and the sections in this Quarterly Report on Form 10-Q titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.

Unless otherwise indicated, information contained in this Quarterly Report on Form 10-Q concerning our industry, including industry statistics and forecasts, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from publicly available information

24

released by independent industry analysts and other third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data, and our experience in, and knowledge of, such industry and markets, which we believe to be reasonable. In addition, projections, forecasts, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described in “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” These and other factors could cause results to differ materially from those expressed and forecasts in the estimates made by the independent parties and by us.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

As used herein, the terms “Harmony,” “we,” “us,” “our” and “the Company” refer to Harmony Biosciences Holdings, Inc., a Delaware corporation and our operating subsidiary, Harmony Biosciences, LLC.

Further, we have in-licensed from Bioprojet the registered trademark product name WAKIX® in the United States. We also have registered trademark protection in the United States for KNOW NARCOLEPSY®, REM AT THE WRONG TIME® and NON-REM AT THE WRONG TIME®, as well as our brand and logo HB®, HB HARMONY BIOSCIENCES® and HARMONY BIOSCIENCES®. This report also includes trademarks, service marks and trade names of other companies. Trademarks, service marks and trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

Company Overview

We are a commercial-stage, pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Our product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (“MOA”) specifically designed to increase histamine signaling in the brain by binding to H3 receptors. In August 2019, WAKIX was approved by the U.S. Food and Drug Administration (the “FDA”) for the treatment of excessive daytime sleepiness (“EDS”) in adult patients with narcolepsy, and its U.S. commercial launch was initiated in November 2019. In October 2020, WAKIX was approved by the FDA for the treatment of cataplexy in adult patients with narcolepsy. WAKIX is the first-and-only approved product for patients with narcolepsy that is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration (the “DEA”).

We believe that pitolisant’s ability to regulate histamine gives it the potential to provide therapeutic benefit in other rare neurological diseases that are mediated through H3 receptors and histamine signaling. We have applied a mechanism-based approach to managing the life cycle of pitolisant and identified idiopathic hypersomnia (“IH”), another central disorder of hypersomnolence like narcolepsy, as our next potential new indication for WAKIX, which received orphan drug designation by the FDA in September 2023 and Fast Track Designation in November 2023. In April 2022, we initiated a Phase 3 registrational trial, the INTUNE Study, to evaluate the efficacy and safety of pitolisant in adult patients with IH. We completed enrollment in the INTUNE study in May 2023 and we announced topline data in October 2023. While the primary endpoint did not meet statistical significance, we believe the totality of the data showed favorable numerical trends for pitolisant in the treatment of adult patients with IH and we met with the FDA in March 2024 to discuss the path forward for IH. Following our meeting with the FDA, we plan to submit a supplemental NDA (“sNDA”) for IH in the second half of 2024 based on the totality of the data obtained from the INTUNE study and from other sources.

We are focusing our development efforts on other rare neurological disorders in which EDS is a prominent symptom, including Prader-Willi Syndrome (“PWS”) and myotonic dystrophy, otherwise known as

25

dystrophia myotonica (“DM”). Based on the positive signals from the data from our Phase 2 proof-of-concept signal detection clinical trial to evaluate pitolisant for the treatment of EDS and other key behavioral symptoms in patients with PWS, an end-of-phase 2 meeting with the FDA was held in June 2023. We aligned with the FDA on the proposed Phase 3 registration study design to support further investigation of pitolisant as a potential treatment to address the unmet medical need for children, adolescents and adults with PWS experiencing EDS, for which there is currently no approved treatment. In October 2023, we received FDA alignment regarding the study design for the Phase 3 TEMPO study in patients with PWS, which we believe will satisfy the requirements for both the registrational trial and one of the two requirements for pediatric exclusivity for pitolisant. In February 2024, the FDA granted Orphan Drug designation to pitolisant for the treatment of PWS. The Phase 3 registrational trial, the TEMPO study, was initiated in March 2024. In June 2021, we initiated a Phase 2 proof-of-concept signal detection clinical trial to evaluate pitolisant for the treatment of EDS, fatigue and cognitive dysfunction in adult patients with DM1 and announced topline results from this trial in the fourth quarter of 2023, in which clinically meaningful improvements were demonstrated in EDS and fatigue. The safety profile was consistent with the established safety profile of pitolisant.

Our partner, Bioprojet completed a Phase 3 trial in pediatric patients with narcolepsy and submitted the trial data to the European Medicines Agency (the “EMA”) seeking approval for a pediatric narcolepsy indication. In January 2023, Bioprojet received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) and in March 2023, the EMA granted approval for the marketing authorization of WAKIX for the treatment of narcolepsy with or without cataplexy in children six and older. Based on the data from the positive Phase 3 trial conducted by Bioprojet, we submitted an sNDA for pediatric narcolepsy in December 2023. On June 24, 2024, we announced that the FDA approved our sNDA for WAKIX for the treatment of EDS in pediatric patients six years of age and older with narcolepsy.

We remain committed to obtaining pediatric exclusivity for WAKIX. The initiation of the PWS Phase 3 registrational trial, the TEMPO study, and the approval for EDS in pediatric narcolepsy are supportive of our efforts in obtaining pediatric exclusivity for WAKIX.

We also seek to expand our pipeline through the acquisition of additional assets that focus on addressing the unmet needs of patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. We are targeting assets that will allow us to further leverage the expertise and infrastructure that we have successfully built at Harmony so we can optimize the benefit of internal synergies. Consistent with this objective, in July 2022, we entered into a License and Commercialization Agreement (the “2022 LCA”) with Bioprojet whereby we obtained exclusive rights to manufacture, develop and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon the agreement of both parties. We have made progress in the development of two new formulations of pitolisant, Pitolisant Gastro-resistant (“Pitolisant GR”) and Pitolisant High Dose (“Pitolisant HD”). Both formulations entered clinical studies in the fourth quarter of 2023. We received data from the Pitolisant GR pilot bioequivalence study, which supports further development of Pitolisant GR. We received data from the Pitolisant HD pilot pharmacokinetics study in June 2024, which also supports advancing this development program toward pivotal trials. Provisional patents have been filed for both of these formulations with the potential for patent protection to the mid-2040’s.

In October 2023, we completed the acquisition of Zynerba Pharmaceuticals, Inc. (together with its subsidiary, Zynerba Pharmaceutical Pty, Ltd., “Zynerba”), a clinical-stage pharmaceutical company focused on innovative pharmaceutically manufactured transdermal cannabidiol therapies for orphan neurobehavioral disorders. Zynerba’s drug candidate is ZYN002, the first and only pharmaceutically manufactured synthetic cannabidiol gel, devoid of THC, and formulated as a patent protected, permeation-enhanced gel for transdermal delivery. ZYN002 is currently in a pivotal Phase 3 trial, the RECONNECT study, for the treatment of Fragile X Syndrome (“FXS”). Topline data from this Phase 3 study is anticipated in mid-2025. ZYN002 has patent protection for the treatment of FXS until 2038. Based on the positive proof-of-concept (“PoC”) study in 22q deletion syndrome, another rare disorder with prominent neurobehavioral symptoms, we are working with the FDA to align on the primary endpoint and finalize the Phase 3 protocol.

26

In April 2024, we entered into a sublicense agreement with Bioprojet for an orexin-2 receptor agonist (OX2R) (the “Licensed Compound”) to be evaluated for the treatment of narcolepsy and other potential indications (the “Sublicense”). Under the Sublicense, we have obtained the exclusive right to develop, manufacture and commercialize the Licensed Compound in the United States and Latin American territories, which are rights that Bioprojet originally licensed from Teijin Pharma, the innovator of the Licensed Compound. We plan to file an IND in mid-2025 and begin first-in-human studies in the second half of 2025.

Additionally, in April 2024, the Company acquired all of the issued and outstanding capital stock of Epygenix, pursuant to the terms of a stock purchase agreement. As a result, we now have an exclusive license relating to the use of clemizole (“EPX-100”), initially for the treatment of Dravet Syndrome (“DS”) and Lennox-Gastaut Syndrome (“LGS”). EPX-100 is currently in a late-stage registrational trial for DS with plans to initiate a pivotal phase 3 clinical trial in patients with LGS later this year.

In August 2021, we acquired HBS-102, a Melanin-concentrating hormone receptor 1 (MCHR1) antagonist previously developed as CSTI-100/ALB-127258(a)/ALB-127258 (the “Compound”), along with intellectual property and other assets related to the development, manufacture, and commercialization of the Compound from ConSynance Therapeutics, Inc. We acquired full development and commercialization rights for HBS-102 globally, but we have provided an indication-limited grant-back license to ConSynance for the development and commercialization of the Compound in Greater China. We conducted a preclinical PoC study to assess the effect of HBS-102 on hyperphagia, weight gain and other metabolic parameters in a mouse model of PWS. The study is now completed, and initial results are encouraging. We anticipate receiving the final report in the second half of 2024. A 13-week toxicology study is complete, and the preliminary results are encouraging.

Pitolisant was developed by Bioprojet and approved by the EMA in 2016 for the treatment of narcolepsy in adult patients with or without cataplexy and in 2021 for the treatment of EDS in adult patients with obstructive sleep apnea. We acquired an exclusive license to develop, manufacture and commercialize pitolisant in the United States pursuant to our license agreement with Bioprojet (as amended, the “2017 LCA”) in July 2017. Pitolisant was granted Orphan Drug Designation for the treatment of narcolepsy by the FDA in 2010. It received Breakthrough Therapy designation for the treatment of cataplexy in patients with narcolepsy and Fast Track status for the treatment of EDS and cataplexy in patients with narcolepsy in April 2018.

Our operations are conducted by our wholly owned subsidiaries, Harmony Biosciences, LLC and Zynerba, which is now known as Harmony Biosciences Management, Inc. as of July 1, 2024.

Commercial Performance Metrics

As of June 30, 2024, we continued to see growth in the number of unique healthcare professional (“HCP”) prescribers of WAKIX since it became available in November 2019. The average number of patients on WAKIX for the three months ended June 30, 2024, was approximately 6,550. Additionally, as of June 30, 2024, we have secured formulary access for more than 80% of all insured lives (Commercial, Medicare and Medicaid) in the United States.

Financial Operations Overview

Net Product Revenue

Net product revenue includes gross product shipments less provisions for sales discounts and allowances, which includes trade allowances, rebates to government and commercial entities, and other discounts. Although we expect net sales to increase over time, provisions for sales discounts and allowances may fluctuate based on the mix of sales to different customer segments and/or changes in our estimates.

27

Cost of Product Sales

Cost of product sales includes manufacturing and distribution costs, the cost of API, FDA program fees, royalties due to third parties on net product sales, freight, shipping, handling, storage costs and salaries of employees involved with oversight of production. We expect the cost of product sales to increase as we continue to ramp up production in order to meet future demand for WAKIX and diversify our supply chain for WAKIX.

The shelf life of WAKIX is three years from date of manufacture, with the earliest expiration of current inventory expected to be June 2025. We regularly review our inventory levels and expect write-offs from time to time. We will continue to assess inventory levels in future periods as demand for WAKIX and the rate of inventory turnover evolves. We currently have adequate supply of WAKIX to cover demand into the fourth quarter of 2025, with additional API on-hand inventory to support at least 36 months beyond this time frame.

Research and Development Expenses

Research and development expenses primarily include development programs for potential new indications for pitolisant in patients with IH, PWS, DM and the development of ZYN002 in patients with FXS. We also incur research and development expenses related to our team of Medical Science Liaisons (“MSLs”) who interact with key opinion leaders, with a focus on the science, the role of histamine in sleep-wake state stability and the novel mechanism of action of pitolisant. In addition, our MSLs support our market access team with the presentation of clinical data to payors upon request and our clinical development team to identify potential clinical trial sites. Research and development costs are expensed as incurred. We have significantly increased our research and development efforts as we advance our clinical programs and assess other product candidates to expand our pipeline. Research and development expenses also include:

employee-related expenses, such as salaries, share-based compensation, benefits and travel expenses for our research and development personnel;
direct third-party costs such as expenses incurred under agreements with clinical research organizations (“CROs”), and contract manufacturing organizations (“CMOs”);
manufacturing costs in connection with producing materials for use in conducting clinical trials;
costs related to packaging and labelling of clinical supplies;
other third-party expenses (e.g., consultants, advisors) directly attributable to the development of our product candidates;
acquired in-process research and development; and
amortization expense for assets used in research and development activities.

A significant portion of our research and development costs are external costs, such as fees paid to CROs and CMOs, central laboratories, contractors, and consultants in connection with our clinical development programs. Internal expenses primarily relate to personnel who are deployed across multiple programs.

Product candidates in later stages of clinical development generally have higher development costs in the current period than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, milestone payments, and the cost of submitting an NDA to the FDA (and/or other regulatory authorities). We expect our research and development expenses to be significant over the next several years as we advance our current clinical development programs and prepare to seek regulatory

28

approval for additional indications for pitolisant, complete the Phase 3 clinical trial for ZYN002, and advance Pitolisant GR, Pitolisant HD, ZYN002 and HBS-102 to develop toward new indications.

At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of any additional indications for pitolisant or other product candidates that we move forward for regulatory approval. There are numerous risks and uncertainties associated with developing product candidates, including uncertainty related to:

the duration, costs and timing of clinical trials of our current development programs and any further clinical trials related to new product candidates;
the sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;
the impact of the COVID-19 pandemic, including any future resurgence or new variants, on the ability to initiate new clinical trials and/or maintain the continuity of ongoing clinical trials, including our ability to access sleep labs in order to conduct objective sleep testing, that could be impacted by future shelter-in-place orders and needs of the health care system to focus on managing patients affected by COVID-19;
receiving Bioprojets consent to pursue additional indications for pitolisant;
the acceptance of INDs for our planned clinical trials or future clinical trials;
the successful and timely enrollment and completion of clinical trials;
the successful completion of preclinical studies and clinical trials;
successful data from our clinical programs that support an acceptable risk-benefit profile of our product candidates in the intended populations;
the receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;
establishing agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidate is approved;
the entry into collaborations to further the development of our product candidates;
obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates; and
successfully launching our product candidates and achieving commercial sales, if and when approved.

A change in the outcome of any of these variables with respect to the development of any of our programs or any product candidate we develop would significantly change the costs, timing and viability associated with the development and/or regulatory approval of such programs or product candidates.

Sales and Marketing Expenses

Our sales and marketing expenses primarily relate to the market development and commercialization activities of WAKIX for the treatment of EDS and cataplexy in adult patients with narcolepsy. Market

29

development and commercial activities account for a significant portion of our operating expenses and are expensed as incurred. We expect our sales and marketing expenses to increase in the near- and mid-term to support WAKIX’s indications for the treatment of EDS or cataplexy in adult patients with narcolepsy and to expand our portfolio with the anticipated growth from potential additional indications.

Sales and marketing expenses include:

employee-related expenses, such as salaries, share-based compensation, benefits and travel expenses for our sales, marketing and market access personnel;
healthcare professional-related expenses, including marketing programs, healthcare professional promotional medical education, disease education, conference exhibits and market research;
patient-related expenses, including patient awareness and education programs, disease awareness education, patient reimbursement programs, patient support services and market research;
market access expenses, including payor education, specialty pharmacy programs and services to support the continued commercialization of WAKIX; and
secondary data purchases (i.e., patient claims and prescription data), data warehouse development and data management.

In addition, sales and marketing expenses include external costs such as website development, media placement fees, agency fees for patient, medical education and promotional expenses, market research, analysis of secondary data, conference fees and consulting fees.

General and Administrative Expenses

General and administrative expenses consist primarily of employee-related expenses, such as salaries, share-based compensation, benefits and travel expenses for our personnel in executive, legal, finance and accounting, human resources, investor relations, and other administrative departments. General and administrative expenses also consist of office leases, and professional fees, including legal, tax and accounting and consulting fees.

We anticipate that our general and administrative expenses will increase in the future to support our continued commercialization efforts, ongoing and future potential research and development activities, and increased costs of operating as a public company. These increases will likely be driven by costs associated with the hiring of additional personnel and fees paid to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the SEC, insurance and investor relations costs. If any of our current or future indication expansion programs or new product candidates obtain U.S. regulatory approval, we expect that we would incur significantly increased expenses associated with building a sales and marketing team.

Paragon Agreement

We are party to a right-of-use agreement with Paragon Biosciences, LLC (“Paragon”) whereby we have access to and the right to use certain office space leased by Paragon in Chicago, Illinois. For the three and six months ended June 30, 2024, we paid fees of $0.1 million and $0.2 million, respectively, pursuant to this agreement.

30

Interest Expense

Interest expense consists primarily of interest expense on debt facilities, amortization of debt issuance costs and amortization of premiums on our debt securities.

Interest Income

Interest income consists primarily of cash interest earned on our cash and investment balances and accretion of the discount on our investments in debt securities.

Results of Operations

The following table sets forth selected items in our unaudited condensed consolidated statements of operations for the periods presented:

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2024

    

2023

    

2024

    

2023

(In thousands)

(In thousands)

Net product revenue

$

172,814

$

134,216

$

327,429

$

253,342

Cost of product sales

 

32,144

 

25,008

 

59,628

 

45,788

Gross profit

 

140,670

 

109,208

 

267,801

 

207,554

Operating expenses:

 

  

 

  

 

  

 

  

Research and development

 

63,583

 

14,969

 

85,772

 

28,258

Sales and marketing

 

28,507

 

24,528

 

55,740

 

47,100

General and administrative

 

27,224

 

22,809

 

52,900

 

44,871

Total operating expenses

 

119,314

 

62,306

 

194,412

 

120,229

Operating income

 

21,356

 

46,902

 

73,389

 

87,325

Other (expense) income, net

 

37

 

(31)

 

(104)

 

(29)

Interest expense

(4,404)

(6,217)

(8,939)

(11,948)

Interest income

 

4,705

 

3,441

 

9,133

 

6,527

Net income before provision for income taxes

 

21,694

 

44,095

 

73,479

 

81,875

Income tax expense

 

(10,103)

 

(9,795)

 

(23,554)

 

(18,090)

Net income

$

11,591

$

34,300

$

49,925

$

63,785

Net Product Revenue

Net product revenue increased by $38.6 million, or 28.8%, for the three months ended June 30, 2024, and increased by $74.1 million, or 29.2%, for the six months ended June 30, 2024, compared to the same periods in 2023. The increase for the three months ended June 30, 2024, was primarily due to a 24.1% increase in the number of units shipped, and the impact of a 7% price increase partially offset by higher rebates and co-pay assistance, which resulted in a decrease to net product revenue of approximately 4%. The increase for the six months ended June 30, 2024, was primarily due to a 24.6% increase in the number of units shipped, and the impact of a 7% price increase partially offset by higher rebates and co-pay assistance, which resulted in a decrease to net product revenue of approximately 4%. The price increase occurred in January 2024.

Cost of Product Sales

Cost of product sales increased by $7.1 million, or 28.5%, for the three months ended June 30, 2024, and increased by $13.8 million, or 30.2%, for the six months ended June 30, 2024, compared to the same periods in 2023. Cost of product sales as a percentage of net product revenue was 18.6% and 18.2% for the three and six months ended June 30, 2024, respectively, compared to 18.6% and 18.1% for the three and six months ended June 30, 2023, respectively. The increase in cost of product sales in the period was due to higher sales of WAKIX.

31

Research and Development Expenses

The following table is a summary of our research and development expenses:

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

Change

2024

    

2023

Change

(in thousands)

(in thousands)

Pitolisant

$

7,275

$

8,788

$

(1,513)

$

16,385

$

14,975

$

1,410

ZYN002

3,726

-

3,726

7,605

-

7,605

IPR&D

42,595

-

42,595

42,595

750

41,845

Personnel expenses

5,813

3,759

2,054

11,196

7,361

3,835

Stock-based compensation

1,684

956

728

3,055

1,932

1,123

Other research and development

2,490

1,466

1,024

4,936

3,240

1,696

Total

$

63,583

$

14,969

$

48,614

$

85,772

$

28,258

$

57,514

Research and development expenses increased by $48.6 million, or 324.8%, for the three months ended June 30, 2024, and increased by $57.5 million or 203.5%, for the six months ended June 30, 2024, compared to the same periods in 2023. The increase for the three months ended June 30, 2024 was primarily driven by $42.6 million in IPR&D charges related to the Bioprojet Sublicense Agreement and the acquisition of Epygenix, a $3.7 million increase in research and development expenses for ZYN002, which did not have any expenses in the prior year, a $2.1 million increase in personnel costs associated with higher headcount and a $0.7 million increase in stock compensation associated with new awards partially offset by a $1.5 million decrease in clinical development and regulatory work associated with pitolisant, driven by declines for IH and DM indications.

The increase for the six months ended June 30, 2024 was primarily driven by $42.6 million in IPR&D charges related to the Bioprojet Sublicense Agreement and the acquisition of Epygenix, a $7.6 million increase in research and development expenses for ZYN002, which did not have any expenses in the prior year, a $3.8 million increase in personnel costs associated with higher headcount, a $1.4 million increase in clinical development and regulatory work associated with pitolisant, driven by increases for the PWS indication and a $1.1 million increase in stock compensation associated with new awards, partially offset by a $0.8 million IPR&D charge related to preclinical milestones achieved for HBS-102 during the six months ended June 30, 2023.

Sales and Marketing Expenses

Sales and marketing expenses increased by $4.0 million, or 16.2%, for the three months ended June 30, 2024, and increased by $8.6 million, or 18.3%, for the six months ended June 30, 2024, compared to the same periods in 2023. The increase for the three months ended June 30, 2024, was primarily due to a $1.9 million increase in patient engagement and marketing activities, a $1.1 million increase in personnel costs, and a $1.0 million increase in stock compensation associated with new awards. The increase for the six months ended June 30, 2024, was primarily due to a $4.4 million increase in patient engagement and marketing activities, a $1.9 million increase in personnel costs, and a $1.9 million increase in stock compensation associated with new awards. The increase in patient engagement and marketing activities for both comparable periods was driven by our continued growth of WAKIX and the increase in personnel costs for both comparable periods was related to increased headcount.

General and Administrative Expenses

General and administrative expenses increased by $4.4 million, or 19.4%, for the three months ended June 30, 2024, and increased by $8.0 million, or 17.9%, for the six months ended June 30, 2024, compared to the same periods in 2023. The increase in the three months ended June 30, 2024, was primarily due to a $2.0 million increase in legal and professional fees, primarily associated with patent lawsuits, a $1.5 million increase

32

in stock compensation associated with new awards, and a $1.0 million increase in personnel costs. The increase in the six months ended June 30, 2024, was primarily due to a $3.4 million increase in legal and professional fees, primarily associated with patent lawsuits, a $4.0 million increase in stock compensation associated with new awards, and a $1.5 million increase in personnel costs, partially offset by a $0.4 million decrease in travel expenses.

Interest Expense

Interest expense decreased by $1.8 million, or 29.2%, for the three months ended June 30, 2024, and decreased by $3.0 million, or 25.2%, for the six months ended June 30, 2024, compared to the same periods in 2023. The decrease for the three and six months ended June 30, 2024, was primarily due to lower interest rates as a result of refinancing into the TLA Credit Agreement (defined below).

Interest Income

Interest income increased by $1.3 million, or 36.7%, for the three months ended June 30, 2024, and increased by $2.6 million, or 39.9%, for the six months ended June 30, 2024, compared to the same periods in 2023. The increase for the three and six months ended June 30, 2024, was primarily a result of having higher invested balances, and higher investment yields on those balances, compared to the prior year periods.

Income Taxes

Income tax expense was $10.1 million, representing a 46.6% effective tax rate, for the three months ended June 30, 2024, compared to $9.8 million, representing a 22.2% effective tax rate, for the three months ended June 30, 2023. Income tax expense was $23.6 million, representing a 32.1% effective tax rate, for the six months ended June 30, 2024, compared to $18.1 million, representing a 22.1% effective tax rate, for the six months ended June 30, 2023. The increase in our effective tax rate for both comparable periods was primarily driven by the $17.1M IPR&D charge related to the Epygenix acquisition, which is nondeductible for tax purposes. The effective tax rate of 46.6% for the three months ended June 30, 2024, included 16.5% for nondeductible IPR&D charges and 11.2% in state income taxes, partially offset by a 2.6% benefit from credits. The effective tax rate of 32.1% for the six months ended June 30, 2024, included 4.9% for nondeductible IPR&D charges and 7.4% in state income taxes, partially offset by a 1.5% benefit from credits.

Liquidity, Sources of Funding and Capital Resources

Overview

As of June 30, 2024, we had cash, cash equivalents, and investments of $434.1 million, outstanding debt of $188.8 million and an accumulated deficit of $93.4 million.

The unaudited condensed consolidated financial statements have been prepared as though we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

We believe that our existing cash, cash equivalents and investments on hand as of June 30, 2024, will enable us to meet our operational liquidity needs and fund our planned investing activities for the next 12 months. We have based our liquidity and cash flow projections on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we expect.

Term Loan A Credit Agreement

In July 2023, we entered into a Credit Agreement (the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as “Administrative Agent”, and certain lenders. The TLA Credit Agreement provides for a five-year senior secured term loan (the “TLA Term Loan”) in an aggregate principal amount of $185.0 million.  

33

In September 2023, we entered into the First Incremental Amendment (the “First Incremental Amendment”) with the Administrative Agent and Bank of America, N.A., as incremental lender. The First Incremental Amendment provides for an incremental senior secured term loan (the “Incremental Term Loan”) in an aggregate principal amount of $15.0 million. The First Incremental Amendment amends the TLA Credit Agreement and provides that the Incremental Term Loan will have identical terms as the TLA Term Loan.

The repayment schedule for both the TLA Term Loan and the Incremental Term Loan (together, the “Term Loans”) consists of $3.8 million quarterly principal payments, which commence on December 31, 2023, increasing to $5.0 million quarterly principal payments beginning on December 31, 2025, with a $115.0 million payment due on the maturity date of July 26, 2028. The Term Loans bear interest at a per annum rate equal to, at our option, (i) a base rate plus a specified margin ranging from 2.50% to 3.00%, based on our senior secured net leverage ratio (as defined in the TLA Credit Agreement) or (ii) Term SOFR plus a credit spread adjustment of 0.10% plus a specified margin ranging from 3.50% to 4.00%, based on our senior secured net leverage ratio.

The TLA Credit Agreement contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. We were in compliance with all covenants as of June 30, 2024.

Share Repurchases

In October 2023, our Board of Directors approved a share repurchase program (the “October 2023 Repurchase Program”) providing for the repurchase of shares of common stock in an aggregate amount of up to $200,000, excluding commissions and transaction fees. The October 2023 Repurchase Program may be suspended, terminated, or modified at any time for any reason. During the three and six months ended June 30, 2024, no shares of common stock were repurchased and cancelled by the Company under the October 2023 Repurchase Program. As of June 30, 2024, the remaining amount of common stock authorized for repurchases was $150.0 million.

Zynerba Acquisition

In October 2023, we completed a tender offer (the “Tender Offer”) to acquire all of the outstanding shares of common stock of Zynerba (“Zynerba Common Stock”).

Under the terms of the Tender Offer, we paid (i) $1.1059 per share of Zynerba Common Stock (the “Common Cash Amount”), the aggregate amount of which was $60,000 and was paid at closing, plus (ii) one contingent value right (each, a “CVR”) per share of Zynerba Common Stock (the “Common CVR Amount”), which represents the right to receive up to approximately $2.5444 per share of Zynerba Common Stock, subject to the achievement of certain clinical, regulatory and sales-based milestones. The Common CVR Amounts are to be paid in cash, subject to any applicable withholding of taxes and without interest. The aggregate consideration we paid to acquire the Zynerba Common Stock upon completion of the Tender Offer was $60 million, exclusive of transaction related fees. We financed the acquisition with cash on hand.

On July 1, 2024, we announced the change of the name of our wholly owned subsidiary from “Zynerba Pharmaceuticals, Inc.” to “Harmony Biosciences Management, Inc.” As of July 1, 2024, Zynerba Pharmaceuticals, Inc. is now known as Harmony Biosciences Management, Inc.

Epygenix Acquisition

In April 2024, we acquired all of the issued and outstanding capital stock of Epygenix, pursuant to the terms of a stock purchase agreement. In connection with the closing of the transaction, we paid the former stockholders of Epygenix up front consideration of $35.0 million less a working capital adjustment. In addition, we will also be obligated to pay up to $130.0 million upon the achievement of development and regulatory milestones and up to $515.0 million upon the achievement of certain sales-based milestones, in each case to

34

Epygenix’s former stockholders. As a result, the Company now has an exclusive license relating to the use of clemizole, initially for the treatment of DS and LGS.

Asset Purchase Agreement

In August 2021, we entered into an asset purchase agreement with ConSynance Therapeutics, Inc. (the “APA”) to acquire HBS-102, a potential first-in-class molecule with a novel mechanism of action. Under the terms of the APA, we acquired full development and commercialization rights globally, with the exception of Greater China, for $3.5 million. Additionally, there are payments due upon the achievement of certain milestones below, including $1.0 million for additional preclinical milestones (see “Recent Milestone Payments”), $19.0 million for development milestones, $44.0 million for regulatory milestones and $110.0 million for sales milestones.

License Agreements

In April 2024, we entered into a sublicense agreement with Bioprojet for an orexin-2 receptor agonist (OX2R) (the “Licensed Compound”) to be evaluated for the treatment of narcolepsy and other potential indications (the “Sublicense”). Under the Sublicense, the Company obtained the exclusive right to develop, manufacture and commercialize the Licensed Compound in the United States and Latin American territories (the “Licensed Territories”), which are rights that Bioprojet originally licensed from Teijin Pharma, the innovator of the Licensed Compound. The Licensed Compound is currently in pre-clinical development with a Clinical Trial Application currently anticipated in mid-2025. Under the Sublicense, the Company will pay Bioprojet an upfront license fee of $25.5 million and will also be obligated to pay up to $127.5 million upon achievement of development and regulatory milestones and up to $240.0 million upon achievement of sales-based milestones, as well as royalty rates in the mid-teens on potential sales in the Licensed Territories.  

In July 2022, we entered into the 2022 LCA with Bioprojet whereby we obtained exclusive rights to manufacture, develop and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon the agreement of both parties. We paid an initial, non-refundable $30.0 million licensing fee in October 2022 and additional payments of up to $155.0 million are potentially due under the 2022 LCA upon the achievement of certain future development and sales-based milestones. In addition, certain payments will become due upon the achievement of development milestones for new indications and formulations as agreed upon by both parties. The 2022 LCA also includes a fixed trademark royalty and a tiered royalty based on net sales of any new products commercialized, which will be payable to Bioprojet on a quarterly basis.

Recent Milestone Payments

There were no milestones achieved or paid during the three and six months ended June 30, 2024.  

Cash Flows

The following table sets forth a summary of our cash flows for the six months ended June 30, 2024, and 2023:

Six Months Ended June 30, 

    

2024

    

2023

Selected cash flow data

(In thousands)

Cash provided by (used in):

 

  

 

  

Operating activities

$

73,758

$

79,622

Investing activities

 

(61,042)

 

(9,561)

Financing activities

 

(7,080)

 

3,070

35

Operating Activities

Net cash provided by operating activities for the six months ended June 30, 2024, primarily consisted of net income of $49.9 million adjusted for non-cash items of $42.6 million related to acquired IPR&D, $21.4 million related to stock-based compensation expense, and $12.2 million related to intangible amortization and depreciation, offset by $17.8 million related to deferred tax assets. Net working capital excluding cash increased by $34.8 million.

Net cash provided by operating activities for the six months ended June 30, 2023, consisted of net income of $63.8 million adjusted for non-cash items of $7.6 million related to deferred tax assets, $12.1 million related to intangible amortization and depreciation and $14.4 million related to stock-based compensation expense. Net working capital excluding cash decreased by $3.3 million.

Investing Activities

Net cash used in investing activities for the six months ended June 30, 2024, was $61.0 million, which was primarily attributable to $46.3 million in purchases of debt securities, a $25.5 million license fee paid to Bioprojet, $33.1 million net cash consideration paid for the acquisition of Epygenix, and $0.6 million in purchases of property and equipment, partially offset by $44.5 million from maturities of investments.

Net cash used in investing activities for the six months ended June 30, 2023, was $9.6 million, which was primarily attributable to $72.8 million in purchases of debt securities, partially offset by $63.5 million in proceeds from sales and maturities of investments and $0.2 million in purchases of property and equipment.

Financing Activities

Net cash used in financing activities for the six months ended June 30, 2024, was $7.1 million, which primarily consisted of $7.5 million in principal payments associated with the TLA Credit Agreement, partially offset by $0.7 million in proceeds from the exercise of stock options, and $0.3 million of employee withholding tax payments related to stock-based awards.

Net cash provided by financing activities for the six months ended June 30, 2023, was $3.0 million, which primarily consisted of $4.6 million in proceeds from exercised options offset by a $1.0 million principal payment associated with the Blackstone Credit Agreement and $0.5 million of employee withholding tax payments related to stock-based awards.

Critical Accounting Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of expenses during the reporting periods. In accordance with GAAP, we evaluate our estimates and judgments on an ongoing basis.

Significant estimates include assumptions used in the determination of the amount of revenue recognized on sales of WAKIX, costs incurred under services type agreements related to the performance of research and development activities, and the measurement of compensation expense pursuant to stock-based awards. We base our estimates on contractual terms, historical experience, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

36

We define our critical accounting policies as those under GAAP that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. During the quarter covered by this report, there were no material changes to the accounting policies and assumptions previously disclosed, except as disclosed in Note 3 to the unaudited condensed consolidated financial statements contained herein.

Recent Accounting Pronouncements

See Note 3 to our unaudited condensed consolidated financial statements for recent accounting pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Fluctuation Risk

We are exposed to market risk related to changes in interest rates. We invest a portion of our cash in investment-grade, interest-bearing securities. The primary objectives of our investment activities are to preserve principal, maintain liquidity and maximize total return. In order to achieve these objectives, we invest in money market funds, U.S. government and agency securities, corporate bonds and commercial paper in accordance with our investment policy. Our investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of our investments to preserve principal and maintain liquidity. All investment securities have a credit rating of at least A-2/P-2/F2 from at least two National Recognized Statistical Rating Organizations. We do not have any direct investments in asset-backed securities, collateralized debt or loan obligations, or structured investment vehicles. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. Based on our $387.8 million of investments in money market funds, U.S. treasury notes, corporate bonds and municipal obligations as of June 30, 2024, an immediate 10% change in market interest rates would not have a material impact on the fair market value of our investment portfolio or on our financial position or results of operations.

As of June 30, 2024, we had $188.8 million in borrowings outstanding. The Term Loans bear interest at a per annum rate equal to, at our option, (i) a base rate plus a specified margin ranging from 2.50% to 3.00%, based on our senior secured net leverage ratio (as defined in the TLA Credit Agreement) or (ii) Term SOFR plus a credit spread adjustment of 0.10% plus a specified margin ranging from 3.50% to 4.00%, based on our senior secured net leverage ratio. Based on the $188.8 million of principal outstanding as of June 30, 2024, an immediate 10% change in the SOFR would not have a material impact on our debt-related obligations, financial position or results of operations.

Foreign Currency Fluctuation Risk

We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we have contracted with and may continue to contract with foreign vendors that are located in Europe. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.

Inflation Fluctuation Risk

Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations for each of the three months ended June 30, 2024, and 2023.

37

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, including our principal executive officer and our principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of June 30, 2024. Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2024, our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations or financial condition.

ANDA Litigation

On September 27, 2023, we and our licensor, Bioprojet, received notice from Lupin Limited (“Lupin”) pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “Lupin Notice Letter”) that Lupin has submitted ANDA No. 218846 (the “Lupin ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX® before the expiration of U.S. Patent Nos. 8,486,947 (“’947 patent”) and 8,207,197 (“’197 patent”). On September 27, 2023, we and Bioprojet received notice from Novugen Pharma Sdn. Bhd. (“Novugen”) pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “Novugen Notice Letter”) that Novugen has submitted ANDA No. 218834 (the “Novugen ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX® before the expiration of the ’947 patent and ’197 patent. The ’947 patent and the ‘197 patent are listed with respect to WAKIX® in the FDA’s Orange Book and will expire in September 2029 and March 2030, respectively. The Lupin Notice Letter and the Novugen Notice Letter assert that their generic product will not infringe the ’947 patent and the ‘197 patent and/or that the ’947 patent and the ‘197 patent are invalid or unenforceable. On November 9, 2023, we, Bioprojet and Bioprojet’s wholly owned subsidiary, Bioprojet Pharma SAS (“Bioprojet Pharma”), filed a complaint for patent infringement of the ’947

38

patent and the ‘197 patent against Lupin, Novugen and certain of their affiliates and agents in the United States District Court for the District of Delaware in response to the filing of their respective ANDAs with the FDA.

On October 12, 2023, we and Bioprojet received notice from Novitium Pharma LLC (“Novitium”), pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “Novitium Notice Letter”), that Novitium has submitted ANDA No. 218495 (the “Novitium ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX® before the expiration of U.S. Patent No. 8,354,430 (the “’430 patent”), which is also listed with respect to WAKIX® in the FDA’s Orange Book and will expire in February 2026, ’947 patent, and ’197 patent. On October 12, 2023, we and Bioprojet received notice from Zenara Pharma Pvt. Ltd. (“Zenara”), pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “Zenara Notice Letter”), that Zenara has submitted ANDA No. 218796 (the “Zenara ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX® before the expiration of the ’430 patent, ’947 patent and the ’197 patent. On October 14, 2023, we and Bioprojet received notice from AET Pharma US, Inc. (“AET”), pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “AET Notice Letter”), that AET has submitted ANDA No. 218892 (the “AET ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX® before the expiration of the ’947 patent and the ’197 patent. On October 16, 2023, we and Bioprojet received notice from Annora Pharma Private Limited (“Annora”), pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “Annora Notice Letter”), that Annora has submitted ANDA No. 218832 (the “Annora ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX® before the expiration of the ’430 patent, the ’947 patent and the ’197 patent. AET’s Notice Letter asserts that AET’s generic product will not infringe the ’947 patent and the ‘197 patent and/or that ’947 patent and the ‘197 patent are invalid or unenforceable. The Annora Notice Letter asserts that its generic product will not infringe the ‘430 patent, ’947 patent and the ‘197 patent and/or that the ‘430 patent, ’947 patent and the ‘197 patent are invalid or unenforceable. The Novitium Notice Letter asserts that its generic product will not infringe the ‘430 patent, ’947 patent and the ‘197 patent and/or that the ‘430 patent, ’947 patent and the ‘197 patent are invalid or unenforceable. The Zenara Notice Letter asserts that its generic product will not infringe the ‘430 patent, ’947 patent and the ‘197 patent and/or that the ‘430 patent, ’947 patent and the ‘197 patent are invalid or unenforceable. On November 21, 2023, we, Bioprojet and Bioprojet Pharma filed a complaint for patent infringement of the ’947 patent and the ‘197 patent against AET, Annora, Novitium and Zenara and certain of their affiliates and agents and for patent infringement of the ’430 patent against Annora, Novitium and Zenara and certain of their affiliates and agents in the United States District Court for the District of Delaware in response to their filing of their respective ANDAs with the FDA.

In October 2023, MSN Pharmaceuticals Inc. (“MSN Pharma”) sent correspondence to us and Bioprojet stating that MSN Pharma has submitted ANDA No. 218873 (the “MSN ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX®. On December 8, 2023, MSN Laboratories Private Limited (“MSN”) filed a declaratory judgment action in the United States District Court for the Eastern District of Virginia against Bioprojet claiming that the ‘430 patent, the ’947 patent and the ‘197 patent will not be infringed by MSN’s generic version of WAKIX® and that the ‘947 patent is invalid. On December 11, 2023, we, Bioprojet and Bioprojet Pharma filed a complaint in the United States District Court for the District of Delaware for patent infringement of the ‘430 patent, the ’947 patent and the ‘197 patent against MSN and MSN Pharma. On January 12, 2024, the declaratory judgment action was transferred from the United States District Court for the Eastern District of Virginia to the United States District Court for the District of Delaware.

On April 15, 2024, the United States District Court for the District of Delaware issued a scheduling order consolidating the cases described above for all purposes up to and including trial (the “Scheduling Order”). The Scheduling Order set March 27, 2025, as the date for the hearing on claim construction and scheduled a four-day bench trial beginning on February 17, 2026.

39

Item 1A. Risk Factors.

In addition to the other information included in this report, you should carefully consider the discussion of risk factors affecting the Company as set forth in Part I, Item 1A "Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2023, which could materially affect our business, financial condition or future results. The risks described in these reports are not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, and operating results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Rule 10b5-1 Trading Arrangements

During the three months ended June 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.  ​

40

Item 6. Exhibits.

Exhibit

Incorporated by Reference

No.

    

Exhibit Description

    

Form

    

Date

   

Number

2.1+

Agreement and Plan of Merger, dated August 14, 2023, by and among Harmony Biosciences Holdings, Inc., Xylophone Acquisition Corp. and Zynerba Pharmaceuticals, Inc.

8-K/A

September 14, 2023

2.1

3.1

Amended and Restated Certificate of Incorporation of Harmony Biosciences Holdings, Inc.

8-K

August 21, 2020

3.1

3.2

Amended and Restated Bylaws.

8-K

August 21, 2020

3.2

10.1*

Amendment No. 1 to License and Commercialization Agreement, dated July 31, 2022, by and between Bioprojet Société Civile de Recherche and Harmony Biosciences, LLC.

10-Q

April 30, 2024

10.1

10.2*

Amendment No. 2 to License and Commercialization Agreement, dated July 28, 2017, by and between Bioprojet Société Civile de Recherche and Harmony Biosciences, LLC.

10-Q

April 30, 2024

10.2

10.3#

Employment Letter between Harmony Biosciences, LLC, and Kumar Budur, as amended.

8-K

May 3, 2024

10.1

31.1*

Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101*

The following financial statements from the Companys Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 formatted in Inline XBRL: (i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Stockholders Equity and (vi) Notes to Financial Statements, tagged as blocks of text and including detailed tags.

104*

Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101)

*

Filed herewith.

**

Furnished herewith. This certification is deemed furnished, and not filed, with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Harmony Biosciences Holdings, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

+

Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 for any schedules so furnished.

#

Indicates management contract or compensatory plan or arrangement.

41

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HARMONY BIOSCIENCES HOLDINGS, INC.

By:

/s/ Jeffrey M. Dayno

Name:

 

Jeffrey M. Dayno

Title:

President, Chief Executive Officer and Director (principal executive officer)

Date:

 

August 6, 2024

By:

 

/s/ Sandip Kapadia

Name:

 

Sandip Kapadia

Title:

Chief Financial Officer and Chief Administrative Officer (principal financial officer)

Date:

 

August 6, 2024

42

EX-31.1 2 hrmy-20240630xex31d1.htm EX-31.1

Exhibit 31.1

Certification of Principal Executive Officer

I, Jeffrey M. Dayno, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of Harmony Biosciences Holdings, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 6, 2024

By:

/s/ Jeffrey M. Dayno

Jeffrey M. Dayno

President, Chief Executive Officer and Director

(Principal Executive Officer)


EX-31.2 3 hrmy-20240630xex31d2.htm EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer

I, Sandip Kapadia, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of Harmony Biosciences Holdings, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and

5.

The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.

Date: August 6, 2024

By:

/s/ Sandip Kapadia

Sandip Kapadia

Chief Financial Officer and Chief Administrative Officer

(Principal Financial Officer and Principal Accounting Officer)


EX-32.1 4 hrmy-20240630xex32d1.htm EX-32.1

Exhibit 32.1

Certification of Principal Executive Officer

Pursuant To 18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of The Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Harmony Biosciences Holdings, Inc. (the “Company”) for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer’s knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 6, 2024

By:

/s/ Jeffrey M. Dayno

Jeffrey M. Dayno

President, Chief Executive Officer and Director

(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as a part of the Report or on a separate disclosure document.


EX-32.2 5 hrmy-20240630xex32d2.htm EX-32.2

Exhibit 32.2

Certification of Principal Financial Officer

Pursuant To 18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of The Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Harmony Biosciences Holdings, Inc. (the “Company”) for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer’s knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 6, 2024

By:

/s/ Sandip Kapadia

Sandip Kapadia

Chief Financial Officer and Chief Administrative Officer

(Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as a part of the Report or on a separate disclosure document.


EX-101.SCH 6 hrmy-20240630.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - ACQUISITIONS - Purchase Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 99940403 - Disclosure - ACQUISITIONS - Net Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Debt - Balances of Long-term Debt, Net (Details) calc 2 link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - LEASES - Future payments (Details) (Calc2) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 99941102 - Disclosure - DEBT - Balances of Long-term Debt, Net (Details) link:presentationLink link:calculationLink link:definitionLink 99941103 - Disclosure - DEBT - Future Minimum Payments (Details) link:presentationLink link:calculationLink link:definitionLink 99941104 - Disclosure - DEBT - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99941202 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941204 - Disclosure - LEASES - Future Payments (Details) link:presentationLink link:calculationLink link:definitionLink 99941701 - Disclosure - INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES (Details) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - ACQUISITIONS (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - DEBT - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 99941401 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 99941501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details) link:presentationLink link:calculationLink link:definitionLink 99941504 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details) link:presentationLink link:calculationLink link:definitionLink 99941505 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details) link:presentationLink link:calculationLink link:definitionLink 99941506 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99941603 - Disclosure - EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 99941801 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 995211501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 995211601 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 995211701 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 995211801 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 99920302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 99931503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 99931603 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 99931703 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 99941203 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941502 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 99941601 - Disclosure - EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details) link:presentationLink link:calculationLink link:definitionLink 99941602 - Disclosure - EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 hrmy-20240630_cal.xml EX-101.CAL EX-101.DEF 8 hrmy-20240630_def.xml EX-101.DEF EX-101.LAB 9 hrmy-20240630_lab.xml EX-101.LAB EX-101.PRE 10 hrmy-20240630_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2024
Aug. 02, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2024  
Document Transition Report false  
Entity File Number 001-39450  
Entity Registrant Name HARMONY BIOSCIENCES HOLDINGS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 82-2279923  
Entity Address, Postal Zip Code 19462  
Entity Address, Address Line One 630 W.  
Entity Address, Address Line Two Germantown Pike  
Entity Address, Address Line Three Suite 215  
Entity Address, City or Town Plymouth Meeting  
Entity Address, State or Province PA  
City Area Code 484  
Local Phone Number 539-9800  
Title of 12(b) Security Common Stock, par value $0.00001 value per share  
Trading Symbol HRMY  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   56,834,745
Entity Central Index Key 0001802665  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --12-31  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
CURRENT ASSETS:    
Cash and cash equivalents $ 317,296 $ 311,660
Investments, short-term 29,614 41,800
Trade receivables, net 83,157 74,140
Inventory, net 5,643 5,363
Prepaid expenses 16,127 12,570
Other current assets 6,507 5,537
Total current assets 458,344 451,070
NONCURRENT ASSETS:    
Property and equipment, net 754 371
Restricted cash 270 270
Investments, long-term 87,178 72,169
Intangible assets, net 125,186 137,108
Deferred tax asset 180,186 144,162
Other noncurrent assets 6,465 6,298
Total noncurrent assets 400,039 360,378
TOTAL ASSETS 858,383 811,448
CURRENT LIABILITIES:    
Trade payables 22,683 17,730
Accrued compensation 9,641 23,747
Accrued expenses 91,644 99,494
Current portion of long-term debt 15,000 15,000
Other current liabilities 7,614 7,810
Total current liabilities 146,582 163,781
NONCURRENT LIABILITIES:    
Long-term debt, net 171,422 178,566
Other noncurrent liabilities 1,796 2,109
Total noncurrent liabilities 173,218 180,675
TOTAL LIABILITIES 319,800 344,456
COMMITMENTS AND CONTINGENCIES (Note 13)
STOCKHOLDERS' EQUITY:    
Common stock-$0.00001 par value; 500,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively; 56,833,771 and 56,769,081 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 1 1
Additional paid in capital 632,168 610,266
Accumulated other comprehensive (loss) income (234) 2
Accumulated deficit (93,352) (143,277)
TOTAL STOCKHOLDERS' EQUITY 538,583 466,992
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 858,383 $ 811,448
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2024
Dec. 31, 2023
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS    
Common stock, par value $ 0.00001 $ 0.00001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 56,833,771 56,769,081
Common stock, shares outstanding 56,833,771 56,769,081
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME        
Net product revenue $ 172,814 $ 134,216 $ 327,429 $ 253,342
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember
Cost of product sold $ 32,144 $ 25,008 $ 59,628 $ 45,788
Cost, Product and Service [Extensible Enumeration] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember
Gross profit $ 140,670 $ 109,208 $ 267,801 $ 207,554
Operating expenses:        
Research and development 63,583 14,969 85,772 28,258
Sales and marketing 28,507 24,528 55,740 47,100
General and administrative 27,224 22,809 52,900 44,871
Total operating expenses 119,314 62,306 194,412 120,229
Operating income 21,356 46,902 73,389 87,325
Other (expense) income, net 37 (31) (104) (29)
Interest expense (4,404) (6,218) (8,939) (11,949)
Interest income 4,705 3,442 9,133 6,528
Income before income taxes 21,694 44,095 73,479 81,875
Income tax expense (10,103) (9,795) (23,554) (18,090)
Net income 11,591 34,300 49,925 63,785
Unrealized (loss) income on investments (63) (491) (236) (371)
Comprehensive income $ 11,528 $ 33,809 $ 49,689 $ 63,414
EARNINGS PER SHARE:        
Basic $ 0.20 $ 0.57 $ 0.88 $ 1.07
Diluted $ 0.20 $ 0.56 $ 0.87 $ 1.05
Weighted average number of shares of common stock - basic 56,802,357 59,974,123 56,786,873 59,853,808
Weighted average number of shares of common stock - diluted 57,541,696 60,743,953 57,571,570 60,997,410
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Total
Beginning balance at Dec. 31, 2022 $ 1 $ 675,118 $ (151) $ (272,130) $ 402,838
Beginning balance, shares at Dec. 31, 2022 59,615,731        
Net Income (Loss)       63,785 63,785
Unrealized loss on investments     (371)   (371)
Exercise of stock options   4,069     4,069
Exercise of stock options , Shares 383,927        
Stock-based compensation   14,851     14,851
Ending balance at Jun. 30, 2023 $ 1 694,038 (522) (208,345) 485,172
Ending balance, shares at Jun. 30, 2023 59,999,658        
Beginning balance at Mar. 31, 2023 $ 1 685,716 (31) (242,645) 443,041
Beginning balance, shares at Mar. 31, 2023 59,954,618        
Net Income (Loss)       34,300 34,300
Unrealized loss on investments     (491)   (491)
Exercise of stock options   674     674
Exercise of stock options , Shares 45,040        
Stock-based compensation   7,648     7,648
Ending balance at Jun. 30, 2023 $ 1 694,038 (522) (208,345) 485,172
Ending balance, shares at Jun. 30, 2023 59,999,658        
Beginning balance at Dec. 31, 2023 $ 1 610,266 2 (143,277) 466,992
Beginning balance, shares at Dec. 31, 2023 56,769,081        
Net Income (Loss)       49,925 49,925
Unrealized loss on investments     (236)   (236)
Exercise of options and restricted stock units   420     $ 420
Exercise of options and restricted stock units, Shares 64,690        
Exercise of stock options , Shares         46,996
Stock-based compensation   21,482     $ 21,482
Ending balance at Jun. 30, 2024 $ 1 632,168 (234) (93,352) 538,583
Ending balance, shares at Jun. 30, 2024 56,833,771        
Beginning balance at Mar. 31, 2024 $ 1 620,507 (171) (104,943) 515,394
Beginning balance, shares at Mar. 31, 2024 56,791,214        
Net Income (Loss)       11,591 11,591
Unrealized loss on investments     (63)   (63)
Exercise of stock options   573     573
Exercise of stock options , Shares 42,557        
Stock-based compensation   11,088     11,088
Ending balance at Jun. 30, 2024 $ 1 $ 632,168 $ (234) $ (93,352) $ 538,583
Ending balance, shares at Jun. 30, 2024 56,833,771        
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income $ 49,925 $ 63,785
Adjustments to reconcile net income to net cash used in operating activities:    
Depreciation 254 206
Intangible amortization 11,922 11,922
Acquired in-process research & development (IPR&D) expense 42,595  
Stock-based and employee stock purchase compensation expense 21,482 14,851
Stock appreciation rights market adjustment (85) (497)
Debt issuance costs amortization 356 840
Deferred taxes (17,756) (7,635)
Amortization of premiums and accretion of discounts on Investment securities (1,220) (1,312)
Other non-cash expenses 1,126 799
Change in operating assets and liabilities:    
Trade receivables (9,017) (9,072)
Inventory (280) (557)
Prepaid expenses and other assets (4,004) 2,227
Trade payables 3,555 2,777
Other liabilities (25,095) 1,288
Net cash provided by operating activities 73,758 79,622
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of investment securities (46,317) (72,847)
Proceeds from maturities and sales of investment securities 44,481 63,491
Purchase of property and equipment (637) (205)
Acquisition of Zynerba Pharmaceuticals, Inc., net of cash acquired (33,069)  
Payment of license fee (25,500)  
Net cash used in investing activities (61,042) (9,561)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Principal repayment of long term debt (7,500) (1,000)
Payments of employee withholding taxes related to stock-based awards (269) (514)
Proceeds from exercised options 689 4,584
Net cash (used in) provided by financing activities (7,080) 3,070
NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH 5,636 73,131
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-Beginning of period 311,930 244,534
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-End of period 317,566 317,665
Supplemental Disclosure of Cash Flow Information:    
Cash paid during the year for interest 8,944 10,691
Cash paid during the year for taxes $ 42,093 $ 19,890
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ORGANIZATION AND DESCRIPTION OF BUSINESS
6 Months Ended
Jun. 30, 2024
ORGANIZATION AND DESCRIPTION OF BUSINESS  
ORGANIZATION AND DESCRIPTION OF BUSINESS

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

The Company

Harmony Biosciences Holdings, Inc., and its consolidated subsidiaries (the “Company”), was founded in July 2017 as Harmony Biosciences II, LLC, a Delaware limited liability company. The Company converted to a Delaware corporation named Harmony Biosciences II, Inc. in September 2017 and, in February 2020, the Company changed its name to Harmony Biosciences Holdings, Inc. The Company’s operations are conducted in its wholly owned subsidiaries, Harmony Biosciences, LLC (“Harmony”), and Harmony Biosciences Management, Inc. The Company is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders as well as patients living with other neurological diseases who have unmet medical needs. The Company is headquartered in Plymouth Meeting, Pennsylvania.

On October 10, 2023, the Company completed a tender offer to acquire all of the outstanding shares of common stock of Zynerba Pharmaceuticals, Inc. (together with its subsidiary, Zynerba Pharmaceutical Pty, Ltd., “Zynerba”). Zynerba is a clinical-stage pharmaceutical company focused on innovative pharmaceutically produced transdermal cannabidiol therapies for orphan neurobehavioral disorders, including Fragile X Syndrome. As of July 1, 2024, Zynerba was renamed and is known as Harmony Biosciences Management, Inc.

On April 30, 2024, the Company acquired all of the issued and outstanding capital stock of Epygenix Therapeutics, Inc., a Wyoming corporation (“Epygenix”). As a result, the Company now has an exclusive license relating to the use of clemizole, initially for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LIQUIDITY AND CAPITAL RESOURCES
6 Months Ended
Jun. 30, 2024
LIQUIDITY AND CAPITAL RESOURCES  
LIQUIDITY AND CAPITAL RESOURCES

2. LIQUIDITY AND CAPITAL RESOURCES

The unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $93,352 and $143,277, as of June 30, 2024, and December 31, 2023, respectively. As of June 30, 2024, the Company had cash, cash equivalents and investments of $434,088.

The Company believes that its existing cash, cash equivalents and investments on hand as of June 30, 2024, as well as additional cash generated from operating and financing activities will meet its operational liquidity needs and fund its planned investing activities for the next twelve months from the date of issuance of these unaudited condensed consolidated financial statements.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated balance sheet as of June 30, 2024, the unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2024, and 2023, and the unaudited condensed consolidated statements of operations and comprehensive income and the unaudited condensed consolidated statements of shareholders’ equity for the three and six months ended June 30, 2024, and 2023, are unaudited. The

balance sheet as of December 31, 2023, was derived from audited financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2024, and the results of its operations and its cash flows for the three and six months ended June 30, 2024, and 2023. The unaudited condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Reclassifications

Certain prior period amounts within the unaudited condensed consolidated statements of operations and comprehensive income have been reclassified to conform to current period presentation. In particular, interest expense and interest income were previously classified together as interest expense, net and are now separately classified as interest expense and interest income, respectively. The reclassification of these items had no impact on net income, earnings per share or accumulated deficit in current or prior periods.

Significant Risks and Uncertainties

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, clinical trial results of the Company’s product candidates; the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products, if approved; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates.

The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company’s research and development efforts will result in successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes.

Operating Segments

The Company holds all its tangible assets, conducts its operations, and generates its revenue in the United States. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.

Fair Value of Financial Instruments

The Company’s unaudited condensed consolidated financial statements include cash, cash equivalents, restricted cash, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value.

It is the Company’s policy to measure non-financial assets and liabilities at fair value on a nonrecurring basis. These non-financial assets and liabilities are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes.

The Company measures certain assets and liabilities at fair value based on the fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

Money market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of June 30, 2024, or December 31, 2023.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents and restricted cash consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds and debt securities that approximate fair value. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.

    

As of

    

June 30, 

    

December 31, 

2024

2023

Cash and cash equivalents

$

317,296

$

311,660

Restricted cash

 

270

 

270

Total cash, cash equivalents, and restricted cash shown in the statements of cash flows

$

317,566

$

311,930

Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program.

Investments

The Company’s investments consist of debt securities that are classified as available-for-sale. Short-term and long-term investments are carried at fair value and unrealized gains and losses are recorded as a

component of accumulated comprehensive income in stockholders’ equity. Interest income earned on cash and investment balances, accretion of the discount on investments in debt securities, amortization of premiums and realized gains and losses, if any, are recorded in interest income on the unaudited condensed consolidated statement of operations and comprehensive income. Realized gains and losses that result from the sale of investments are determined on a specific identification basis.

At each reporting period, the Company reviews any unrealized losses position to determine if the decline in the fair value of the underlying investments is a result of credit losses or other factors. If the assessment indicates that a credit loss exists, any impairment is recognized as an allowance for credit losses in our consolidated statement of operations.

Concentrations of Risk

Substantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of June 30, 2024, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 41% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 35% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 24% of gross accounts receivable. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 39% of gross accounts receivable, CVS Caremark, which accounted for 32% of gross accounts receivable; and Pantherx, which accounted for 29% of gross accounts receivable.

For the six months ended June 30, 2024, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 40% of gross product revenue; Accredo accounted for 33% of gross product revenue; and Pantherx accounted for 27% of gross product revenue. For the six months ended June 30, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 35% of gross product revenue; Pantherx accounted for 33% of gross product revenue; and Accredo accounted for 32% of gross product revenue.

The Company depends on a single supplier for its product and a single supplier for its active pharmaceutical ingredient.

Share Repurchases

The Company accounts for share repurchases as constructive retirements, whereby it reduces common stock and additional paid-in capital by the amount of the original issuance, with any excess purchase price recorded as a reduction to retained earnings. Under this method, issued and outstanding shares of common stock are reduced by the amount of shares of common stock repurchased, and no treasury stock is recognized on the condensed consolidated financial statements.

Business Combinations

Business combinations and asset acquisitions are accounted for in accordance with FASB ASC 805 Business Combinations. Refer to Note 4, Acquisitions, for a more detailed discussion of the Company’s acquisitions of Zynerba and Epygenix.

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This ASU is effective for annual reporting periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 is required to be applied retrospectively to all prior periods presented in the financial statements. The Company has one reportable segment and is currently evaluating the impact that ASU 2023-07 will have on its condensed consolidated financial statements.

In December 2023, the FASB issued Accounting Standards Update (“ASU”) No 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 expands disclosures in the rate reconciliation and requires disclosure of income taxes paid by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its condensed consolidated financial statements.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ACQUISITIONS
6 Months Ended
Jun. 30, 2024
ACQUISITIONS  
ACQUISITIONS

4. ACQUISITIONS

Acquisition of Zynerba

In October 2023, the Company completed a tender offer to purchase the outstanding common stock of Zynerba (“Zynerba Common Stock”) for (i) $1.1059 per share of Zynerba Common Stock (the “Common Cash Amount”), the aggregate amount of which was $60,000 and was paid at closing, plus (ii) one contingent value right (each, a “CVR”) per share of Zynerba Common Stock (the “Common CVR Amount”), which represents the right to receive up to approximately $2.5444 per share of Zynerba Common Stock, subject to the achievement of certain clinical, regulatory and sales-based milestones. The Common CVR Amounts are to be paid in cash, subject to any applicable withholding of taxes and without interest. The aggregate amount of consideration to acquire Zynerba Common Stock was $60,000, excluding transaction related fees of $2,645 and was paid by the Company using cash on hand.

The Zynerba Acquisition was accounted for as an asset acquisition under ASC Topic 805, Business Combinations, because substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable IPR&D asset, ZYN002, Zynerba’s lead asset. ZYN002 is the first and only pharmaceutically manufactured, synthetic cannabidiol, devoid of THC, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system and is currently in Phase III clinical trial for the potential treatment of Fragile X Syndrome. The Company recognized the acquired assets and assumed liabilities based on the consideration paid, including transaction costs, on a relative fair value basis, and after first allocating the preliminary excess of the fair value of net assets acquired over the purchase price consideration to certain qualifying assets, principally, the IPR&D asset.

Acquisition of Epygenix

On April 30, 2024, the Company acquired all of the issued and outstanding capital stock of Epygenix pursuant to the terms of a stock purchase agreement. In connection with the closing of the transaction, the Company paid the former stockholders of Epygenix up front consideration of $35,000 less a working capital

adjustment. In addition, the Company will be obligated to pay up to $130,000 upon the achievement of development and regulatory milestones and up to $515,000 upon the achievement of certain sales-based milestones, in each case to Epygenix’s former stockholders. As a result, the Company now has an exclusive license relating to the use of clemizole, initially for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.

The total purchase consideration for Epygenix was as follows:

Cash consideration paid to selling shareholders and to settle restricted stock units ("RSUs")

$

32,686

Transaction costs

450

Total purchase consideration

$

33,136

The acquisition of Epygenix was accounted for as an asset acquisition under ASC Topic 805, Business Combinations. The Company did not acquire any outputs and there was not an acquired substantive process in place to create outputs. The Company recognized the acquired assets and assumed liabilities based on the consideration paid, including transaction costs, on a relative fair value basis, and after first allocating the preliminary excess of the fair value of net assets acquired over the purchase price consideration to certain qualifying assets, principally, the IPR&D asset. In accordance with the accounting for asset acquisitions, an entity that acquires IPR&D assets in an asset acquisition follows the guidance in ASC Topic 730, Research and Development, which requires that both tangible and intangible identifiable research and development assets with no alternative future use be allocated a portion of the consideration transferred and recorded as research and development expense at the acquisition date. As a result, the Company recorded a charge of $17,095 related to acquired in-process research and development expense during the three and six months ended June 30, 2024.

The following table shows the allocation of the purchase consideration based on the relative fair value of assets acquired and liabilities assumed by the Company, after reducing the excess fair value of the IPR&D asset as described above:

Assets acquired

Acquired in-process research and development

$

17,095

Deferred tax asset

18,268

Other assets

590

Total assets acquired

$

35,953

Total liabilities assumed

$

2,817

Net assets acquired

$

33,136

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INVESTMENTS
6 Months Ended
Jun. 30, 2024
INVESTMENTS  
INVESTMENTS

5. INVESTMENTS

The carrying value and amortized cost of the Company’s available-for-sale debt securities, summarized by type of security, consisted of the following:

June 30, 2024

Amortized

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

Short-term:

Commercial paper

$

16,175

1

(5)

$

16,171

Corporate debt securities

13,443

4

(4)

13,443

Total short-term investments

$

29,618

5

(9)

$

29,614

Long-term:

Corporate debt securities

59,793

37

(87)

59,743

U.S. government securities

27,615

(180)

27,435

Total long-term investments

$

87,408

37

(267)

$

87,178

December 31, 2023

Amortized

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

Short-term:

Commercial paper

$

23,832

36

(3)

$

23,865

Corporate debt securities

15,968

28

15,996

U.S. government securities

1,940

(1)

1,939

Total short-term investments

$

41,740

64

(4)

$

41,800

Long-term:

Commercial paper

$

744

$

744

Corporate debt securities

42,688

81

(28)

42,741

U.S. government securities

28,795

7

(118)

28,684

Total long-term investments

$

72,227

88

(146)

$

72,169

The Company classifies investments with an original maturity of less than one year as current and investments with an original maturity date of greater than one year as noncurrent on its unaudited condensed consolidated balance sheet. The investments classified as noncurrent have original maturity dates ranging from 1-2 years. The Company did not have any available-for-sale debt security investments in a continuous unrealized loss position of greater than 12 months as of June 30, 2024, and December 31, 2023, respectively.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1
FAIR VALUE MEASUREMENTS
6 Months Ended
Jun. 30, 2024
FAIR VALUE MEASUREMENTS  
FAIR VALUE MEASUREMENTS

6. FAIR VALUE MEASUREMENTS

Money market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of June 30, 2024, or December 31, 2023.

The Company’s assets measured at fair value consisted of the following:

June 30, 2024

December 31, 2023

Total

Level 1

Level 2

Total

Level 1

Level 2

Assets

Cash equivalents

$

270,989

270,989

$

244,569

243,685

884

Commercial paper

16,171

16,171

24,609

24,609

Corporate debt securities

73,186

73,186

58,737

58,737

U.S. government securities

27,435

27,435

30,623

30,623

Total

$

387,781

270,989

116,792

$

358,538

243,685

114,853

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INVENTORY
6 Months Ended
Jun. 30, 2024
INVENTORY  
INVENTORY

7. INVENTORY

Inventory, net consisted of the following:

    

As of

    

June 30, 

    

December 31, 

2024

2023

Raw materials

$

1,135

$

1,060

Work in process

 

1,744

 

2,020

Finished goods

 

2,764

 

2,283

Total inventory, net

$

5,643

$

5,363

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INTANGIBLE ASSETS
6 Months Ended
Jun. 30, 2024
INTANGIBLE ASSETS  
INTANGIBLE ASSETS

8. INTANGIBLE ASSETS

In August 2019, the Company received FDA approval of WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (“EDS”) in adult patients with narcolepsy. This event triggered a milestone payment of $75,000 under the provisions of the 2017 LCA (defined below) which the Company capitalized as an intangible asset. The Company determined a useful life of 10 years for such intangible asset, and, as of June 30, 2024, the remaining useful life was 5.3 years.

In October 2020, the Company received FDA approval for the New Drug Application (“NDA”) for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. This event triggered a milestone payment of $100,000 under the provisions of the 2017 LCA which the Company capitalized as an intangible asset and paid in January of 2021. The Company determined a useful life of 9 years for such intangible asset, and, as of June 30, 2024, the remaining useful life was 5.3 years.

In February 2022, the Company attained $500,000 in life-to-date aggregate net sales of WAKIX in the United States. This event triggered a final $40,000 payment under the provisions of the 2017 LCA which the Company capitalized as an intangible asset and paid in March of 2022. The Company determined a useful life of 7.6 years for such intangible asset, and, as of June 30, 2024, the remaining useful life was 5.3 years.

Amortization expense was $5,961 for each of the three months ended June 30, 2024, and 2023, respectively, and $11,922 for each of the six months ended June 30, 2024, and 2023, respectively, and is recorded in general and administrative on the unaudited condensed consolidated statements of operations and comprehensive income.

The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:

Years ending December 31, 

    

2024 (excluding the six months ended June 30, 2024)

$

11,923

2025

 

23,845

2026

 

23,845

2027

 

23,845

2028

 

23,845

Thereafter

17,883

Total

$

125,186

The gross carrying amount and net book value of the intangible asset is as follows:

    

As of

    

June 30, 

    

December 31, 

2024

2023

Gross Carrying Amount

$

215,000

$

215,000

Accumulated Amortization

 

(89,814)

 

(77,892)

Net Book Value

$

125,186

$

137,108

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS
6 Months Ended
Jun. 30, 2024
LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS  
LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS

9. LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS

License Agreements

In July 2017, Harmony entered into a License Agreement (the “2017 LCA”) with Bioprojet Société Civile de Recherche (“Bioprojet”) whereby Harmony acquired the exclusive right to commercialize the pharmaceutical compound pitolisant for the treatment, and/or prevention, of narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, and Parkinson’s disease as well as any other indications unanimously agreed by the parties in the United States and its territories. A milestone payment of $50,000 was due upon acceptance by the FDA of pitolisant’s NDA, which was achieved in February 2019 and was expensed within research and development for the year ended December 31, 2019. A milestone payment of $77,000, which included a $2,000 fee that is described below, was due upon FDA approval of WAKIX (pitolisant) for treatment of EDS in adult patients with narcolepsy, which was achieved in August 2019. The $2,000 payment and $75,000 milestone payment were paid in August and November 2019, respectively. In addition, a milestone payment of $102,000, which included a $2,000 fee was due upon the FDA approval of the NDA for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. The $2,000 payment was paid in October 2020 and a $100,000 milestone payment was paid in January 2021. A final $40,000 milestone payment was paid to Bioprojet in March 2022 upon WAKIX attaining $500,000 in aggregate net sales in the United States. The 2017 LCA also requires a fixed trademark royalty and a tiered royalty based on net sales, which is payable to Bioprojet on a quarterly basis. The Company incurred $30,199 and $22,542 for the three months ended June 30, 2024, and 2023, respectively, and $54,937 and $41,602 for the six months ended June 30, 2024, and 2023, respectively, for sales-based, trademark and tiered royalties recognized as cost of product sold. As of June 30, 2024, and December 31, 2023, the Company had accrued $30,199 and $40,419, respectively, for sales-based, trademark and tiered royalties.  

In July 2022, Harmony entered into a License and Commercialization Agreement (the “2022 LCA”) with Bioprojet whereby Harmony obtained exclusive rights to manufacture, use and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon agreement of both parties. Harmony paid an initial, non-refundable $30,000 licensing fee in October 2022 and additional payments of up to $155,000 are potentially due under the 2022 LCA upon the achievement of certain future development and sales-based milestones. In addition, there are other payments due upon achievement of development milestones for new indications and formulations as agreed upon by both parties. The 2022 LCA also requires a fixed trademark royalty and a tiered royalty based on net sales upon commercialization, which will be payable to Bioprojet on a quarterly basis.

In April 2024, the Company announced that it entered into a sublicense agreement with Bioprojet for an orexin-2 receptor agonist (OX2R) (the “Licensed Compound”) to be evaluated for the treatment of narcolepsy and other potential indications (the “Sublicense”). Under the Sublicense, the Company obtained the exclusive right to develop, manufacture and commercialize the Licensed Compound in the United States and Latin American territories (the “Licensed Territories”), which are rights that Bioprojet originally licensed from Teijin Pharma, the innovator of the Licensed Compound. The Licensed Compound is currently in pre-clinical development with a Clinical Trial Application currently anticipated in mid-2025. Under the Sublicense, the Company paid Bioprojet an upfront license fee of $25,500, which the Company recognized as an IPR&D charge recorded in research and development within the unaudited condensed consolidated statements of operations and comprehensive income for the three and six months ended June 30, 2024, and will also be obligated to pay up to $127,500 upon achievement of development and regulatory milestones and up to $240,000 upon

achievement of sales-based milestones, as well as royalty rates in the mid-teens on any sales of product using the Licensed Compound in the Licensed Territories.

Agreement Related to Intellectual Property

In August 2021, the Company entered into an asset purchase agreement with ConSynance Therapeutics, Inc. (the “APA”) to acquire HBS-102 (formerly referred to as “CSTI-100”), a potential first-in-class molecule with a novel mechanism of action. Under the terms of the APA, the Company acquired full development and commercialization rights globally, with the exception of Greater China, for $3,500. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identified asset. In March 2023, the Company achieved a preclinical milestone, which triggered a $750 payment under the provisions of the APA, which the Company recognized as an IPR&D charge recorded in research and development within the unaudited condensed consolidated statement of operations and comprehensive income for the six months ended June 30, 2023. There are additional payments due under the APA upon the achievement of certain milestones including $1,000 for preclinical milestones, $19,000 for development milestones, $44,000 for regulatory milestones and $110,000 for sales milestones.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ACCRUED EXPENSES
6 Months Ended
Jun. 30, 2024
ACCRUED EXPENSES  
ACCRUED EXPENSES

10. ACCRUED EXPENSES

Accrued expenses consist of the following:

    

As of

    

June 30, 

    

December 31, 

2024

2023

Royalties due to Bioprojet

$

30,199

$

40,419

Rebates and other sales deductions

 

43,570

 

38,842

Interest

2,993

3,354

Sales and marketing

 

3,343

 

2,354

Research and development

 

7,201

 

9,835

Professional fees, consulting, and other services

 

2,053

 

2,195

Other expenses

 

2,285

 

2,495

$

91,644

$

99,494

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEBT
6 Months Ended
Jun. 30, 2024
DEBT  
DEBT

11. DEBT

Term Loan A Credit Agreement

In July 2023, the Company entered into a Credit Agreement (the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as “Administrative Agent”, and certain lenders. The TLA Credit Agreement provides for a five-year senior secured term loan (the “TLA Term Loan”) in an aggregate principal amount of $185,000.

In September 2023, the Company entered into the First Incremental Amendment (the “First Incremental Amendment”) with the Administrative Agent and Bank of America, N.A., as incremental lender. The First Incremental Amendment provides for an incremental senior secured term loan (the “Incremental Term Loan”) in an aggregate principal amount of $15,000. The First Incremental Amendment amends the TLA Credit Agreement and provides that the Incremental Term Loan will have identical terms as the TLA Term Loan.

The repayment schedule for both the TLA Term Loan and the Incremental Term Loan (together, the “Term Loans”) consists of quarterly $3,750 principal payments, which commence on December 31, 2023, increasing to quarterly $5,000 principal payments beginning on December 31, 2025, with a $115,000 payment due on the maturity date of July 26, 2028. The Term Loans bear interest at a per annum rate equal to, at the Company’s option, (i) a base rate plus a specified margin ranging from 2.50% to 3.00%, based on the

Company’s senior secured net leverage ratio (as defined in the TLA Credit Agreement) or (ii) Term SOFR plus a credit spread adjustment of 0.10% plus a specified margin ranging from 3.50% to 4.00%, based on the Company’s senior secured net leverage ratio.

The net cash received related to the Term Loans as a result of the transactions, less debt issuance costs of $2,997, was $197,003. The debt issuance costs related to the Term Loans will be amortized as additional interest expense over the loan term of the TLA Credit Agreement. The fair value of the Term Loans as of June 30, 2024, was $187,863.

Long-term debt, net consists of the following:

    

June 30, 

    

December 31, 

2024

2023

Principal amount

$

188,750

$

196,250

Unamortized debt discount associated with debt financing costs

 

(2,328)

 

(2,684)

Total debt, net

186,422

193,566

Less current portion

(15,000)

(15,000)

Long-term debt, net

$

171,422

$

178,566

Future minimum payments relating to total debt, net as of June 30, 2024, for the periods indicated below consists of the following:

Years ending December 31, 

2024 (excluding the six months ended June 30, 2024)

$

7,500

2025

 

16,250

2026

 

20,000

2027

 

20,000

2028

 

125,000

Thereafter

Total

$

188,750

Interest expense related to the Company’s long-term debt, net, is included in interest expense within the unaudited condensed consolidated statements of operations and comprehensive income and consists of the following:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

2024

    

2023

2024

    

2023

Interest on principal balance

$

4,228

$

5,794

$

8,583

$

11,109

Amortization of deferred financing costs

 

176

 

424

 

356

 

840

Total term loan interest expense

$

4,404

$

6,218

$

8,939

$

11,949

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES
6 Months Ended
Jun. 30, 2024
LEASES  
LEASES

12. LEASES

In June 2018, the Company entered into an operating lease for approximately fifteen thousand square feet of office space in Plymouth Meeting, PA, which expires in May 2024. The Company subsequently entered into two separate operating leases for additional office space in Plymouth Meeting, PA, which include approximately thirteen thousand square feet and seven thousand square feet of additional office space, respectively, and expire in May 2024. In March 2024, the Company amended its existing operating leases for office space in Plymouth Meeting to extend their terms through June 2025. The terms of the lease payments provide for rental payments on a monthly basis and on a graduated scale. The Company also leases a fleet of automobiles that are used by its sales representatives and are classified as operating leases.

Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future lease payments using our incremental borrowing rate. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Our leases have remaining lease terms of less than 1 year to 3 years, some of which may include the option to extend or terminate the leases.

The Company recorded operating lease costs of $622 and $444 for the three months ended June 30, 2024, and 2023, respectively and $1,131 and $822 for the six months ended June 30, 2024, and 2023, respectively.

As of June 30, 2024, the weighted-average remaining lease term for operating leases was 1.7 years and the weighted-average discount rate for operating leases was 7.56%.

Supplemental balance sheet information related to operating leases was as follows:

Leases

Classification

June 30, 2024

  

December 31, 2023

Assets

Operating lease right-of-use assets

Other noncurrent assets

$

2,508

$

2,344

Liabilities

Operating lease liability, current portion

Other current liabilities

$

1,786

$

1,437

Operating lease liability, long-term

Other long-term liabilities

854

1,082

Total operating lease liabilities

$

2,640

$

2,519

Supplemental cash flow information related to operating leases was as follows:

June 30, 2024

June 30, 2023

Operating cash flows from operating leases

$

1,075

$

922

Right of use assets obtained in exchange for operating lease obligations

$

1,254

$

615

Future payments under noncancelable operating leases with initial terms of one year or more as of June 30, 2024, consisted of the following:

Years ending December 31, 

    

2024 (excluding the six months ended June 30, 2024)

$

1,047

2025

 

1,250

2026

 

495

2027

 

12

2028

 

Thereafter

 

Total lease payments

2,804

Less: imputed interest

(164)

Total lease liabilities

$

2,640

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2024
COMMITMENTS AND CONTINGENCIES.  
COMMITMENTS AND CONTINGENCIES

13. COMMITMENTS AND CONTINGENCIES

Litigation

From time to time, the Company is subject to claims and suits arising in the ordinary course of business. The Company accrues such liabilities when they are known, if they are deemed probable and can be reasonably estimated. As of June 30, 2024, there were no material claims or suits outstanding.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS' EQUITY
6 Months Ended
Jun. 30, 2024
STOCKHOLDERS' EQUITY  
STOCKHOLDERS' EQUITY

14. STOCKHOLDERS’ EQUITY

Common Stock

The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the Company’s stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive any dividends declared by the Company’s board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. The Company’s common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.

Share Repurchase Program

In October 2023, the Company’s Board of Directors approved a share repurchase program (the “October 2023 Repurchase Program”) providing for the repurchase of shares of common stock in an aggregate amount of up to $200,000, excluding commissions and transaction fees. The October 2023 Repurchase Program may be suspended, terminated, or modified at any time for any reason. During the three and six months ended June 30, 2024, and 2023, no shares of common stock were repurchased and cancelled by the Company. As of June 30, 2024, the remaining amount of common stock authorized for repurchases was $150,000.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION
6 Months Ended
Jun. 30, 2024
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION  
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION

15. STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION

2020 Stock Incentive Plan

In August 2020, the Company adopted, and its stockholders approved, the 2020 Incentive Award Plan (the “2020 Plan”), in order to facilitate the grant of cash and equity incentives to directors, employees (including the Company’s named executive officers) and consultants of the Company and its subsidiaries. The 2020 Plan provides for the grant of stock options, including incentive stock options (“ISOs”) and non-qualified stock options (“NSOs”), SARs, restricted stock, dividend equivalents, restricted stock units (“RSUs”) and other stock or cash-based awards.

Stock options and stock appreciation rights under the 2020 Plan have a 10-year contractual term and vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). RSUs vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). As of June 30, 2024, there were 7,654,586 shares of common stock available for issuance under the 2020 Plan. The number of shares that may be issued under the 2020 Plan automatically increases on January 1 of each year in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors.

2017 Stock Incentive Plan

In August 2017, the Company adopted an equity incentive plan (the “2017 Plan”). Under the 2017 Plan, directors, officers, employees, consultants, and advisors of the Company can be paid incentive compensation measured by the value of the Company’s shares of common stock through grants of stock options, stock appreciation rights (“SARs”), or restricted stock. Following the adoption of the 2020 Plan, no further grants have been, or will be, made under the 2017 Plan. However, the 2017 Plan will continue to govern the terms and conditions of outstanding awards granted under it.

Stock Options

The following table summarizes stock option activity for the six months ended June 30, 2024:

    

    

    

Weighted-

    

Weighted-

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

    

Awards

    

Price

    

Term

    

Value ($000's)

Awards outstanding—December 31, 2023

 

6,316,422

$

32.47

7.17

Awards issued

 

1,307,396

$

30.51

  

Awards exercised

 

(46,996)

$

8.97

  

Awards forfeited

 

(27,791)

$

37.14

  

Awards outstanding—June 30, 2024

 

7,549,031

$

32.26

7.20

$

27,893

Awards exercisable—June 30, 2024

3,772,766

$

30.50

6.30

$

21,050

Stock Appreciation Rights

The following table summarizes SARs activity for the six months ended June 30, 2024:

    

    

    

Weighted-

    

Weighted-

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

    

Awards

    

Price

    

Term

    

Value ($000's)

Awards outstanding—December 31, 2023

 

43,208

$

9.38

5.32

Awards issued

 

$

  

Awards exercised

 

$

  

Awards forfeited

 

$

  

  

Awards outstanding—June 30, 2024

 

43,208

$

9.38

4.83

$

887

Awards exercisable—June 30, 2024

39,556

$

8.98

4.72

$

827

Restricted Stock Units

The following table summarizes RSU activity for the six months ended June 30, 2024:

    

    

Weighted-

Average

Number of

Grant Date

    

Awards

    

Fair Value

Awards outstanding—December 31, 2023

 

330,000

$

31.53

Awards issued

 

464,600

$

30.62

Awards vested

 

(15,000)

$

29.03

Awards forfeited

 

(3,250)

$

30.69

Awards outstanding—June 30, 2024

 

776,350

$

31.03

Value of Stock Options and SARs

The Company values options and SARs using the Black-Scholes option-pricing model. The Company lacks sufficient historical company-specific volatility information. Therefore, the Company estimates expected stock volatility based on historical volatility of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. For SARs, the expected term is based

upon the weighting of certain future events. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for the time periods approximately equal to the expected term of the award. An expected dividend yield of 0% is based on the fact that the Company has never paid cash dividends and does not expect to do so in the foreseeable future.

The assumptions used to value the awards are summarized in the following table.

As of

    

June 30, 

    

December 31, 

    

2024

    

2023

Dividend yield

 

0.00

%  

0.00

%

Expected volatility

 

69.84 - 72.98

%  

74.87 - 80.78

%

Risk-free interest rate

 

4.06 - 4.65

%  

3.42 - 4.62

%

Lack of marketability discount

 

0.00

%  

0.00

%

Expected term (years)

 

2.04 - 6.11

 

2.26 - 10.77

Value of RSUs

The fair value of RSUs is equal to the value of the Company’s common stock on the grant date.

The weighted average per share fair value of awards issued under the 2017 Plan and 2020 Plan was $21.24 and $20.64 on June 30, 2024, and December 31, 2023, respectively.

Stock-Based Compensation Expense

Stock-based compensation expense for the three and six months ended June 30, 2024, and 2023, was recorded in the unaudited condensed consolidated statements of operations and comprehensive income in the following line items:

    

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2024

    

2023

    

2024

    

2023

Research and development expense

$

1,683

$

956

$

3,054

$

1,932

Sales and marketing expense

 

2,100

 

1,146

 

4,094

 

2,219

General and administrative expense

 

7,180

 

5,691

 

14,249

 

10,203

$

10,963

$

7,793

$

21,397

$

14,354

Stock-based compensation expense related to options and RSUs issued under the 2017 Plan and 2020 Plan is included in stockholder’s equity, and a liability for SARs is included in other non-current liabilities, in the Company’s unaudited condensed consolidated balance sheet. As of June 30, 2024, the total unrecognized stock-based compensation expense was $68,926 and $19,749 for stock options and RSUs, respectively. This amount will be recognized in the Company’s consolidated statement of operations over a weighted average period of 2.6 years.

Employee Stock Purchase Plan

The 2020 Employee Stock Purchase Plan (“ESPP”) was adopted by the Company’s Board of Directors on April 30, 2021. The ESPP permits eligible employees to purchase shares of the Company’s common stock at a 15% discount from the lesser of the fair market value per share of the Company’s common stock on the first day of the offering period or the fair market value of the Company’s common stock on the purchase date. Funds are collected from employees through after-tax payroll deductions. The total number of shares reserved for issuance under the ESPP was initially 629,805, which automatically increases on January 1 of each year in an amount equal to the lesser of (i) 1.0% of the shares of the Company’s common stock outstanding on

December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors. It is intended that the ESPP meet the requirements for an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. There were 10,707 and 14,043 shares issued under the ESPP for each of the three and six months ended June 30, 2024, and 2023, respectively. The discount on the ESPP was $78 and $103 for the three months ended June 30, 2024, and 2023, respectively, and $158 and $208 for the six months ended June 30, 2024, and 2023, respectively, and is recorded within stock-based compensation expense.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EARNINGS PER SHARE
6 Months Ended
Jun. 30, 2024
EARNINGS PER SHARE  
EARNINGS PER SHARE

16. EARNINGS PER SHARE

Basic earnings per share is calculated by dividing net income by the weighted average number of shares of common stock outstanding. Diluted net income per share of common is computed under the treasury stock method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income, the potential dilutive effects of stock options, stock appreciation rights and restricted stock units.

The following table sets forth the computation of basic and diluted net income per share:

    

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

    

2024

    

2023

Numerator

 

  

 

  

  

 

  

Net income

$

11,591

$

34,300

$

49,925

$

63,785

Denominator

 

  

 

  

 

  

 

  

Net income per share of common stock - basic

$

0.20

$

0.57

$

0.88

$

1.07

Net income per share of common stock- diluted

$

0.20

$

0.56

$

0.87

$

1.05

Weighted average number of shares of common stock - basic

 

56,802,357

 

59,974,123

 

56,786,873

 

59,853,808

Weighted average number of shares of common stock - diluted

 

57,541,696

 

60,743,953

 

57,571,570

 

60,997,410

Securities outstanding that were included in the computation above, utilizing the treasury stock method are as follows:

    

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

    

2024

    

2023

Stock options, SARs, and RSUs to purchase common stock

739,339

769,830

784,697

1,143,602

Potential shares of common stock issuable that were excluded from the computation of diluted weighted-average shares outstanding excluded from the numerator, are as follows:

    

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

    

2024

    

2023

Stock options, SARs, and RSUs to purchase common stock

 

7,629,250

 

5,520,235

7,583,892

 

5,146,464

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES
6 Months Ended
Jun. 30, 2024
INCOME TAXES  
INCOME TAXES

17. INCOME TAXES

A reconciliation between the statutory federal income tax rate and the Company’s effective income tax rate for the three and six months ended June 30, 2024, and 2023 is as follows:

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

2024

    

2023

Federal income tax rate

21.0

%  

21.0

%

21.0

%  

21.0

%

Stock-based compensation

(0.7)

(0.5)

(0.2)

(1.5)

State taxes

11.2

4.0

7.4

5.1

Credits

(2.6)

(2.9)

(1.6)

(2.9)

Nondeductible IPR&D

16.5

4.9

Valuation allowance

0.6

0.3

Other

0.6

0.6

0.3

0.4

Total

46.6

%  

22.2

%

32.1

%  

22.1

%

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RELATED-PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2024
RELATED-PARTY TRANSACTIONS  
RELATED-PARTY TRANSACTIONS

18. RELATED-PARTY TRANSACTIONS

The Company was party to a management agreement for professional services provided by a related party, Paragon Biosciences, LLC (“Paragon”). Paragon is an entity that shares common ownership with the Company. In addition, the Chairman of the Company’s board of directors is the Founder, Chairman and CEO of Paragon. The Company is also party to a right of use agreement with Paragon whereby it has access to and the right to use certain office space leased by Paragon in Chicago, IL. The Company incurred $72 and $74 for the three months ended June 30, 2024, and 2023, respectively, and incurred $145 and $145 for the six months ended June 30, 2024, and 2023, respectively, in expenses to Paragon, which are included in general and administrative in the unaudited condensed consolidated statements of operations and comprehensive loss. As of June 30, 2024, and December 31, 2023, there were no amounts due to or due from related parties included in the unaudited condensed consolidated balance sheets.

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Pay vs Performance Disclosure        
Net Income (Loss) $ 11,591 $ 34,300 $ 49,925 $ 63,785
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Insider Trading Arrangements
3 Months Ended
Jun. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Basis of Presentation

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated balance sheet as of June 30, 2024, the unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2024, and 2023, and the unaudited condensed consolidated statements of operations and comprehensive income and the unaudited condensed consolidated statements of shareholders’ equity for the three and six months ended June 30, 2024, and 2023, are unaudited. The

balance sheet as of December 31, 2023, was derived from audited financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2024, and the results of its operations and its cash flows for the three and six months ended June 30, 2024, and 2023. The unaudited condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Reclassifications

Reclassifications

Certain prior period amounts within the unaudited condensed consolidated statements of operations and comprehensive income have been reclassified to conform to current period presentation. In particular, interest expense and interest income were previously classified together as interest expense, net and are now separately classified as interest expense and interest income, respectively. The reclassification of these items had no impact on net income, earnings per share or accumulated deficit in current or prior periods.

Significant Risks and Uncertainties

Significant Risks and Uncertainties

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, clinical trial results of the Company’s product candidates; the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products, if approved; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates.

The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company’s research and development efforts will result in successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes.

Operating Segments

Operating Segments

The Company holds all its tangible assets, conducts its operations, and generates its revenue in the United States. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company’s unaudited condensed consolidated financial statements include cash, cash equivalents, restricted cash, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value.

It is the Company’s policy to measure non-financial assets and liabilities at fair value on a nonrecurring basis. These non-financial assets and liabilities are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes.

The Company measures certain assets and liabilities at fair value based on the fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

Money market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of June 30, 2024, or December 31, 2023.

Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents and restricted cash consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds and debt securities that approximate fair value. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.

    

As of

    

June 30, 

    

December 31, 

2024

2023

Cash and cash equivalents

$

317,296

$

311,660

Restricted cash

 

270

 

270

Total cash, cash equivalents, and restricted cash shown in the statements of cash flows

$

317,566

$

311,930

Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program.

Investments

Investments

The Company’s investments consist of debt securities that are classified as available-for-sale. Short-term and long-term investments are carried at fair value and unrealized gains and losses are recorded as a

component of accumulated comprehensive income in stockholders’ equity. Interest income earned on cash and investment balances, accretion of the discount on investments in debt securities, amortization of premiums and realized gains and losses, if any, are recorded in interest income on the unaudited condensed consolidated statement of operations and comprehensive income. Realized gains and losses that result from the sale of investments are determined on a specific identification basis.

At each reporting period, the Company reviews any unrealized losses position to determine if the decline in the fair value of the underlying investments is a result of credit losses or other factors. If the assessment indicates that a credit loss exists, any impairment is recognized as an allowance for credit losses in our consolidated statement of operations.

Concentrations of Risk

Concentrations of Risk

Substantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of June 30, 2024, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 41% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 35% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 24% of gross accounts receivable. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 39% of gross accounts receivable, CVS Caremark, which accounted for 32% of gross accounts receivable; and Pantherx, which accounted for 29% of gross accounts receivable.

For the six months ended June 30, 2024, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 40% of gross product revenue; Accredo accounted for 33% of gross product revenue; and Pantherx accounted for 27% of gross product revenue. For the six months ended June 30, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 35% of gross product revenue; Pantherx accounted for 33% of gross product revenue; and Accredo accounted for 32% of gross product revenue.

The Company depends on a single supplier for its product and a single supplier for its active pharmaceutical ingredient.

Share Repurchases

Share Repurchases

The Company accounts for share repurchases as constructive retirements, whereby it reduces common stock and additional paid-in capital by the amount of the original issuance, with any excess purchase price recorded as a reduction to retained earnings. Under this method, issued and outstanding shares of common stock are reduced by the amount of shares of common stock repurchased, and no treasury stock is recognized on the condensed consolidated financial statements.

Business Combinations

Business Combinations

Business combinations and asset acquisitions are accounted for in accordance with FASB ASC 805 Business Combinations. Refer to Note 4, Acquisitions, for a more detailed discussion of the Company’s acquisitions of Zynerba and Epygenix.

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This ASU is effective for annual reporting periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 is required to be applied retrospectively to all prior periods presented in the financial statements. The Company has one reportable segment and is currently evaluating the impact that ASU 2023-07 will have on its condensed consolidated financial statements.

In December 2023, the FASB issued Accounting Standards Update (“ASU”) No 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 expands disclosures in the rate reconciliation and requires disclosure of income taxes paid by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its condensed consolidated financial statements.

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of reconciliation of cash, cash equivalents, and restricted cash The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.

    

As of

    

June 30, 

    

December 31, 

2024

2023

Cash and cash equivalents

$

317,296

$

311,660

Restricted cash

 

270

 

270

Total cash, cash equivalents, and restricted cash shown in the statements of cash flows

$

317,566

$

311,930

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ACQUISITIONS (Tables)
6 Months Ended
Jun. 30, 2024
ACQUISITIONS  
Schedule of purchase consideration and allocation of purchase consideration

Cash consideration paid to selling shareholders and to settle restricted stock units ("RSUs")

$

32,686

Transaction costs

450

Total purchase consideration

$

33,136

Assets acquired

Acquired in-process research and development

$

17,095

Deferred tax asset

18,268

Other assets

590

Total assets acquired

$

35,953

Total liabilities assumed

$

2,817

Net assets acquired

$

33,136

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INVESTMENTS (Tables)
6 Months Ended
Jun. 30, 2024
INVESTMENTS  
Schedule of carrying value and amortized cost of available-for-sale debt securities

The carrying value and amortized cost of the Company’s available-for-sale debt securities, summarized by type of security, consisted of the following:

June 30, 2024

Amortized

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

Short-term:

Commercial paper

$

16,175

1

(5)

$

16,171

Corporate debt securities

13,443

4

(4)

13,443

Total short-term investments

$

29,618

5

(9)

$

29,614

Long-term:

Corporate debt securities

59,793

37

(87)

59,743

U.S. government securities

27,615

(180)

27,435

Total long-term investments

$

87,408

37

(267)

$

87,178

December 31, 2023

Amortized

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

Short-term:

Commercial paper

$

23,832

36

(3)

$

23,865

Corporate debt securities

15,968

28

15,996

U.S. government securities

1,940

(1)

1,939

Total short-term investments

$

41,740

64

(4)

$

41,800

Long-term:

Commercial paper

$

744

$

744

Corporate debt securities

42,688

81

(28)

42,741

U.S. government securities

28,795

7

(118)

28,684

Total long-term investments

$

72,227

88

(146)

$

72,169

XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1
FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Jun. 30, 2024
FAIR VALUE MEASUREMENTS  
Schedule of assets measured at fair value

The Company’s assets measured at fair value consisted of the following:

June 30, 2024

December 31, 2023

Total

Level 1

Level 2

Total

Level 1

Level 2

Assets

Cash equivalents

$

270,989

270,989

$

244,569

243,685

884

Commercial paper

16,171

16,171

24,609

24,609

Corporate debt securities

73,186

73,186

58,737

58,737

U.S. government securities

27,435

27,435

30,623

30,623

Total

$

387,781

270,989

116,792

$

358,538

243,685

114,853

XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INVENTORY (Tables)
6 Months Ended
Jun. 30, 2024
INVENTORY  
Schedule of inventory net

Inventory, net consisted of the following:

    

As of

    

June 30, 

    

December 31, 

2024

2023

Raw materials

$

1,135

$

1,060

Work in process

 

1,744

 

2,020

Finished goods

 

2,764

 

2,283

Total inventory, net

$

5,643

$

5,363

XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INTANGIBLE ASSETS (Tables)
6 Months Ended
Jun. 30, 2024
INTANGIBLE ASSETS  
Schedule of future annual amortization expense for unamortized intangible assets

The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:

Years ending December 31, 

    

2024 (excluding the six months ended June 30, 2024)

$

11,923

2025

 

23,845

2026

 

23,845

2027

 

23,845

2028

 

23,845

Thereafter

17,883

Total

$

125,186

Schedule of gross carrying amount and net book value of intangible assets

The gross carrying amount and net book value of the intangible asset is as follows:

    

As of

    

June 30, 

    

December 31, 

2024

2023

Gross Carrying Amount

$

215,000

$

215,000

Accumulated Amortization

 

(89,814)

 

(77,892)

Net Book Value

$

125,186

$

137,108

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ACCRUED EXPENSES (Tables)
6 Months Ended
Jun. 30, 2024
ACCRUED EXPENSES  
Schedule of accrued expenses

Accrued expenses consist of the following:

    

As of

    

June 30, 

    

December 31, 

2024

2023

Royalties due to Bioprojet

$

30,199

$

40,419

Rebates and other sales deductions

 

43,570

 

38,842

Interest

2,993

3,354

Sales and marketing

 

3,343

 

2,354

Research and development

 

7,201

 

9,835

Professional fees, consulting, and other services

 

2,053

 

2,195

Other expenses

 

2,285

 

2,495

$

91,644

$

99,494

XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEBT (Tables)
6 Months Ended
Jun. 30, 2024
DEBT  
Schedule of long-term debt, net

Long-term debt, net consists of the following:

    

June 30, 

    

December 31, 

2024

2023

Principal amount

$

188,750

$

196,250

Unamortized debt discount associated with debt financing costs

 

(2,328)

 

(2,684)

Total debt, net

186,422

193,566

Less current portion

(15,000)

(15,000)

Long-term debt, net

$

171,422

$

178,566

Schedule of future minimum payments relating to total debt

Future minimum payments relating to total debt, net as of June 30, 2024, for the periods indicated below consists of the following:

Years ending December 31, 

2024 (excluding the six months ended June 30, 2024)

$

7,500

2025

 

16,250

2026

 

20,000

2027

 

20,000

2028

 

125,000

Thereafter

Total

$

188,750

Schedule of interest expense related to the company's long-term debt

Interest expense related to the Company’s long-term debt, net, is included in interest expense within the unaudited condensed consolidated statements of operations and comprehensive income and consists of the following:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

2024

    

2023

2024

    

2023

Interest on principal balance

$

4,228

$

5,794

$

8,583

$

11,109

Amortization of deferred financing costs

 

176

 

424

 

356

 

840

Total term loan interest expense

$

4,404

$

6,218

$

8,939

$

11,949

XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES (Tables)
6 Months Ended
Jun. 30, 2024
LEASES  
Schedule of supplemental balance sheet and cash flow information related to operating leases

Supplemental balance sheet information related to operating leases was as follows:

Leases

Classification

June 30, 2024

  

December 31, 2023

Assets

Operating lease right-of-use assets

Other noncurrent assets

$

2,508

$

2,344

Liabilities

Operating lease liability, current portion

Other current liabilities

$

1,786

$

1,437

Operating lease liability, long-term

Other long-term liabilities

854

1,082

Total operating lease liabilities

$

2,640

$

2,519

Supplemental cash flow information related to operating leases was as follows:

June 30, 2024

June 30, 2023

Operating cash flows from operating leases

$

1,075

$

922

Right of use assets obtained in exchange for operating lease obligations

$

1,254

$

615

Schedule of future payments under noncancelable operating leases

Future payments under noncancelable operating leases with initial terms of one year or more as of June 30, 2024, consisted of the following:

Years ending December 31, 

    

2024 (excluding the six months ended June 30, 2024)

$

1,047

2025

 

1,250

2026

 

495

2027

 

12

2028

 

Thereafter

 

Total lease payments

2,804

Less: imputed interest

(164)

Total lease liabilities

$

2,640

XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables)
6 Months Ended
Jun. 30, 2024
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION  
Summary of changes in stock options granted

The following table summarizes stock option activity for the six months ended June 30, 2024:

    

    

    

Weighted-

    

Weighted-

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

    

Awards

    

Price

    

Term

    

Value ($000's)

Awards outstanding—December 31, 2023

 

6,316,422

$

32.47

7.17

Awards issued

 

1,307,396

$

30.51

  

Awards exercised

 

(46,996)

$

8.97

  

Awards forfeited

 

(27,791)

$

37.14

  

Awards outstanding—June 30, 2024

 

7,549,031

$

32.26

7.20

$

27,893

Awards exercisable—June 30, 2024

3,772,766

$

30.50

6.30

$

21,050

Summary of changes in SARs granted

The following table summarizes SARs activity for the six months ended June 30, 2024:

    

    

    

Weighted-

    

Weighted-

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

    

Awards

    

Price

    

Term

    

Value ($000's)

Awards outstanding—December 31, 2023

 

43,208

$

9.38

5.32

Awards issued

 

$

  

Awards exercised

 

$

  

Awards forfeited

 

$

  

  

Awards outstanding—June 30, 2024

 

43,208

$

9.38

4.83

$

887

Awards exercisable—June 30, 2024

39,556

$

8.98

4.72

$

827

Summary of changes in RSUs granted

The following table summarizes RSU activity for the six months ended June 30, 2024:

    

    

Weighted-

Average

Number of

Grant Date

    

Awards

    

Fair Value

Awards outstanding—December 31, 2023

 

330,000

$

31.53

Awards issued

 

464,600

$

30.62

Awards vested

 

(15,000)

$

29.03

Awards forfeited

 

(3,250)

$

30.69

Awards outstanding—June 30, 2024

 

776,350

$

31.03

Summary of assumptions used to value awards

As of

    

June 30, 

    

December 31, 

    

2024

    

2023

Dividend yield

 

0.00

%  

0.00

%

Expected volatility

 

69.84 - 72.98

%  

74.87 - 80.78

%

Risk-free interest rate

 

4.06 - 4.65

%  

3.42 - 4.62

%

Lack of marketability discount

 

0.00

%  

0.00

%

Expected term (years)

 

2.04 - 6.11

 

2.26 - 10.77

Summary of stock-based compensation expense

    

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2024

    

2023

    

2024

    

2023

Research and development expense

$

1,683

$

956

$

3,054

$

1,932

Sales and marketing expense

 

2,100

 

1,146

 

4,094

 

2,219

General and administrative expense

 

7,180

 

5,691

 

14,249

 

10,203

$

10,963

$

7,793

$

21,397

$

14,354

XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EARNINGS PER SHARE (Tables)
6 Months Ended
Jun. 30, 2024
EARNINGS PER SHARE  
Summary of computation of basic and diluted net income (loss) per share

The following table sets forth the computation of basic and diluted net income per share:

    

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

    

2024

    

2023

Numerator

 

  

 

  

  

 

  

Net income

$

11,591

$

34,300

$

49,925

$

63,785

Denominator

 

  

 

  

 

  

 

  

Net income per share of common stock - basic

$

0.20

$

0.57

$

0.88

$

1.07

Net income per share of common stock- diluted

$

0.20

$

0.56

$

0.87

$

1.05

Weighted average number of shares of common stock - basic

 

56,802,357

 

59,974,123

 

56,786,873

 

59,853,808

Weighted average number of shares of common stock - diluted

 

57,541,696

 

60,743,953

 

57,571,570

 

60,997,410

Securities outstanding that were included in the computation above, utilizing the treasury stock method are as follows:

    

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

    

2024

    

2023

Stock options, SARs, and RSUs to purchase common stock

739,339

769,830

784,697

1,143,602

Summary of antidilutive securities excluded from computation of earnings per share

Potential shares of common stock issuable that were excluded from the computation of diluted weighted-average shares outstanding excluded from the numerator, are as follows:

    

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

    

2024

    

2023

Stock options, SARs, and RSUs to purchase common stock

 

7,629,250

 

5,520,235

7,583,892

 

5,146,464

XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES (Tables)
6 Months Ended
Jun. 30, 2024
INCOME TAXES  
Schedule of reconciliation between statutory federal income tax rate and the Company's effective income tax rate

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

2024

    

2023

Federal income tax rate

21.0

%  

21.0

%

21.0

%  

21.0

%

Stock-based compensation

(0.7)

(0.5)

(0.2)

(1.5)

State taxes

11.2

4.0

7.4

5.1

Credits

(2.6)

(2.9)

(1.6)

(2.9)

Nondeductible IPR&D

16.5

4.9

Valuation allowance

0.6

0.3

Other

0.6

0.6

0.3

0.4

Total

46.6

%  

22.2

%

32.1

%  

22.1

%

XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LIQUIDITY AND CAPITAL RESOURCES (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
LIQUIDITY AND CAPITAL RESOURCES    
Accumulated deficit $ 93,352 $ 143,277
Cash, cash equivalents and investments $ 434,088  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Cash and cash equivalents $ 317,296 $ 311,660    
Restricted cash 270 270    
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows $ 317,566 $ 311,930 $ 317,665 $ 244,534
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)
6 Months Ended 12 Months Ended
Jun. 30, 2024
segment
product
Institution
customer
Jun. 30, 2023
customer
Dec. 31, 2023
customer
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]      
Number of approved commercial products | product 1    
Number of operating segments | segment 1    
Number of reportable segments | segment 1    
Number Of financial institutions | Institution 5    
Three Customers | Accounts Receivable | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]      
Number of customers | customer 3   3
Concentration risk percentage 100.00%   100.00%
Three Customers | Product Revenues | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]      
Number of customers | customer 3 3  
Concentration risk percentage 100.00% 100.00%  
Accredo Health Group, Inc | Accounts Receivable | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]      
Concentration risk percentage 35.00%   39.00%
Accredo Health Group, Inc | Product Revenues | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]      
Concentration risk percentage 33.00% 32.00%  
Caremark LLC | Accounts Receivable | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]      
Concentration risk percentage 41.00%   32.00%
Caremark LLC | Product Revenues | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]      
Concentration risk percentage 40.00% 35.00%  
PANTHERx Specialty Pharmacy LLC | Accounts Receivable | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]      
Concentration risk percentage 24.00%   29.00%
PANTHERx Specialty Pharmacy LLC | Product Revenues | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]      
Concentration risk percentage 27.00% 33.00%  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ACQUISITIONS (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2024
USD ($)
Oct. 31, 2023
USD ($)
Right
$ / shares
Jun. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
ACQUISITIONS        
Transaction costs   $ 2,645    
Acquired in-process research and development expense       $ 42,595
Zynerba Acquisition        
ACQUISITIONS        
Cash consideration per common stock | $ / shares   $ 1.1059    
Aggregate consideration   $ 60,000    
Number of contingent value right per common stock | Right   1    
Contingent consideration per common stock | $ / shares   $ 2.5444    
Epygenix Acquisition        
ACQUISITIONS        
Aggregate consideration $ 32,686      
Transaction costs 450      
Asset acquisition, upfront consideration paid 35,000      
Amount of fee payable upon achieving development and regulatory milestones 130,000      
Amount of fees payable upon achieving sale-based milestones $ 515,000      
Acquired in-process research and development expense     $ 17,095 $ 17,095
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ACQUISITIONS - Purchase Consideration (Details) - USD ($)
$ in Thousands
1 Months Ended
Apr. 30, 2024
Oct. 31, 2023
ACQUISITIONS    
Transaction costs   $ 2,645
Epygenix Acquisition    
ACQUISITIONS    
Cash consideration paid to selling shareholders and to settle restricted stock units ("RSUs") $ 32,686  
Transaction costs 450  
Total purchase consideration $ 33,136  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ACQUISITIONS - Net Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Apr. 30, 2024
Dec. 31, 2023
Assets acquired      
Deferred tax asset $ 180,186   $ 144,162
TOTAL ASSETS 858,383   811,448
Total liabilities assumed $ 319,800   $ 344,456
Epygenix Acquisition      
Assets acquired      
Acquired in-process research and development   $ 17,095  
Deferred tax asset   18,268  
Other assets   590  
TOTAL ASSETS   35,953  
Total liabilities assumed   2,817  
Net assets acquired   $ 33,136  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Minimum    
Investment securities    
Non current investment maturity term 1 year  
Maximum    
Investment securities    
Non current investment maturity term 2 years  
Short-term    
Investment securities    
Amortized Cost $ 29,618 $ 41,740
Unrealized Gains 5 64
Unrealized Losses (9) (4)
Fair Value 29,614 41,800
Short-term commercial paper    
Investment securities    
Amortized Cost 16,175 23,832
Unrealized Gains 1 36
Unrealized Losses (5) (3)
Fair Value 16,171 23,865
Short-term corporate debt securities    
Investment securities    
Amortized Cost 13,443 15,968
Unrealized Gains 4 28
Unrealized Losses (4)  
Fair Value 13,443 15,996
Short-term U.S. government securities    
Investment securities    
Amortized Cost   1,940
Unrealized Losses   (1)
Fair Value   1,939
Long-term    
Investment securities    
Amortized Cost 87,408 72,227
Unrealized Gains 37 88
Unrealized Losses (267) (146)
Fair Value 87,178 72,169
Long-term commercial paper    
Investment securities    
Amortized Cost   744
Fair Value   744
Long-term corporate debt securities    
Investment securities    
Amortized Cost 59,793 42,688
Unrealized Gains 37 81
Unrealized Losses (87) (28)
Fair Value 59,743 42,741
Long-term U.S. government securities    
Investment securities    
Amortized Cost 27,615 28,795
Unrealized Gains   7
Unrealized Losses (180) (118)
Fair Value $ 27,435 $ 28,684
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1
FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Assets    
Assets $ 387,781 $ 358,538
Cash equivalents    
Assets    
Assets 270,989 244,569
Commercial paper    
Assets    
Assets 16,171 24,609
Corporate debt securities    
Assets    
Assets 73,186 58,737
U.S. government securities    
Assets    
Assets 27,435 30,623
Level 1    
Assets    
Assets 270,989 243,685
Level 1 | Cash equivalents    
Assets    
Assets 270,989 243,685
Level 2    
Assets    
Assets 116,792 114,853
Level 2 | Cash equivalents    
Assets    
Assets   884
Level 2 | Commercial paper    
Assets    
Assets 16,171 24,609
Level 2 | Corporate debt securities    
Assets    
Assets 73,186 58,737
Level 2 | U.S. government securities    
Assets    
Assets $ 27,435 $ 30,623
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INVENTORY (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
INVENTORY    
Raw materials $ 1,135 $ 1,060
Work in process 1,744 2,020
Finished goods 2,764 2,283
Total inventory, net $ 5,643 $ 5,363
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INTANGIBLE ASSETS - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2022
Feb. 28, 2022
Oct. 31, 2020
Aug. 31, 2019
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Intangible Assets                
Net product revenue         $ 172,814 $ 134,216 $ 327,429 $ 253,342
Amortization expense         $ 5,961 $ 5,961 $ 11,922 $ 11,922
WAKIX                
Intangible Assets                
Useful life of intangible asset 7 years 7 months 6 days              
Remaining useful life         5 years 3 months 18 days   5 years 3 months 18 days  
Final payment paid $ 40,000              
WAKIX | United States                
Intangible Assets                
Net product revenue   $ 500,000            
WAKIX | Daytime Sleepiness                
Intangible Assets                
License agreement milestone payments paid       $ 75,000        
Useful life of intangible asset       10 years        
Remaining useful life         5 years 3 months 18 days   5 years 3 months 18 days  
NDA for WAKIX. | Cataplexy                
Intangible Assets                
License agreement milestone payments paid     $ 100,000          
Useful life of intangible asset     9 years          
Remaining useful life         5 years 3 months 18 days   5 years 3 months 18 days  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details)
$ in Thousands
Jun. 30, 2024
USD ($)
Future annual amortization expense  
2024 (excluding the six months ended June 30, 2024) $ 11,923
2025 23,845
2026 23,845
2027 23,845
2028 23,845
Thereafter 17,883
Total $ 125,186
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
INTANGIBLE ASSETS    
Gross Carrying Amount $ 215,000 $ 215,000
Accumulated Amortization (89,814) (77,892)
Net Book Value $ 125,186 $ 137,108
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2024
Mar. 31, 2023
Jul. 31, 2022
Mar. 31, 2022
Aug. 31, 2021
Jan. 31, 2021
Oct. 31, 2020
Nov. 30, 2019
Aug. 31, 2019
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Feb. 28, 2019
License Agreements and Asset Purchase Agreements                              
Cost of product sold                   $ 32,144 $ 25,008 $ 59,628 $ 45,788    
Accrued Sales Based Trademark and Royalties                   30,199   30,199   $ 40,419  
All Countries Excluding Greater China | HBS-102 | Asset Purchase Agreement with ConSynance Therapeutics                              
License Agreements and Asset Purchase Agreements                              
Consideration transferred         $ 3,500                    
Payment for intellectual property upon preclinical milestones         1,000                    
Payment for intellectual property upon developmental milestones         19,000                    
Payment for intellectual property upon regulatory milestones         44,000                    
Payment for intellectual property upon sales milestones         $ 110,000                    
All Countries Excluding Greater China | HBS-102 | Asset Purchase Agreement with ConSynance Therapeutics | Research and development expense                              
License Agreements and Asset Purchase Agreements                              
Payment related to achievement of preclinical milestone.   $ 750,000                          
Bioprojet                              
License Agreements and Asset Purchase Agreements                              
Licensing agreement milestone fees                 $ 2,000            
License agreement milestone payments paid               $ 75,000 2,000            
License agreement, additional milestone payment due                 102,000            
Bioprojet | Upon Acceptance by FDA of Pitolisant's                              
License Agreements and Asset Purchase Agreements                              
License agreement, milestone payment due                             $ 50,000
License agreement, upfront non-refundable licensing fees paid     $ 30,000                        
License agreement, maximum additional milestone payment due     $ 155,000                        
Bioprojet | Upon FDA Approval of WAKIX                              
License Agreements and Asset Purchase Agreements                              
License agreement, milestone payment due                 77,000            
Licensing agreement milestone fees                 $ 2,000            
License agreement milestone payments paid           $ 100,000 $ 2,000                
Bioprojet | Sales-based, trademark and tiered royalties                              
License Agreements and Asset Purchase Agreements                              
Cost of product sold                   30,199 $ 22,542 54,937 $ 41,602    
Accrued Sales Based Trademark and Royalties                   $ 30,199   30,199   $ 40,419  
Bioprojet | Orexin-2 receptor agonist (OX2R)                              
License Agreements and Asset Purchase Agreements                              
Payment of upfront license fee $ 25,500                     $ 25,500      
Amount of fee payable upon achieving development and regulatory milestones 127,500                            
Amount of fees payable upon achieving sale-based milestones $ 240,000                            
Bioprojet | United States                              
License Agreements and Asset Purchase Agreements                              
Amount of Aggregate Net Sales Attaining       $ 500,000                      
Bioprojet | Attaining $500,000 Aggregate Net Sales | United States | Upon FDA Approval of WAKIX                              
License Agreements and Asset Purchase Agreements                              
Final payment paid       $ 40,000                      
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
ACCRUED EXPENSES    
Royalties due to Bioprojet $ 30,199 $ 40,419
Rebates and other sales deductions 43,570 38,842
Interest 2,993 3,354
Sales and marketing 3,343 2,354
Research and development 7,201 9,835
Professional fees, consulting, and other services 2,053 2,195
Other expenses 2,285 2,495
Accrued liabilities $ 91,644 $ 99,494
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEBT - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 6 Months Ended
Jul. 31, 2023
Jun. 30, 2024
Sep. 30, 2023
Term Loans      
DEBT      
Debt issuance costs   $ 2,997  
Net cash received   197,003  
Fair value of loan   187,863  
Term Loans | Repayment Of Debt Commencing On December 31 2023      
DEBT      
Periodic payment principal   3,750  
Term Loans | Repayment Of Debt Beginning On December 31 2025      
DEBT      
Periodic payment principal   5,000  
Term Loans | Repayment of Debt Due on Maturity Date of July 26, 2028      
DEBT      
Periodic payment principal   $ 115,000  
Term Loans | Base rate | Minimum      
DEBT      
Basis spread on variable rate   2.50%  
Term Loans | Base rate | Maximum      
DEBT      
Basis spread on variable rate   3.00%  
Term Loans | SOFR      
DEBT      
Credit spread adjustment rate   0.10%  
Term Loans | SOFR | Minimum      
DEBT      
Basis spread on variable rate   3.50%  
Term Loans | SOFR | Maximum      
DEBT      
Basis spread on variable rate   4.00%  
TLA Term Loan      
DEBT      
Term of loan 5 years    
Aggregate principal amount $ 185,000    
Incremental Term Loan      
DEBT      
Aggregate principal amount     $ 15,000
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEBT - Balances of Long-term Debt, Net (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
DEBT    
Principal amount $ 188,750 $ 196,250
Unamortized debt discount associated with debt financing costs (2,328) (2,684)
Total debt, net 186,422 193,566
Less current portion (15,000) (15,000)
Long-term debt, net $ 171,422 $ 178,566
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEBT - Future Minimum Payments (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Future minimum payments    
2024 (excluding the six months ended June 30, 2024) $ 7,500  
2025 16,250  
2026 20,000  
2027 20,000  
2028 125,000  
Total $ 188,750 $ 196,250
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEBT - Interest Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
DEBT        
Interest on principal balance $ 4,228 $ 5,794 $ 8,583 $ 11,109
Amortization of deferred financing costs 176 424 356 840
Total term loan interest expense $ 4,404 $ 6,218 $ 8,939 $ 11,949
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES (Details)
ft² in Thousands, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2018
ft²
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
LEASES          
Operating lease square feet of office space 15        
Additional office space leased one 13        
Additional office space leased two 7        
Lessee, Operating Lease, Existence of Option to Extend [true false]       true  
Lessee, Operating Lease, Existence of Option to Terminate [true false]       true  
Operating lease costs | $   $ 622 $ 444 $ 1,131 $ 822
Weighted average remaining lease term   1 year 8 months 12 days   1 year 8 months 12 days  
Weighted-average discount rate for operating leases   7.56%   7.56%  
Minimum          
LEASES          
Lease terms   1 year   1 year  
Maximum          
LEASES          
Lease terms   3 years   3 years  
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Assets    
Operating lease right-of-use assets $ 2,508 $ 2,344
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Noncurrent Other Assets Noncurrent
Liabilities    
Operating lease liability, current portion $ 1,786 $ 1,437
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other Liabilities Current Other Liabilities Current
Operating lease liability, long-term $ 854 $ 1,082
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other Liabilities Noncurrent Other Liabilities Noncurrent
Total operating lease liabilities $ 2,640 $ 2,519
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
LEASES    
Operating cash flows from operating leases $ 1,075 $ 922
Right of use assets obtained in exchange for operating lease obligations $ 1,254 $ 615
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES - Future Payments (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Years ending December 31,    
2024 (excluding the six months ended June 30, 2024) $ 1,047  
2025 1,250  
2026 495  
2027 12  
Total lease payments 2,804  
Less: imputed interest (164)  
Total lease liabilities $ 2,640 $ 2,519
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS' EQUITY (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 31, 2024
shares
Mar. 31, 2023
shares
Jun. 30, 2024
USD ($)
Vote
shares
Jun. 30, 2023
shares
Oct. 31, 2023
USD ($)
Equity, Class of Treasury Stock [Line Items]          
Number of votes for each common stock | Vote     1    
October 2023 Repurchase Program          
Equity, Class of Treasury Stock [Line Items]          
Repurchase of shares of common stock approved         $ 200,000
Shares of common stock repurchased and retired | shares 0 0 0 0  
Remaining authorized repurchase amount     $ 150,000    
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2021
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Stock Incentive Plan and Stock-based Compensation            
Weighted average period       2 years 7 months 6 days    
Employee Stock Option            
Stock Incentive Plan and Stock-based Compensation            
Unrecognized stock-based compensation expense   $ 68,926   $ 68,926    
Restricted Stock Units            
Stock Incentive Plan and Stock-based Compensation            
Weighted average per share fair value of awards issued (in USD per share)       $ 30.62    
Unrecognized stock-based compensation expense   $ 19,749   $ 19,749    
2020 Plan            
Stock Incentive Plan and Stock-based Compensation            
Stock options contractual term       10 years    
Total number of shares available for issuance   7,654,586   7,654,586    
Percentage of increment of common stock outstanding       4.00%    
2017 and 2020 Plans | Restricted Stock Units            
Stock Incentive Plan and Stock-based Compensation            
Weighted average per share fair value of awards issued (in USD per share)       $ 21.24   $ 20.64
Employee Stock Purchase Plan            
Stock Incentive Plan and Stock-based Compensation            
Total number of shares available for issuance 629,805          
Percentage of increment of common stock outstanding 1.00%          
ESPP permits eligible employees to purchase shares of common stock at discount 15.00%          
Shares issued under the ESPP   10,707 14,043 10,707 14,043  
Amount of discount on ESSP   $ 78 $ 103 $ 158 $ 208  
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details)
$ / shares in Units, $ in Thousands
6 Months Ended
Dec. 31, 2023
$ / shares
shares
Jun. 30, 2024
USD ($)
$ / shares
shares
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION    
Number of Awards, Awards outstanding, Beginning balance | shares   6,316,422
Number of Awards, Awards issued | shares   1,307,396
Number of Awards, Awards exercised | shares   (46,996)
Number of Awards, Awards forfeited | shares   (27,791)
Number of Awards, Awards outstanding, Ending balance | shares 6,316,422 7,549,031
Number of Awards, Awards exercisable | shares   3,772,766
Weighted-Average Exercise Price, Awards outstanding, Beginning balance | $ / shares   $ 32.47
Weighted-Average Exercise Price, Awards issued | $ / shares   30.51
Weighted-Average Exercise Price, Awards exercised | $ / shares   8.97
Weighted-Average Exercise Price, Awards forfeited | $ / shares   37.14
Weighted-Average Exercise Price, Awards outstanding, Ending balance | $ / shares $ 32.47 32.26
Weighted-Average Exercise Price, Awards exercisable | $ / shares   $ 30.50
Weighted-Average Remaining Contractual Term 7 years 2 months 1 day 7 years 2 months 12 days
Weighted-Average Remaining Contractual Term, Awards exercisable   6 years 3 months 18 days
Aggregate Intrinsic Value, Awards outstanding, Ending balance | $   $ 27,893
Aggregate Intrinsic Value, Awards exercisable | $   $ 21,050
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended
Dec. 31, 2023
Jun. 30, 2024
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Weighted-Average Remaining Contractual Term 5 years 3 months 25 days 4 years 9 months 29 days
Weighted-Average Remaining Contractual Term, Awards exercisable   4 years 8 months 19 days
Stock Appreciation Rights (SARs)    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Number of Awards, Awards outstanding, Beginning balance   43,208
Number of Awards, Awards issued   0
Number of Awards, Awards outstanding, Ending balance 43,208 43,208
Number of Awards, Awards exercisable   39,556
Weighted-Average Exercise Price, Awards outstanding, Beginning balance   $ 9.38
Weighted-Average Exercise Price, Awards issued   0
Weighted-Average Exercise Price, Awards outstanding, Ending balance $ 9.38 9.38
Weighted-Average Exercise Price, Awards exercisable   $ 8.98
Aggregate Intrinsic Value, Awards outstanding, Ending balance   $ 887
Aggregate Intrinsic Value, Awards exercisable   $ 827
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details) - Restricted Stock Units
6 Months Ended
Jun. 30, 2024
$ / shares
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Number of Awards, Awards outstanding, Beginning balance | shares 330,000
Number of Awards, Awards issued | shares 464,600
Number of Awards, Awards vested | shares (15,000)
Number of Awards, Awards forfeited | shares (3,250)
Number of Awards, Awards outstanding, Ending balance | shares 776,350
Weighted-Average Grant Date Fair Value, Awards outstanding, Beginning balance | $ / shares $ 31.53
Weighted-Average Grant Date Fair Value, Awards issued | $ / shares 30.62
Weighted-Average Grant Date Fair Value, Awards vested | $ / shares 29.03
Weighted-Average Grant Date Fair Value, Awards forfeited | $ / shares 30.69
Weighted-Average Grant Date Fair Value, Awards outstanding, Ending balance | $ / shares $ 31.03
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details)
6 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Dividend yield 0.00% 0.00%
Expected volatility, minimum 69.84% 74.87%
Expected volatility, maximum 72.98% 80.78%
Risk-free interest rate, minimum 4.06% 3.42%
Risk-free interest rate, maximum 4.65% 4.62%
Lack of marketability discount 0.00% 0.00%
Minimum    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected term (years) 2 years 14 days 2 years 3 months 3 days
Maximum    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected term (years) 6 years 1 month 9 days 10 years 9 months 7 days
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation expense $ 10,963 $ 7,793 $ 21,397 $ 14,354
Research and development expense        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation expense 1,683 956 3,054 1,932
Sales and marketing expense        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation expense 2,100 1,146 4,094 2,219
General and administrative expense        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation expense $ 7,180 $ 5,691 $ 14,249 $ 10,203
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Numerator        
Net Income (Loss) $ 11,591 $ 34,300 $ 49,925 $ 63,785
Denominator        
Net income per share of common stock - basic $ 0.20 $ 0.57 $ 0.88 $ 1.07
Net income per share of common stock - diluted $ 0.20 $ 0.56 $ 0.87 $ 1.05
Weighted average number of shares of common stock - basic 56,802,357 59,974,123 56,786,873 59,853,808
Weighted average number of shares of common stock - diluted 57,541,696 60,743,953 57,571,570 60,997,410
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
EARNINGS PER SHARE        
Securities outstanding included in the computation - Stock options, SARs, and RSUs to purchase common stock 739,339 769,830 784,697 1,143,602
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
EARNINGS PER SHARE        
Potential shares of common stock issuable excluded from computation - Stock options, SARs, and RSUs to purchase common stock 7,629,250 5,520,235 7,583,892 5,146,464
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
INCOME TAXES        
Federal income tax rate 21.00% 21.00% 21.00% 21.00%
Stock-based compensation (0.70%) (0.50%) (0.20%) (1.50%)
State taxes 11.20% 4.00% 7.40% 5.10%
Credits (2.60%) (2.90%) (1.60%) (2.90%)
Nondeductible IPR&D 16.50%   4.90%  
Valuation allowance 0.60%   0.30%  
Other 0.60% 0.60% 0.30% 0.40%
Total 46.60% 22.20% 32.10% 22.10%
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RELATED-PARTY TRANSACTIONS (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Related-party Transactions          
General and administrative $ 27,224 $ 22,809 $ 52,900 $ 44,871  
Amounts due to related parties $ 0   $ 0   $ 0
Other Liability, Related Party, Type [Extensible Enumeration] Related party   Related party   Related party
Amounts due from related parties $ 0   $ 0   $ 0
Other Receivable, after Allowance for Credit Loss, Related Party, Type [Extensible Enumeration] Related party   Related party   Related party
Related party          
Related-party Transactions          
General and administrative $ 72 $ 74 $ 145 $ 145  
EXCEL 85 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 87 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 89 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 203 349 1 false 62 0 false 11 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 995200105 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Sheet http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Statements 4 false false R5.htm 995200300 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 995200400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 995210101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://www.harmonybiosciences.com/role/DisclosureOrganizationAndDescriptionOfBusiness ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 7 false false R8.htm 995210201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES Sheet http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResources LIQUIDITY AND CAPITAL RESOURCES Notes 8 false false R9.htm 995210301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 995210401 - Disclosure - ACQUISITIONS Sheet http://www.harmonybiosciences.com/role/DisclosureAcquisitions ACQUISITIONS Notes 10 false false R11.htm 995210501 - Disclosure - INVESTMENTS Sheet http://www.harmonybiosciences.com/role/DisclosureInvestments INVESTMENTS Notes 11 false false R12.htm 995210601 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurements FAIR VALUE MEASUREMENTS Notes 12 false false R13.htm 995210701 - Disclosure - INVENTORY Sheet http://www.harmonybiosciences.com/role/DisclosureInventory INVENTORY Notes 13 false false R14.htm 995210801 - Disclosure - INTANGIBLE ASSETS Sheet http://www.harmonybiosciences.com/role/DisclosureIntangibleAssets INTANGIBLE ASSETS Notes 14 false false R15.htm 995210901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS Sheet http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreements LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS Notes 15 false false R16.htm 995211001 - Disclosure - ACCRUED EXPENSES Sheet http://www.harmonybiosciences.com/role/DisclosureAccruedExpenses ACCRUED EXPENSES Notes 16 false false R17.htm 995211101 - Disclosure - DEBT Sheet http://www.harmonybiosciences.com/role/DisclosureDebt DEBT Notes 17 false false R18.htm 995211201 - Disclosure - LEASES Sheet http://www.harmonybiosciences.com/role/DisclosureLeases LEASES Notes 18 false false R19.htm 995211301 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.harmonybiosciences.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 19 false false R20.htm 995211401 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.harmonybiosciences.com/role/DisclosureStockholdersEquity STOCKHOLDERS' EQUITY Notes 20 false false R21.htm 995211501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensation STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION Notes 21 false false R22.htm 995211601 - Disclosure - EARNINGS PER SHARE Sheet http://www.harmonybiosciences.com/role/DisclosureEarningsPerShare EARNINGS PER SHARE Notes 22 false false R23.htm 995211701 - Disclosure - INCOME TAXES Sheet http://www.harmonybiosciences.com/role/DisclosureIncomeTaxes INCOME TAXES Notes 23 false false R24.htm 995211801 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactions RELATED-PARTY TRANSACTIONS Notes 24 false false R25.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 25 false false R26.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 26 false false R27.htm 99920302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 27 false false R28.htm 99930303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies 28 false false R29.htm 99930403 - Disclosure - ACQUISITIONS (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureAcquisitionsTables ACQUISITIONS (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureAcquisitions 29 false false R30.htm 99930503 - Disclosure - INVESTMENTS (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureInvestmentsTables INVESTMENTS (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureInvestments 30 false false R31.htm 99930603 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurements 31 false false R32.htm 99930703 - Disclosure - INVENTORY (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureInventoryTables INVENTORY (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureInventory 32 false false R33.htm 99930803 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureIntangibleAssets 33 false false R34.htm 99931003 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureAccruedExpenses 34 false false R35.htm 99931103 - Disclosure - DEBT (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureDebtTables DEBT (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureDebt 35 false false R36.htm 99931203 - Disclosure - LEASES (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureLeasesTables LEASES (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureLeases 36 false false R37.htm 99931503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensation 37 false false R38.htm 99931603 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareTables EARNINGS PER SHARE (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureEarningsPerShare 38 false false R39.htm 99931703 - Disclosure - INCOME TAXES (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesTables INCOME TAXES (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureIncomeTaxes 39 false false R40.htm 99940201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResourcesDetails LIQUIDITY AND CAPITAL RESOURCES (Details) Details http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResources 40 false false R41.htm 99940301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) Details 41 false false R42.htm 99940302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Details 42 false false R43.htm 99940401 - Disclosure - ACQUISITIONS (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails ACQUISITIONS (Details) Details http://www.harmonybiosciences.com/role/DisclosureAcquisitionsTables 43 false false R44.htm 99940402 - Disclosure - ACQUISITIONS - Purchase Consideration (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureAcquisitionsPurchaseConsiderationDetails ACQUISITIONS - Purchase Consideration (Details) Details 44 false false R45.htm 99940403 - Disclosure - ACQUISITIONS - Net Assets Acquired and Liabilities Assumed (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails ACQUISITIONS - Net Assets Acquired and Liabilities Assumed (Details) Details 45 false false R46.htm 99940501 - Disclosure - INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details) Details 46 false false R47.htm 99940601 - Disclosure - FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details) Details 47 false false R48.htm 99940701 - Disclosure - INVENTORY (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureInventoryDetails INVENTORY (Details) Details http://www.harmonybiosciences.com/role/DisclosureInventoryTables 48 false false R49.htm 99940801 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails INTANGIBLE ASSETS - Additional Information (Details) Details 49 false false R50.htm 99940802 - Disclosure - INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details) Details 50 false false R51.htm 99940803 - Disclosure - INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details) Details 51 false false R52.htm 99940901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) Details http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreements 52 false false R53.htm 99941001 - Disclosure - ACCRUED EXPENSES (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails ACCRUED EXPENSES (Details) Details http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesTables 53 false false R54.htm 99941101 - Disclosure - DEBT - Additional Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails DEBT - Additional Information (Details) Details 54 false false R55.htm 99941102 - Disclosure - DEBT - Balances of Long-term Debt, Net (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails DEBT - Balances of Long-term Debt, Net (Details) Details 55 false false R56.htm 99941103 - Disclosure - DEBT - Future Minimum Payments (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails DEBT - Future Minimum Payments (Details) Details 56 false false R57.htm 99941104 - Disclosure - DEBT - Interest Expense (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails DEBT - Interest Expense (Details) Details 57 false false R58.htm 99941201 - Disclosure - LEASES (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLeasesDetails LEASES (Details) Details http://www.harmonybiosciences.com/role/DisclosureLeasesTables 58 false false R59.htm 99941202 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails LEASES - Supplemental Balance Sheet Information (Details) Details 59 false false R60.htm 99941203 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails LEASES - Supplemental Cash Flow Information (Details) Details 60 false false R61.htm 99941204 - Disclosure - LEASES - Future Payments (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails LEASES - Future Payments (Details) Details 61 false false R62.htm 99941401 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://www.harmonybiosciences.com/role/DisclosureStockholdersEquity 62 false false R63.htm 99941501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details) Details 63 false false R64.htm 99941502 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details) Details 64 false false R65.htm 99941503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details) Details 65 false false R66.htm 99941504 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details) Details 66 false false R67.htm 99941505 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details) Details 67 false false R68.htm 99941506 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details) Details 68 false false R69.htm 99941601 - Disclosure - EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details) Details 69 false false R70.htm 99941602 - Disclosure - EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfSecuritiesOutstandingIncludedInComputationAboveUtilizingTreasuryStockMethodDetails EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details) Details 70 false false R71.htm 99941603 - Disclosure - EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 71 false false R72.htm 99941701 - Disclosure - INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details) Details 72 false false R73.htm 99941801 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails RELATED-PARTY TRANSACTIONS (Details) Details http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactions 73 false false All Reports Book All Reports hrmy-20240630.xsd hrmy-20240630_cal.xml hrmy-20240630_def.xml hrmy-20240630_lab.xml hrmy-20240630_pre.xml hrmy-20240630x10q.htm http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 92 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hrmy-20240630x10q.htm": { "nsprefix": "hrmy", "nsuri": "http://www.harmonybiosciences.com/20240630", "dts": { "schema": { "local": [ "hrmy-20240630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "hrmy-20240630_cal.xml" ] }, "definitionLink": { "local": [ "hrmy-20240630_def.xml" ] }, "labelLink": { "local": [ "hrmy-20240630_lab.xml" ] }, "presentationLink": { "local": [ "hrmy-20240630_pre.xml" ] }, "inline": { "local": [ "hrmy-20240630x10q.htm" ] } }, "keyStandard": 292, "keyCustom": 57, "axisStandard": 20, "axisCustom": 0, "memberStandard": 26, "memberCustom": 35, "hidden": { "total": 26, "http://xbrl.sec.gov/dei/2024": 4, "http://fasb.org/us-gaap/2024": 22 }, "contextCount": 203, "entityCount": 1, "segmentCount": 62, "elementCount": 620, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 720, "http://xbrl.sec.gov/dei/2024": 31, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 2 }, "report": { "R1": { "role": "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:ShortTermInvestments", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } }, "R3": { "role": "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_AVnQ6ehNF0KknXZCVgI7Pg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_AVnQ6ehNF0KknXZCVgI7Pg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome", "longName": "995200200 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:GrossProfit", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } }, "R5": { "role": "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "995200300 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e8B3tSNlX060o673nM7_gw", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e8B3tSNlX060o673nM7_gw", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.harmonybiosciences.com/role/DisclosureOrganizationAndDescriptionOfBusiness", "longName": "995210101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS", "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResources", "longName": "995210201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES", "shortName": "LIQUIDITY AND CAPITAL RESOURCES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "hrmy:LiquidityAndCapitalResourcesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "hrmy:LiquidityAndCapitalResourcesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.harmonybiosciences.com/role/DisclosureAcquisitions", "longName": "995210401 - Disclosure - ACQUISITIONS", "shortName": "ACQUISITIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.harmonybiosciences.com/role/DisclosureInvestments", "longName": "995210501 - Disclosure - INVESTMENTS", "shortName": "INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurements", "longName": "995210601 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.harmonybiosciences.com/role/DisclosureInventory", "longName": "995210701 - Disclosure - INVENTORY", "shortName": "INVENTORY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssets", "longName": "995210801 - Disclosure - INTANGIBLE ASSETS", "shortName": "INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreements", "longName": "995210901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS", "shortName": "LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "hrmy:LicenseAndAssetPurchaseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "hrmy:LicenseAndAssetPurchaseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.harmonybiosciences.com/role/DisclosureAccruedExpenses", "longName": "995211001 - Disclosure - ACCRUED EXPENSES", "shortName": "ACCRUED EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebt", "longName": "995211101 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeases", "longName": "995211201 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.harmonybiosciences.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211301 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquity", "longName": "995211401 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensation", "longName": "995211501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShare", "longName": "995211601 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxes", "longName": "995211701 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactions", "longName": "995211801 - Disclosure - RELATED-PARTY TRANSACTIONS", "shortName": "RELATED-PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsTables", "longName": "99930403 - Disclosure - ACQUISITIONS (Tables)", "shortName": "ACQUISITIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.harmonybiosciences.com/role/DisclosureInvestmentsTables", "longName": "99930503 - Disclosure - INVESTMENTS (Tables)", "shortName": "INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsTables", "longName": "99930603 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.harmonybiosciences.com/role/DisclosureInventoryTables", "longName": "99930703 - Disclosure - INVENTORY (Tables)", "shortName": "INVENTORY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsTables", "longName": "99930803 - Disclosure - INTANGIBLE ASSETS (Tables)", "shortName": "INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesTables", "longName": "99931003 - Disclosure - ACCRUED EXPENSES (Tables)", "shortName": "ACCRUED EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebtTables", "longName": "99931103 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeasesTables", "longName": "99931203 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables", "longName": "99931503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareTables", "longName": "99931603 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesTables", "longName": "99931703 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResourcesDetails", "longName": "99940201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES (Details)", "shortName": "LIQUIDITY AND CAPITAL RESOURCES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:InvestmentsAndCash", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "hrmy:LiquidityAndCapitalResourcesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } }, "R41": { "role": "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "longName": "99940301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "99940302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "hrmy:NumberOfApprovedCommercialProducts", "unitRef": "Unit_Standard_product_Q4owhQzmKE2GiKVkxodswQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "hrmy:SignificantRisksAndUncertaintiesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "hrmy:NumberOfApprovedCommercialProducts", "unitRef": "Unit_Standard_product_Q4owhQzmKE2GiKVkxodswQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "hrmy:SignificantRisksAndUncertaintiesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails", "longName": "99940401 - Disclosure - ACQUISITIONS (Details)", "shortName": "ACQUISITIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_10_1_2023_To_10_31_2023_jvJ1qjDJ9kKiRFv8zTzf8Q", "name": "us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2023_To_10_31_2023_us-gaap_AssetAcquisitionAxis_hrmy_ZynerbaAcquisitionMember_2TSEI5T34k-ih7VCzDvT_Q", "name": "hrmy:AssetAcquisitionConsiderationTransferredOnCommonCashAmountPaidPerShare", "unitRef": "Unit_Divide_USD_shares_AVnQ6ehNF0KknXZCVgI7Pg", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } }, "R44": { "role": "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsPurchaseConsiderationDetails", "longName": "99940402 - Disclosure - ACQUISITIONS - Purchase Consideration (Details)", "shortName": "ACQUISITIONS - Purchase Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_10_1_2023_To_10_31_2023_jvJ1qjDJ9kKiRFv8zTzf8Q", "name": "us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_30_2024_To_4_30_2024_us-gaap_AssetAcquisitionAxis_hrmy_EpygenixAcquisitionMember_Pa6kfb74-EqonXtxg4rCZQ", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:AssetAcquisitionTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } }, "R45": { "role": "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails", "longName": "99940403 - Disclosure - ACQUISITIONS - Net Assets Acquired and Liabilities Assumed (Details)", "shortName": "ACQUISITIONS - Net Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:DeferredIncomeTaxAssetsNet", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_4_30_2024_us-gaap_AssetAcquisitionAxis_hrmy_EpygenixAcquisitionMember_Ez9pLy35Qk2dOb2uVk2UQQ", "name": "hrmy:AcquiredInProcessResearchAndDevelopment", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } }, "R46": { "role": "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails", "longName": "99940501 - Disclosure - INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details)", "shortName": "INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_srt_RangeAxis_srt_MinimumMember_YgqLBIWekUiYbv15P7IYVQ", "name": "hrmy:NonCurrentInvestmentMaturityTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_srt_RangeAxis_srt_MinimumMember_YgqLBIWekUiYbv15P7IYVQ", "name": "hrmy:NonCurrentInvestmentMaturityTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "longName": "99940601 - Disclosure - FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails", "longName": "99940701 - Disclosure - INVENTORY (Details)", "shortName": "INVENTORY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "longName": "99940801 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details)", "shortName": "INTANGIBLE ASSETS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:AmortizationOfIntangibleAssets", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } }, "R50": { "role": "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails", "longName": "99940802 - Disclosure - INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails", "longName": "99940803 - Disclosure - INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "longName": "99940901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details)", "shortName": "LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_1_2021_To_8_31_2021_srt_ProductOrServiceAxis_hrmy_Hbs102Member_srt_StatementGeographicalAxis_hrmy_AllCountriesExcludingChinaMember_us-gaap_AssetAcquisitionAxis_hrmy_AssetPurchaseAgreementWithConsynanceTherapeuticsMember_fuQycptenE-bjP5TfOFJ8w", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } }, "R53": { "role": "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails", "longName": "99941001 - Disclosure - ACCRUED EXPENSES (Details)", "shortName": "ACCRUED EXPENSES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:AccruedRoyaltiesCurrent", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "hrmy:AccruedRebatesAndOtherSalesDeductionsCurrent", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } }, "R54": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "longName": "99941101 - Disclosure - DEBT - Additional Information (Details)", "shortName": "DEBT - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DebtInstrumentAxis_hrmy_TermLoanMember_JCbAC-Y8hE2tmxTLeb98WA", "name": "us-gaap:DeferredFinanceCostsGross", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DebtInstrumentAxis_hrmy_TermLoanMember_JCbAC-Y8hE2tmxTLeb98WA", "name": "us-gaap:DeferredFinanceCostsGross", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails", "longName": "99941102 - Disclosure - DEBT - Balances of Long-term Debt, Net (Details)", "shortName": "DEBT - Balances of Long-term Debt, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "hrmy:UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } }, "R56": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails", "longName": "99941103 - Disclosure - DEBT - Future Minimum Payments (Details)", "shortName": "DEBT - Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails", "longName": "99941104 - Disclosure - DEBT - Interest Expense (Details)", "shortName": "DEBT - Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails", "longName": "99941201 - Disclosure - LEASES (Details)", "shortName": "LEASES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_6_1_2018_To_6_30_2018_hRCqStKgfUucdRKf_AA5qg", "name": "hrmy:OperatingLeaseOfficeSpace", "unitRef": "Unit_Standard_sqft_lMcmWkw2E0KWm3qkdWA3ow", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2018_To_6_30_2018_hRCqStKgfUucdRKf_AA5qg", "name": "hrmy:OperatingLeaseOfficeSpace", "unitRef": "Unit_Standard_sqft_lMcmWkw2E0KWm3qkdWA3ow", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails", "longName": "99941202 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details)", "shortName": "LEASES - Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails", "longName": "99941203 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)", "shortName": "LEASES - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails", "longName": "99941204 - Disclosure - LEASES - Future Payments (Details)", "shortName": "LEASES - Future Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails", "longName": "99941401 - Disclosure - STOCKHOLDERS' EQUITY (Details)", "shortName": "STOCKHOLDERS' EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "hrmy:CommonStockNumberOfVotesPerShare", "unitRef": "Unit_Standard_Vote_RCpiwg4ddk-awhm9rXFQ9g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_RaTZaNPV70aKDpv1URcdoQ", "name": "hrmy:CommonStockNumberOfVotesPerShare", "unitRef": "Unit_Standard_Vote_RCpiwg4ddk-awhm9rXFQ9g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "longName": "99941501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails", "longName": "99941502 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_12_31_2023_SDEQVDxO9EqliFU23TtB0w", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_apRkTo-UrE-N8UPWjFe6DQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_apRkTo-UrE-N8UPWjFe6DQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } }, "R65": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails", "longName": "99941503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_12_31_2023_To_12_31_2023_b8EuiosBgkasxutzkldTbQ", "name": "hrmy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_12_31_2023_To_12_31_2023_b8EuiosBgkasxutzkldTbQ", "name": "hrmy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails", "longName": "99941504 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_b_VpyArE2kGl3fWJzLWIVw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_apRkTo-UrE-N8UPWjFe6DQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_b_VpyArE2kGl3fWJzLWIVw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_apRkTo-UrE-N8UPWjFe6DQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails", "longName": "99941505 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_Standard_pure_p9ntvHlUE0Cydt_zTtzIjg", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_oiITb-NDSEOHj_e62jm2QA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_Standard_pure_p9ntvHlUE0Cydt_zTtzIjg", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "longName": "99941506 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "longName": "99941601 - Disclosure - EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details)", "shortName": "EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R70": { "role": "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfSecuritiesOutstandingIncludedInComputationAboveUtilizingTreasuryStockMethodDetails", "longName": "99941602 - Disclosure - EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details)", "shortName": "EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "Unit_Standard_shares_apRkTo-UrE-N8UPWjFe6DQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "Unit_Standard_shares_apRkTo-UrE-N8UPWjFe6DQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "longName": "99941603 - Disclosure - EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_apRkTo-UrE-N8UPWjFe6DQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_apRkTo-UrE-N8UPWjFe6DQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails", "longName": "99941701 - Disclosure - INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details)", "shortName": "INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_p9ntvHlUE0Cydt_zTtzIjg", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_p9ntvHlUE0Cydt_zTtzIjg", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99941801 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)", "shortName": "RELATED-PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_zZ07ar2m302GerkztaIm3w", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_SDEQVDxO9EqliFU23TtB0w", "name": "us-gaap:OtherReceivables", "unitRef": "Unit_Standard_USD_p35z95Re_0eVE3GJp2Vq0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:OtherReceivables", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240630x10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED EXPENSES", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r51", "r54", "r58", "r1051" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable Current", "terseLabel": "Trade payables", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r51", "r841" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r771" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable Net Current", "terseLabel": "Trade receivables, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r999" ] }, "hrmy_AccredoHealthGroupIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AccredoHealthGroupIncMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accredo Health Group, Inc.", "label": "Accredo Health Group, Inc" } } }, "auth_ref": [] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premiums and accretion of discounts on Investment securities", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r86" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "totalLabel": "Accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r54" ] }, "hrmy_AccruedLiabilitiesOtherThanAccruedCompensationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AccruedLiabilitiesOtherThanAccruedCompensationCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of accrued liabilities other than accrued compensation. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, other than Accrued Compensation, Current", "terseLabel": "Accrued expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedMarketingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedMarketingCostsCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Marketing Costs Current", "terseLabel": "Sales and marketing", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "hrmy_AccruedProfessionalFeesConsultingAndOtherServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AccruedProfessionalFeesConsultingAndOtherServices", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued professional fees, consulting, and other services.", "label": "Accrued Professional Fees Consulting And Other Services", "terseLabel": "Professional fees, consulting, and other services" } } }, "auth_ref": [] }, "hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AccruedRebatesAndOtherSalesDeductionsCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued rebates and other sales deductions.", "label": "Accrued Rebates And Other Sales Deductions Current", "terseLabel": "Rebates and other sales deductions" } } }, "auth_ref": [] }, "hrmy_AccruedResearchAndDevelopmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AccruedResearchAndDevelopmentCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued research and development current", "label": "Accrued Research And Development Current", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Royalties Current", "terseLabel": "Royalties due to Bioprojet", "verboseLabel": "Accrued Sales Based Trademark and Royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r54", "r792" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r19", "r20", "r71", "r179", "r642", "r672", "r673" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive (loss) income", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r10", "r20", "r495", "r498", "r553", "r668", "r669", "r977", "r978", "r979", "r987", "r988", "r989", "r991" ] }, "hrmy_AcquiredInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AcquiredInProcessResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of acquired in-process research and development.", "label": "Acquired In-Process Research and Development", "terseLabel": "Acquired in-process research and development" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r907" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r63" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r689", "r987", "r988", "r989", "r991", "r1060", "r1125" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r920" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r920" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r920" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r920" ] }, "hrmy_AdjustmentForAmortizationOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AdjustmentForAmortizationOfDebtIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Adjustment for Amortization of Debt Issuance Costs", "terseLabel": "Debt issuance costs amortization" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r42", "r43", "r417" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r953" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r879", "r889", "r899", "r931" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r882", "r892", "r902", "r934" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r954" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r920" ] }, "hrmy_AllCountriesExcludingChinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AllCountriesExcludingChinaMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to all countries except Greater China.", "label": "All Countries Excluding Greater China" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r927" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r883", "r893", "r903", "r927", "r935", "r939", "r947" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r945" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r447", "r452" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Amortization Of Financing Costs", "verboseLabel": "Amortization of deferred financing costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r80", "r380", "r981", "r1070" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization Of Intangible Assets", "terseLabel": "Intangible amortization", "verboseLabel": "Amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5", "r318", "r325", "r809" ] }, "hrmy_AmountOfAggregateNetSalesAttaining": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AmountOfAggregateNetSalesAttaining", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of aggregate net sales attaining.", "label": "Amount Of Aggregate Net Sales Attaining", "terseLabel": "Amount of Aggregate Net Sales Attaining" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Potential shares of common stock issuable excluded from computation - Stock options, SARs, and RSUs to purchase common stock", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r240" ] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "ACQUISITIONS" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsPurchaseConsiderationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r319", "r320", "r321", "r322", "r323", "r1055" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsPurchaseConsiderationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Consideration transferred", "totalLabel": "Total purchase consideration", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r826", "r1056", "r1057", "r1058" ] }, "hrmy_AssetAcquisitionConsiderationTransferredCommonContingentValueRightPaidPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AssetAcquisitionConsiderationTransferredCommonContingentValueRightPaidPerShare", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The contingent consideration per Common Stock, per the Tender Offer.", "label": "Asset Acquisition, Consideration Transferred, Common Contingent Value Right Paid Per Share", "terseLabel": "Contingent consideration per common stock" } } }, "auth_ref": [] }, "hrmy_AssetAcquisitionConsiderationTransferredNumberOfContingentValueRightPerCommonStock": { "xbrltype": "integerItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AssetAcquisitionConsiderationTransferredNumberOfContingentValueRightPerCommonStock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of contingent value right per Common Stock, for each holder of Common Stock upon the closing of the Tender Offer.", "label": "Asset Acquisition, Consideration Transferred, Number of Contingent Value Right per Common Stock", "terseLabel": "Number of contingent value right per common stock" } } }, "auth_ref": [] }, "hrmy_AssetAcquisitionConsiderationTransferredOnCommonCashAmountPaidPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AssetAcquisitionConsiderationTransferredOnCommonCashAmountPaidPerShare", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash amount paid per Common Stock, per the Tender Offer.", "label": "Asset Acquisition, Consideration Transferred, on Common Cash Amount Paid Per Share", "terseLabel": "Cash consideration per common stock" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsPurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Transaction costs", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r826", "r1056", "r1057", "r1058" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsPurchaseConsiderationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r319", "r320", "r321", "r322", "r323", "r1055" ] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsPurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Line Items]", "terseLabel": "ACQUISITIONS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1055" ] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsPurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r1055" ] }, "us-gaap_AssetAcquisitionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsTables" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table Text Block]", "terseLabel": "Schedule of purchase consideration and allocation of purchase consideration", "documentation": "Tabular disclosure of asset acquisition." } } }, "auth_ref": [ "r1055" ] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitions" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Text Block]", "terseLabel": "ACQUISITIONS", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": [ "r1055" ] }, "hrmy_AssetAcquisitionUpfrontConsiderationPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AssetAcquisitionUpfrontConsiderationPaid", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for upfront consideration in asset acquisition.", "label": "Asset Acquisition, Upfront Consideration Paid", "terseLabel": "Asset acquisition, upfront consideration paid" } } }, "auth_ref": [] }, "hrmy_AssetPurchaseAgreementWithConsynanceTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "AssetPurchaseAgreementWithConsynanceTherapeuticsMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to asset purchase agreement with ConSynance Therapeutics.", "label": "Asset Purchase Agreement with ConSynance Therapeutics [Member]", "terseLabel": "Asset Purchase Agreement with ConSynance Therapeutics" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r110", "r124", "r175", "r207", "r244", "r246", "r259", "r260", "r300", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r488", "r492", "r528", "r637", "r717", "r803", "r804", "r841", "r870", "r1019", "r1020", "r1076" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets acquired" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r168", "r183", "r207", "r300", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r488", "r492", "r528", "r841", "r1019", "r1020", "r1076" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r506", "r507", "r829" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNet", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "label": "Net Assets", "totalLabel": "Net assets acquired", "documentation": "Amount of net assets (liabilities)." } } }, "auth_ref": [ "r9" ] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets Noncurrent", "totalLabel": "Total noncurrent assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r207", "r300", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r488", "r492", "r528", "r1019", "r1020", "r1076" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets Noncurrent [Abstract]", "terseLabel": "NONCURRENT ASSETS:" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "verboseLabel": "Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r274" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r275" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r271", "r308", "r635" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r272", "r308", "r506", "r629", "r829", "r832", "r1000", "r1063", "r1064", "r1065" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r942" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r943" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r938" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r941" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r940" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r939" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r939" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Base Rate [Member]", "terseLabel": "Base rate", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "hrmy_BioprojetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "BioprojetMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Bioprojet.", "label": "Bioprojet" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r102", "r103", "r104", "r105" ] }, "hrmy_CaremarkLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "CaremarkLLCMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Caremark LLC.", "label": "Caremark LLC" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r24", "r170", "r789" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash equivalents", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r25", "r108" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-End of period", "periodStartLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-Beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the statements of cash flows", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r24", "r84", "r203" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r84" ] }, "hrmy_CataplexyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "CataplexyMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Cataplexy.", "label": "Cataplexy" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r918" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r915" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r913" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfTreasuryStockTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r36", "r37", "r38", "r39" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r919" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r919" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r92", "r348", "r864", "r865", "r866", "r867" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 13)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r59", "r114", "r640", "r703" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r90", "r341", "r342", "r772", "r1011", "r1016" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Total number of shares available for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r62" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r860", "r861", "r862", "r864", "r865", "r866", "r867", "r987", "r988", "r991", "r1060", "r1123", "r1125" ] }, "hrmy_CommonStockNumberOfVotesPerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "CommonStockNumberOfVotesPerShare", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of votes for each common stock.", "label": "Common Stock, Number of Votes per Share", "terseLabel": "Number of votes for each common stock" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r62" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r62", "r704" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r62" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r62", "r704", "r723", "r1125", "r1126" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock Value", "terseLabel": "Common stock-$0.00001 par value; 500,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively; 56,833,771 and 56,769,081 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r62", "r641", "r841" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r924" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r923" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r925" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r922" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r21", "r185", "r187", "r191", "r630", "r652", "r653" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r28", "r29", "r44", "r45", "r265", "r771" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk By Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r28", "r29", "r44", "r45", "r265", "r675", "r771" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk By Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r28", "r29", "r44", "r45", "r265", "r771", "r961" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Credit Risk", "terseLabel": "Concentrations of Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r49", "r130" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Percentage1", "terseLabel": "Concentration risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r28", "r29", "r44", "r45", "r265" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r28", "r29", "r44", "r45", "r265", "r771" ] }, "hrmy_ConcentrationsOfRiskNumberOfFinancialInstitutions": { "xbrltype": "integerItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ConcentrationsOfRiskNumberOfFinancialInstitutions", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number Of financial institutions in which Substantially all of the Company's cash and money market funds are held.", "label": "Concentrations of Risk, Number Of Financial Institutions", "terseLabel": "Number Of financial institutions" } } }, "auth_ref": [] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation Fiscal Year Maturity Schedule Table Text Block", "terseLabel": "Schedule of future minimum payments relating to total debt", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r969", "r986" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r819", "r821", "r829", "r842", "r858", "r1120" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Cost Of Goods And Services Sold", "terseLabel": "Cost of product sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r74", "r75", "r595" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r160", "r161", "r211", "r212", "r362", "r390", "r560", "r578", "r634", "r793", "r795" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r88", "r265" ] }, "hrmy_DaytimeSleepinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "DaytimeSleepinessMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Daytime Sleepiness.", "label": "Daytime Sleepiness" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "DEBT" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r91", "r205", "r334", "r335", "r336", "r337", "r338", "r347", "r348", "r358", "r364", "r365", "r366", "r367", "r368", "r369", "r374", "r381", "r382", "r384", "r535" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r17", "r53", "r54", "r111", "r113", "r213", "r359", "r360", "r361", "r362", "r363", "r365", "r370", "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r810", "r811", "r812", "r813", "r814", "r839", "r983", "r1012", "r1013", "r1014", "r1069", "r1071" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Basis spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails", "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Carrying Amount", "totalLabel": "Total", "verboseLabel": "Principal amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r17", "r113", "r385" ] }, "hrmy_DebtInstrumentCreditSpreadAdjustmentRate": { "xbrltype": "percentItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "DebtInstrumentCreditSpreadAdjustmentRate", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of credit spread adjustment rate.", "label": "Debt Instrument Credit Spread Adjustment Rate", "terseLabel": "Credit spread adjustment rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Fair Value", "terseLabel": "Fair value of loan", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r372", "r527", "r811", "r812", "r1062", "r1063", "r1064", "r1065", "r1066" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "DEBT", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r213", "r359", "r360", "r361", "r362", "r363", "r365", "r370", "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r383", "r810", "r811", "r812", "r813", "r814", "r839", "r983", "r1069", "r1071" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r17", "r213", "r359", "r360", "r361", "r362", "r363", "r365", "r370", "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r810", "r811", "r812", "r813", "r814", "r839", "r983", "r1012", "r1013", "r1014", "r1069", "r1071" ] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Periodic payment principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r17" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r17", "r34", "r35", "r48", "r94", "r95", "r213", "r359", "r360", "r361", "r362", "r363", "r365", "r370", "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r383", "r810", "r811", "r812", "r813", "r814", "r839", "r983", "r1069", "r1071" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Term", "terseLabel": "Term of loan", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Finance Costs Gross", "terseLabel": "Debt issuance costs", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1069", "r1071" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r456", "r457" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred taxes", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r86" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r33" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r415", "r420", "r448", "r449", "r451", "r823" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r874" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r906" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "verboseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r917" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "EARNINGS PER SHARE", "terseLabel": "EARNINGS PER SHARE:", "verboseLabel": "Denominator" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic", "terseLabel": "Basic", "verboseLabel": "Net income per share of common stock - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r192", "r219", "r220", "r221", "r222", "r223", "r224", "r230", "r232", "r237", "r238", "r239", "r243", "r483", "r486", "r503", "r504", "r631", "r654", "r797" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share Diluted", "terseLabel": "Diluted", "verboseLabel": "Net income per share of common stock - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r192", "r219", "r220", "r221", "r222", "r223", "r224", "r232", "r237", "r238", "r239", "r243", "r483", "r486", "r503", "r504", "r631", "r654", "r797" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS PER SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r229", "r240", "r241", "r242" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r459", "r825" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Federal income tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r208", "r459", "r474", "r825" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r463", "r825", "r985", "r1052" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent", "terseLabel": "Nondeductible IPR&D", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense." } } }, "auth_ref": [ "r985", "r1052", "r1054" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation Other Adjustments", "terseLabel": "Other", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r825", "r985", "r1052", "r1053" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent", "terseLabel": "Stock-based compensation", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r959", "r1052", "r1053" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State taxes", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r461", "r825", "r985", "r1052" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Credits", "negatedLabel": "Credits", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r462", "r464", "r985", "r1052" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Employee Benefits Current", "terseLabel": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r54" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r450" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r450" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "hrmy_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "EmployeeStockPurchasePlanMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line3", "terseLabel": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r872" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r872" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r872" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r956" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r872" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r872" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r872" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r872" ] }, "hrmy_EpygenixAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "EpygenixAcquisitionMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsPurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Epygenix acquisition.", "label": "Epygenix Acquisition [Member]", "terseLabel": "Epygenix Acquisition" } } }, "auth_ref": [] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r911" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r952" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r952" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r952" ] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r166", "r188", "r189", "r190", "r214", "r215", "r216", "r218", "r223", "r225", "r227", "r245", "r301", "r302", "r332", "r402", "r472", "r473", "r480", "r481", "r482", "r484", "r485", "r486", "r494", "r495", "r496", "r497", "r498", "r499", "r502", "r529", "r530", "r531", "r532", "r533", "r534", "r536", "r538", "r553", "r650", "r668", "r669", "r670", "r689", "r747" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r921" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r879", "r889", "r899", "r931" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r876", "r886", "r896", "r928" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r927" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r506", "r507", "r517", "r829" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r506", "r507", "r517", "r829" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of assets measured at fair value", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": [ "r506", "r507" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r372", "r406", "r407", "r408", "r409", "r410", "r411", "r505", "r507", "r508", "r509", "r510", "r516", "r517", "r519", "r565", "r566", "r567", "r811", "r812", "r819", "r820", "r821", "r829", "r832" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "FAIR VALUE MEASUREMENTS" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r512", "r514", "r515", "r516", "r519", "r520", "r521", "r522", "r523", "r628", "r829", "r833" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r372", "r406", "r411", "r507", "r517", "r565", "r819", "r820", "r821", "r829" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r372", "r406", "r411", "r507", "r508", "r517", "r566", "r811", "r812", "r819", "r820", "r821", "r829" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r372", "r406", "r407", "r408", "r409", "r410", "r411", "r505", "r507", "r508", "r509", "r510", "r516", "r517", "r519", "r565", "r566", "r567", "r811", "r812", "r819", "r820", "r821", "r829", "r832" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Of Financial Instruments Policy", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r8" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r311", "r383", "r400", "r500", "r524", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r651", "r808", "r829", "r830", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r842", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r1002", "r1003", "r1004", "r1005", "r1061", "r1063", "r1064", "r1065", "r1066", "r1067" ] }, "hrmy_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Asset Useful Life", "terseLabel": "Useful life of intangible asset", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets Accumulated Amortization", "negatedLabel": "Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r173", "r315", "r324", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r326", "r785", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year", "terseLabel": "2024 (excluding the six months ended June 30, 2024)", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1127" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r326", "r785", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r326", "r785", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r326", "r785", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r317", "r319", "r320", "r321", "r323", "r324", "r327", "r328", "r596", "r597", "r785" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Future annual amortization expense" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets [Line Items]", "verboseLabel": "Intangible Assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r317", "r324", "r327", "r328", "r330", "r596", "r785", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r317", "r319", "r320", "r321", "r323", "r324", "r327", "r328", "r785" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets Net", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r596", "r1008" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets Remaining Amortization Period1", "terseLabel": "Remaining useful life", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r596" ] }, "hrmy_FiveYearSeniorSecuredTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "FiveYearSeniorSecuredTermLoanMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to five-year senior secured term loan (the \"TLA Term Loan\").", "label": "Five-year Senior Secured Term Loan [Member]", "terseLabel": "TLA Term Loan" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r883", "r893", "r903", "r935" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r883", "r893", "r903", "r935" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r883", "r893", "r903", "r935" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r883", "r893", "r903", "r935" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r883", "r893", "r903", "r935" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r916" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "General And Administrative Expense.", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r78", "r727" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r78" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r72", "r76", "r123", "r207", "r300", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r528", "r799", "r803", "r993", "r995", "r996", "r997", "r998", "r1019" ] }, "hrmy_Hbs102Member": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "Hbs102Member", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to HBS 102.", "label": "HBS-102" } } }, "auth_ref": [] }, "hrmy_InProcessResearchAndDevelopmentAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "InProcessResearchAndDevelopmentAcquired", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of in-process research and development acquired.", "label": "In-Process Research and Development Acquired", "terseLabel": "Acquired in-process research & development (IPR&D) expense", "verboseLabel": "Acquired in-process research and development expense" } } }, "auth_ref": [] }, "hrmy_IncentiveAwardPlanTwoThousandTwentyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "IncentiveAwardPlanTwoThousandTwentyMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Incentive award plan two thousand twenty.", "label": "2020 Plan" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Income before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r73", "r118", "r123", "r632", "r647", "r799", "r803", "r993", "r995", "r996", "r997", "r998" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r333", "r339", "r340", "r511", "r513", "r518", "r665", "r667", "r732", "r785", "r831", "r1093" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r339", "r340", "r511", "r513", "r518", "r665", "r667", "r732", "r785", "r831", "r1093" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r208", "r455", "r459", "r465", "r466", "r467", "r468", "r469", "r475", "r477", "r478", "r479", "r684", "r825" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense Benefit", "negatedLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r126", "r133", "r226", "r227", "r244", "r250", "r260", "r458", "r459", "r476", "r656", "r825" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid during the year for taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r26", "r202", "r470", "r471" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Accounts Payable Trade", "terseLabel": "Trade payables", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Trade receivables", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfSecuritiesOutstandingIncludedInComputationAboveUtilizingTreasuryStockMethodDetails" ], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Securities outstanding included in the computation - Stock options, SARs, and RSUs to purchase common stock", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r233", "r234", "r235", "r239", "r419" ] }, "hrmy_IncrementalTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "IncrementalTermLoanMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Incremental Term Loan.", "label": "Incremental Term Loan [Member]", "terseLabel": "Incremental Term Loan" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r883", "r893", "r903", "r927", "r935", "r939", "r947" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r945" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r875", "r951" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r875", "r951" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r875", "r951" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r316", "r329", "r331", "r784", "r785" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Gross Excluding Goodwill", "terseLabel": "Gross Carrying Amount", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r172" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Net Excluding Goodwill", "terseLabel": "Intangible assets, net", "totalLabel": "Net Book Value", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r317", "r1008", "r1010" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS" } } }, "auth_ref": [] }, "hrmy_IntellectualPropertyPaymentDueUponAchievementOfDevelopmentalMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "IntellectualPropertyPaymentDueUponAchievementOfDevelopmentalMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of intellectual property payment due upon achievement of developmental milestones.", "label": "Intellectual Property Payment Due Upon Achievement of Developmental Milestones", "terseLabel": "Payment for intellectual property upon developmental milestones" } } }, "auth_ref": [] }, "hrmy_IntellectualPropertyPaymentDueUponAchievementOfPreclinicalMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "IntellectualPropertyPaymentDueUponAchievementOfPreclinicalMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of intellectual property payment due upon achievement of preclinical milestones.", "label": "Intellectual Property Payment Due Upon Achievement of Preclinical Milestones", "terseLabel": "Payment for intellectual property upon preclinical milestones" } } }, "auth_ref": [] }, "hrmy_IntellectualPropertyPaymentDueUponAchievementOfRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "IntellectualPropertyPaymentDueUponAchievementOfRegulatoryMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of intellectual property payment due upon achievement of regulatory milestones.", "label": "Intellectual Property Payment Due Upon Achievement of Regulatory Milestones", "terseLabel": "Payment for intellectual property upon regulatory milestones" } } }, "auth_ref": [] }, "hrmy_IntellectualPropertyPaymentDueUponAchievementOfSalesMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "IntellectualPropertyPaymentDueUponAchievementOfSalesMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of intellectual property payment due upon achievement of sales milestones.", "label": "Intellectual Property Payment Due Upon Achievement of Sales Milestones", "terseLabel": "Payment for intellectual property upon sales milestones" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense Debt", "totalLabel": "Total term loan interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r80", "r378", "r387", "r813", "r814" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense Debt Excluding Amortization", "terseLabel": "Interest on principal balance", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r80", "r379", "r813", "r814" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Interest Expense", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r249", "r980" ] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Interest Income And Interest Expense Disclosure Table [Text Block]", "terseLabel": "Schedule of interest expense related to the company's long-term debt", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid Net", "terseLabel": "Cash paid during the year for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r197", "r200", "r201" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest Payable, Current", "terseLabel": "Interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r54" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INVENTORY" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventory" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORY", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r312" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Finished Goods", "terseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r973" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory Net", "terseLabel": "Inventory, net", "totalLabel": "Total inventory, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r180", "r790", "r841" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Raw Materials", "terseLabel": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r975" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Work In Process", "terseLabel": "Work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r974" ] }, "us-gaap_InvestmentIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNonoperating", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Investment Income, Nonoperating", "terseLabel": "Interest income", "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations." } } }, "auth_ref": [ "r79" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r655", "r678", "r679", "r680", "r681", "r757", "r758" ] }, "us-gaap_InvestmentsAndCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsAndCash", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "label": "Investments and Cash", "terseLabel": "Cash, cash equivalents and investments", "documentation": "Sum of investments and unrestricted cash as of the balance sheet date." } } }, "auth_ref": [ "r1087", "r1090" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "INVESTMENTS" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestments" ], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "INVESTMENTS", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r120", "r134", "r267", "r269", "r525", "r526", "r1085" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of supplemental balance sheet and cash flow information related to operating leases", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1073" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "LEASES" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "LEASES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r543", "r552" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r543", "r552" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r544" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]", "documentation": "Indicates (true false) whether lessee has option to terminate operating lease." } } }, "auth_ref": [ "r544" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of future payments under noncancelable operating leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1074" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "2024 (excluding the six months ended June 30, 2024)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1074" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease terms", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r552", "r1072" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r537" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "terseLabel": "Total liabilities assumed", "totalLabel": "TOTAL LIABILITIES", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r17", "r53", "r54", "r55", "r57", "r58", "r59", "r60", "r207", "r300", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r489", "r492", "r493", "r528", "r702", "r798", "r870", "r1019", "r1076", "r1077" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r67", "r115", "r644", "r841", "r984", "r1006", "r1068" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r55", "r169", "r207", "r300", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r489", "r492", "r493", "r528", "r841", "r1019", "r1076", "r1077" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Noncurrent", "totalLabel": "Total noncurrent liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r17", "r57", "r58", "r59", "r60", "r207", "r300", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r489", "r492", "r493", "r528", "r1019", "r1076", "r1077" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Noncurrent [Abstract]", "terseLabel": "NONCURRENT LIABILITIES:" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementAdditionalMilestonePaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAgreementAdditionalMilestonePaymentsDue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement additional milestone payments due.", "label": "License Agreement Additional Milestone Payments Due", "terseLabel": "License agreement, additional milestone payment due" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementFinalPaymentPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAgreementFinalPaymentPaid", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement final payment paid.", "label": "License Agreement Final Payment Paid", "terseLabel": "Final payment paid" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementMaximumAdditionalMilestonePaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAgreementMaximumAdditionalMilestonePaymentsDue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement maximum additional milestone payments due.", "label": "License Agreement Maximum Additional Milestone Payments Due", "terseLabel": "License agreement, maximum additional milestone payment due" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfDevelopmentAndRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfDevelopmentAndRegulatoryMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of license agreement maximum additional milestone payments due upon achievement of development and regulatory milestones.", "label": "License Agreement Maximum Additional Milestone Payments Due Upon Achievement of Development and Regulatory Milestones", "terseLabel": "Amount of fee payable upon achieving development and regulatory milestones" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfSalesBasedMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfSalesBasedMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of license agreement maximum additional milestone payments due upon achievement of sales-based milestones.", "label": "License Agreement Maximum Additional Milestone Payments Due Upon Achievement of Sales-based Milestones", "terseLabel": "Amount of fees payable upon achieving sale-based milestones" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementMilestonePaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAgreementMilestonePaymentsDue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement milestone payments Due.", "label": "License Agreement Milestone Payments Due", "terseLabel": "License agreement, milestone payment due" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementMilestonePaymentsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAgreementMilestonePaymentsPaid", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement milestone payments paid.", "label": "License Agreement Milestone Payments Paid", "terseLabel": "License agreement milestone payments paid" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementPreclinicalMilestonePaymentsRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAgreementPreclinicalMilestonePaymentsRecognized", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of preclinical milestone payments recognized under the license agreement.", "label": "License Agreement, Preclinical Milestone Payments Recognized", "terseLabel": "Payment related to achievement of preclinical milestone." } } }, "auth_ref": [] }, "hrmy_LicenseAgreementUpfrontFeePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAgreementUpfrontFeePaid", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to license agreement upfront fees paid.", "label": "License Agreement, Upfront Fee Paid", "terseLabel": "Payment of upfront license fee" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementUpfrontNonRefundableFeePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAgreementUpfrontNonRefundableFeePaid", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to license agreement upfront non-refundable fees paid.", "label": "License Agreement Upfront Non-Refundable Fee Paid", "terseLabel": "License agreement, upfront non-refundable licensing fees paid" } } }, "auth_ref": [] }, "hrmy_LicenseAndAssetPurchaseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAndAssetPurchaseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "License and asset purchase agreements.", "label": "LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS" } } }, "auth_ref": [] }, "hrmy_LicenseAndAssetPurchaseAgreementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAndAssetPurchaseAgreementsLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent License and asset purchase agreements.", "label": "License and Asset Purchase Agreements [Line Items]", "terseLabel": "License Agreements and Asset Purchase Agreements" } } }, "auth_ref": [] }, "hrmy_LicenseAndAssetPurchaseAgreementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAndAssetPurchaseAgreementsTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about license and asset purchase agreements.", "label": "License Agreements and Asset Purchase Agreements [Table]" } } }, "auth_ref": [] }, "hrmy_LicenseAndAssetPurchaseAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicenseAndAssetPurchaseAgreementsTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreements" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of license and asset purchase agreements.", "label": "License and Asset Purchase Agreements [Text Block]", "terseLabel": "LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS" } } }, "auth_ref": [] }, "hrmy_LicensingAgreementMilestoneFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LicensingAgreementMilestoneFees", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Licensing agreement milestone fees", "label": "Licensing Agreement Milestone Fees", "terseLabel": "Licensing agreement milestone fees" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line Of Credit Facility Maximum Borrowing Capacity", "terseLabel": "Aggregate principal amount", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r52", "r56" ] }, "hrmy_LiquidityAndCapitalResourcesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LiquidityAndCapitalResourcesAbstract", "lang": { "en-us": { "role": { "documentation": "Liquidity and capital resources.", "label": "LIQUIDITY AND CAPITAL RESOURCES" } } }, "auth_ref": [] }, "hrmy_LiquidityAndCapitalResourcesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LiquidityAndCapitalResourcesTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResources" ], "lang": { "en-us": { "role": { "documentation": "Liquidity and capital resources.", "label": "Liquidity And Capital Resources [Text Block]", "terseLabel": "LIQUIDITY AND CAPITAL RESOURCES" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "hrmy_LongTermCommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LongTermCommercialPaperMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to long term commercial paper.", "label": "Long-term commercial paper" } } }, "auth_ref": [] }, "hrmy_LongTermCorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LongTermCorporateDebtSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to long term corporate debt securities.", "label": "Long-term corporate debt securities" } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt", "totalLabel": "Total debt, net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r17", "r113", "r371", "r386", "r811", "r812", "r839", "r1088" ] }, "us-gaap_LongTermDebtByMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtByMaturityAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Future minimum payments" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Current Maturities", "negatedLabel": "Less current portion", "terseLabel": "Current portion of long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r176" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r213", "r376" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2028", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r213", "r376" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r213", "r376" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r213", "r376" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2024 (excluding the six months ended June 30, 2024)", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r986" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Noncurrent", "terseLabel": "Long-term debt, net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r177" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-Term Investments", "terseLabel": "Investments, long-term", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r171" ] }, "hrmy_LongTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LongTermInvestmentsMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of more than one year from the date of the balance sheet.", "label": "Long-term" } } }, "auth_ref": [] }, "hrmy_LongTermUsGovernmentSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "LongTermUsGovernmentSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to long term us government securities.", "label": "Long-term U.S. government securities" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Major Customers [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r265", "r818", "r852", "r856", "r1023", "r1092", "r1094", "r1095", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1121", "r1122" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails", "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r135", "r137", "r139", "r140", "r142", "r164", "r165", "r343", "r344", "r345", "r346", "r413", "r453", "r510", "r594", "r664", "r666", "r674", "r694", "r695", "r755", "r759", "r761", "r762", "r764", "r782", "r783", "r807", "r815", "r822", "r832", "r833", "r837", "r838", "r853", "r1021", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r919" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r919" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails", "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r135", "r137", "r139", "r140", "r142", "r164", "r165", "r343", "r344", "r345", "r346", "r413", "r453", "r510", "r594", "r664", "r666", "r674", "r694", "r695", "r755", "r759", "r761", "r762", "r764", "r782", "r783", "r807", "r815", "r822", "r832", "r833", "r837", "r853", "r1021", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r938" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r946" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Customer", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r265", "r818", "r852", "r856", "r1023", "r1092", "r1094", "r1095", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1121", "r1122" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r920" ] }, "hrmy_NdaForWakixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "NdaForWakixMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "NDA for WAKIX.", "label": "NDA for WAKIX [Member]", "terseLabel": "NDA for WAKIX." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r199" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r199" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r84", "r85", "r86" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r77", "r86", "r119", "r167", "r184", "r186", "r190", "r207", "r217", "r219", "r220", "r221", "r222", "r223", "r226", "r227", "r236", "r300", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r483", "r486", "r504", "r528", "r649", "r725", "r745", "r746", "r868", "r1019" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income Loss [Abstract]", "terseLabel": "Numerator" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "hrmy_NonCurrentInvestmentMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "NonCurrentInvestmentMaturityTerm", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity term of non current investments.", "label": "Non Current Investment Maturity Term", "terseLabel": "Non current investment maturity term" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r919" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r883", "r893", "r903", "r927", "r935" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r910" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r909" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r927" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r946" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r946" ] }, "hrmy_NumberOfApprovedCommercialProducts": { "xbrltype": "integerItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "NumberOfApprovedCommercialProducts", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of approved commercial products.", "label": "Number Of Approved Commercial Products", "terseLabel": "Number of approved commercial products" } } }, "auth_ref": [] }, "hrmy_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "NumberOfMajorCustomers", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of major customers.", "label": "Number Of Major Customers", "terseLabel": "Number of customers" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r804", "r994" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r800", "r806", "r994" ] }, "hrmy_October2023ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "October2023ShareRepurchaseProgramMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to October 2023 Share Repurchase Program.", "label": "October 2023 Share Repurchase Program [Member]", "terseLabel": "October 2023 Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Operating Income Loss", "totalLabel": "Operating income", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r123", "r799", "r993", "r995", "r996", "r997", "r998" ] }, "hrmy_OperatingLeaseAdditionalOfficeSpaceLeasedOne": { "xbrltype": "areaItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "OperatingLeaseAdditionalOfficeSpaceLeasedOne", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease additional office space one, leased.", "label": "Operating Lease Additional Office Space Leased, One", "terseLabel": "Additional office space leased one" } } }, "auth_ref": [] }, "hrmy_OperatingLeaseAdditionalOfficeSpaceLeasedTwo": { "xbrltype": "areaItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "OperatingLeaseAdditionalOfficeSpaceLeasedTwo", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease additional office space two, leased.", "label": "Operating Lease Additional Office Space Leased, Two", "terseLabel": "Additional office space leased two" } } }, "auth_ref": [] }, "hrmy_OperatingLeaseAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "OperatingLeaseAssetAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating Lease, Asset [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r545", "r840" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Years ending December 31," } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails", "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r540" ] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability [Abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liability, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r540" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r541" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liability, long-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r540" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r541" ] }, "hrmy_OperatingLeaseOfficeSpace": { "xbrltype": "areaItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "OperatingLeaseOfficeSpace", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease office space.", "label": "Operating Lease Office Space", "terseLabel": "Operating lease square feet of office space" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r542", "r546" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r539" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r541" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate for operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r549", "r840" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r548", "r840" ] }, "hrmy_Orexin2ReceptorAgonistOx2rMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "Orexin2ReceptorAgonistOx2rMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to orexin-2 receptor agonist (OX2R) (the \"Licensed Compound\").", "label": "Orexin-2 Receptor Agonist (OX2R) [Member]", "terseLabel": "Orexin-2 receptor agonist (OX2R)" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "ORGANIZATION AND DESCRIPTION OF BUSINESS" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureOrganizationAndDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r50", "r106", "r676", "r677" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities Current", "terseLabel": "Other expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r54" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsNetAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "label": "Other Assets", "terseLabel": "Other assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r109", "r174", "r636", "r804", "r870" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r182", "r841" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets Noncurrent", "terseLabel": "Other noncurrent assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r174" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized loss on investments", "verboseLabel": "Unrealized (loss) income on investments", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r3", "r10", "r107" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Other Liabilities", "terseLabel": "Amounts due to related parties", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r112", "r638", "r698", "r699", "r870", "r1089", "r1124" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r54", "r841" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Noncurrent", "terseLabel": "Other noncurrent liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r58" ] }, "us-gaap_OtherLiabilityRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilityRelatedPartyTypeExtensibleEnumeration", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Other Liability, Related Party, Type [Extensible Enumeration]", "documentation": "Indicates status and type of related party for liability classified as other." } } }, "auth_ref": [ "r1075", "r1089" ] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashExpense", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other Noncash Expense", "terseLabel": "Other non-cash expenses", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": [ "r86" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income Expense", "terseLabel": "Other (expense) income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r81" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r919" ] }, "us-gaap_OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Other Receivable, after Allowance for Credit Loss, Related Party, Type [Extensible Enumeration]", "documentation": "Indicates status and type of related party for receivable, after allowance for credit loss, classified as other." } } }, "auth_ref": [ "r1075" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivables", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Due from (to) Related Party", "terseLabel": "Amounts due from related parties", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r178", "r712", "r804", "r1091" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r881", "r891", "r901", "r933" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r884", "r894", "r904", "r936" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r884", "r894", "r904", "r936" ] }, "hrmy_PANTHERxSpecialtyPharmacyLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "PANTHERxSpecialtyPharmacyLLCMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "PANTHERx Specialty Pharmacy LLC.", "label": "PANTHERx Specialty Pharmacy LLC" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r908" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "ACCRUED EXPENSES" } } }, "auth_ref": [] }, "hrmy_PaymentOfLicenseFeeInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "PaymentOfLicenseFeeInvestingActivities", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Cash outflow from payment of license fee in investing activities.", "label": "Payment Of License Fee Investing Activities", "negatedLabel": "Payment of license fee" } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Payments of employee withholding taxes related to stock-based awards", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r196" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchase of investment securities", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r22", "r193", "r268" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition of Zynerba Pharmaceuticals, Inc., net of cash acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r23" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails", "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsPurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "terseLabel": "Aggregate consideration", "verboseLabel": "Cash consideration paid to selling shareholders and to settle restricted stock units (\"RSUs\")", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r125", "r1056", "r1057", "r1058" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r82" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r918" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r918" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r910" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r927" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r920" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r909" ] }, "hrmy_PitolisantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "PitolisantsMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Pitolisant's.", "label": "Upon Acceptance by FDA of Pitolisant's" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r911" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r955" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r910" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense Current", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r181", "r313", "r314", "r791" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r971" ] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Net cash received", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": [ "r195" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from maturities and sales of investment securities", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r193", "r194", "r1001" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from exercised options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r15" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r144", "r145", "r146", "r147", "r148", "r149", "r162", "r262", "r595", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r786", "r816", "r851", "r853", "r854", "r857", "r859", "r970", "r1017", "r1018", "r1023", "r1092", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1121", "r1122" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r144", "r145", "r146", "r147", "r148", "r149", "r162", "r262", "r595", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r786", "r816", "r851", "r853", "r854", "r857", "r859", "r970", "r1017", "r1018", "r1023", "r1092", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1121", "r1122" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Profit Loss", "terseLabel": "Net income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r167", "r184", "r186", "r198", "r207", "r217", "r223", "r226", "r227", "r300", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r483", "r486", "r487", "r490", "r491", "r504", "r528", "r632", "r648", "r688", "r725", "r745", "r746", "r827", "r828", "r869", "r979", "r1019" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r551", "r633", "r646", "r841" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r908" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r908" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails", "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r135", "r137", "r139", "r140", "r142", "r164", "r165", "r343", "r344", "r345", "r346", "r405", "r413", "r443", "r444", "r445", "r453", "r510", "r568", "r577", "r594", "r664", "r666", "r674", "r694", "r695", "r755", "r759", "r761", "r762", "r764", "r782", "r783", "r807", "r815", "r822", "r832", "r833", "r837", "r838", "r853", "r862", "r1015", "r1021", "r1064", "r1079", "r1080", "r1081", "r1082", "r1083" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails", "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r135", "r137", "r139", "r140", "r142", "r164", "r165", "r343", "r344", "r345", "r346", "r405", "r413", "r443", "r444", "r445", "r453", "r510", "r568", "r577", "r594", "r664", "r666", "r674", "r694", "r695", "r755", "r759", "r761", "r762", "r764", "r782", "r783", "r807", "r815", "r822", "r832", "r833", "r837", "r838", "r853", "r862", "r1015", "r1021", "r1064", "r1079", "r1080", "r1081", "r1082", "r1083" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r876", "r886", "r896", "r928" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r266", "r412", "r557", "r558", "r639", "r645", "r697", "r698", "r699", "r700", "r701", "r722", "r724", "r754" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r209", "r210", "r557", "r558", "r559", "r560", "r639", "r645", "r697", "r698", "r699", "r700", "r701", "r722", "r724", "r754" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related-party Transactions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r266", "r728", "r729", "r732" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "RELATED-PARTY TRANSACTIONS" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r266", "r412", "r557", "r558", "r639", "r645", "r697", "r698", "r699", "r700", "r701", "r722", "r724", "r754", "r1075" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED-PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r554", "r555", "r556", "r558", "r561", "r685", "r686", "r687", "r730", "r731", "r732", "r751", "r753" ] }, "hrmy_RepaymentOfDebtBeginningOnDecember312025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "RepaymentOfDebtBeginningOnDecember312025Member", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to repayment of debt beginning on December 31, 2025.", "label": "Repayment Of Debt Beginning On December 31 2025" } } }, "auth_ref": [] }, "hrmy_RepaymentOfDebtCommencingOnDecember312023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "RepaymentOfDebtCommencingOnDecember312023Member", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to repayment of debt commencing on December 31, 2023.", "label": "Repayment Of Debt Commencing On December 31 2023" } } }, "auth_ref": [] }, "hrmy_RepaymentOfDebtDueOnMaturityDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "RepaymentOfDebtDueOnMaturityDateMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to repayment of debt Due on Maturity Date of August 9, 2026.", "label": "Repayment of Debt Due on Maturity Date of July 26, 2028" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Long-term Debt", "negatedLabel": "Principal repayment of long term debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r83", "r682" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r160", "r161", "r211", "r212", "r362", "r390", "r560", "r578", "r634", "r794", "r795" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Research And Development Expense.", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r454", "r785", "r803", "r1084" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expense", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r877", "r887", "r897", "r929" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r878", "r888", "r898", "r930" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r885", "r895", "r905", "r937" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r127", "r972", "r982" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResourcesDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings Accumulated Deficit", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r64", "r96", "r643", "r671", "r673", "r683", "r705", "r841" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "terseLabel": "Accumulated deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r166", "r214", "r215", "r216", "r218", "r223", "r225", "r227", "r301", "r302", "r332", "r472", "r473", "r480", "r481", "r482", "r484", "r485", "r486", "r494", "r496", "r497", "r499", "r502", "r536", "r538", "r668", "r670", "r689", "r1125" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Net product revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r121", "r122", "r244", "r247", "r248", "r258", "r260", "r262", "r263", "r265", "r403", "r404", "r595" ] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer." } } }, "auth_ref": [ "r816" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right of use assets obtained in exchange for operating lease obligations", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r547", "r840" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r946" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r946" ] }, "hrmy_SalesBasedTrademarkAndTieredRoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "SalesBasedTrademarkAndTieredRoyaltiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Sales-based, trademark and tiered royalties.", "label": "Sales-based, Trademark and Tiered Royalties [Member]", "terseLabel": "Sales-based, trademark and tiered royalties" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueProductLineMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Product Revenues", "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [ "r960" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Scenario", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r163", "r228", "r414", "r957", "r990" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Summary of antidilutive securities excluded from computation of earnings per share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Investment securities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of carrying value and amortized cost of available-for-sale debt securities", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Debt Table [Text Block]", "terseLabel": "Schedule of long-term debt, net", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Summary of computation of basic and diluted net income (loss) per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r992" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Schedule of reconciliation between statutory federal income tax rate and the Company's effective income tax rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r460", "r825", "r1052" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of stock-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule Of Finite Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r317", "r324", "r327", "r328", "r330", "r596", "r785", "r809" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]", "terseLabel": "Schedule of gross carrying amount and net book value of intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r809", "r1007" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventoryTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Inventory Current Table [Text Block]", "terseLabel": "Schedule of inventory net", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r18", "r68", "r69", "r70" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r46", "r47", "r728", "r729", "r732" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Restricted Cash And Cash Equivalents [Text Block]", "terseLabel": "Schedule of reconciliation of cash, cash equivalents, and restricted cash", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r16", "r108", "r1090" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r416", "r418", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]", "terseLabel": "Summary of changes in RSUs granted", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Stock Appreciation Rights Award Activity Table [Text Block]", "terseLabel": "Summary of changes in SARs granted", "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock appreciation rights awards that were outstanding at the beginning and end of the year, and the number of stock appreciation rights awards that were granted, exercised or converted, forfeited, and expired during the year." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of changes in stock options granted", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r13", "r14", "r97" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Summary of assumptions used to value awards", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r101" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]", "terseLabel": "Schedule of future annual amortization expense for unamortized intangible assets", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r809", "r1009" ] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": [ "r1059" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security12b Title", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r871" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r873" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Geographical", "documentation": "Geographical area." } } }, "auth_ref": [ "r136", "r138", "r141", "r143", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r263", "r264", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r691", "r692", "r693", "r756", "r760", "r763", "r765", "r770", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r787", "r817", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r855", "r862", "r1023", "r1092", "r1094", "r1095", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1121", "r1122" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Operating Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r261", "r263", "r801", "r802", "r805" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Selling And Marketing Expense", "terseLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing expense", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation", "terseLabel": "Stock-based and employee stock purchase compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscount", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of discount from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount", "terseLabel": "Amount of discount on ESSP" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date", "terseLabel": "ESPP permits eligible employees to purchase shares of common stock at discount", "documentation": "Discount rate from fair value on purchase date that participants pay for shares." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Number of Awards, Awards forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r437" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Awards forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r437" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Number of Awards, Awards issued", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r435" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average per share fair value of awards issued (in USD per share)", "verboseLabel": "Weighted-Average Grant Date Fair Value, Awards issued", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r435" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Number of Awards, Awards outstanding, Ending balance", "periodStartLabel": "Number of Awards, Awards outstanding, Beginning balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r432", "r433" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Awards outstanding, Ending balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Awards outstanding, Beginning balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r432", "r433" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Awards, Awards vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r436" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted-Average Grant Date Fair Value, Awards vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r436" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r444" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum", "terseLabel": "Expected volatility, maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum", "terseLabel": "Expected volatility, minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount": { "xbrltype": "percentItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award fair value assumptions lack of marketability discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount", "terseLabel": "Lack of marketability discount" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum", "terseLabel": "Risk-free interest rate, maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum", "terseLabel": "Risk-free interest rate, minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "verboseLabel": "Stock Incentive Plan and Stock-based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r416", "r418", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446" ] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercisableIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercisableIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for aggregate intrinsic value price of vested portions of non equity instrument exercisable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Non Option Equity Instrument Exercisable Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Awards exercisable" } } }, "auth_ref": [] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercisable by participants.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable", "terseLabel": "Number of Awards, Awards exercisable" } } }, "auth_ref": [] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares for exercisable under the non-option equity plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Awards exercisable" } } }, "auth_ref": [] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity instruments other than options exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted-Average Remaining Contractual Term, Awards exercisable" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Number of Awards, Awards issued", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r12" ] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for non-option equity instruments issued during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Awards issued" } } }, "auth_ref": [] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options aggregate intrinsic value outstanding, including both vested and non-vested instruments.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Awards outstanding, Ending balance", "periodStartLabel": "Aggregate Intrinsic Value, Awards outstanding, Beginning balance" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Awards, Awards outstanding, Ending balance", "periodStartLabel": "Number of Awards, Awards outstanding, Beginning balance", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r98", "r99" ] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option equity plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Awards outstanding, Ending balance", "periodStartLabel": "Weighted-Average Exercise Price, Awards outstanding, Beginning balance" } } }, "auth_ref": [] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity instruments other than options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted-Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of Awards, Awards exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Awards exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Number of Awards, Awards forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r430" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Number of Awards, Awards issued", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Awards outstanding, Ending balance", "periodStartLabel": "Aggregate Intrinsic Value, Awards outstanding, Beginning balance", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Number of Awards, Awards outstanding, Ending balance", "periodStartLabel": "Number of Awards, Awards outstanding, Beginning balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r424", "r425" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Awards outstanding, Ending balance", "periodStartLabel": "Weighted-Average Exercise Price, Awards outstanding, Beginning balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r424", "r425" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period", "terseLabel": "Shares issued under the ESPP", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Awards exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r429" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Awards forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r430" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Awards issued", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r428" ] }, "hrmy_ShareBasedCompensationPercentageOfIncrementInCommonStockOutstandingAnnually": { "xbrltype": "percentItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareBasedCompensationPercentageOfIncrementInCommonStockOutstandingAnnually", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of increment in common stock outstanding .", "label": "Share Based Compensation, Percentage of Increment in Common Stock Outstanding Annually", "terseLabel": "Percentage of increment of common stock outstanding" } } }, "auth_ref": [] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [ "r1022" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": [ "r1022" ] }, "hrmy_ShareRepurchasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShareRepurchasesPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Share Repurchases.", "label": "Share Repurchases Policy [Text Block]", "terseLabel": "Share Repurchases" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "verboseLabel": "Stock options contractual term", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r824" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r442" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Awards exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r40" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Awards exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r40" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted-Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r100" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "hrmy_ShortTermCommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShortTermCommercialPaperMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to short term commercial paper.", "label": "Short-term commercial paper" } } }, "auth_ref": [] }, "hrmy_ShortTermCorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShortTermCorporateDebtSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to short term corporate debt securities.", "label": "Short-term corporate debt securities" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-Term Investments", "terseLabel": "Investments, short-term", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r116", "r117", "r976" ] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r766", "r767", "r768", "r788" ] }, "hrmy_ShortTermUsGovernmentSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ShortTermUsGovernmentSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to short term us government securities.", "label": "Short-term U.S. government securities" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r87", "r204" ] }, "hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "SignificantRisksAndUncertaintiesPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Significant risks and uncertainties.", "label": "Significant Risks And Uncertainties Policy [Text Block]", "terseLabel": "Significant Risks and Uncertainties" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r62", "r65", "r66", "r166", "r188", "r189", "r190", "r214", "r215", "r216", "r218", "r223", "r225", "r227", "r245", "r301", "r302", "r332", "r402", "r472", "r473", "r480", "r481", "r482", "r484", "r485", "r486", "r494", "r495", "r496", "r497", "r498", "r499", "r502", "r529", "r530", "r531", "r532", "r533", "r534", "r536", "r538", "r553", "r650", "r668", "r669", "r670", "r689", "r747" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r136", "r138", "r141", "r143", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r263", "r264", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r691", "r692", "r693", "r756", "r760", "r763", "r765", "r770", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r787", "r817", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r855", "r862", "r1023", "r1092", "r1094", "r1095", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1121", "r1122" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r214", "r215", "r216", "r245", "r538", "r595", "r678", "r690", "r696", "r697", "r698", "r699", "r700", "r701", "r704", "r707", "r708", "r709", "r710", "r711", "r713", "r714", "r715", "r716", "r718", "r719", "r720", "r721", "r722", "r724", "r726", "r727", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r747", "r863" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Statement Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r163", "r228", "r414", "r957", "r958", "r990" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r214", "r215", "r216", "r245", "r266", "r538", "r595", "r678", "r690", "r696", "r697", "r698", "r699", "r700", "r701", "r704", "r707", "r708", "r709", "r710", "r711", "r713", "r714", "r715", "r716", "r718", "r719", "r720", "r721", "r722", "r724", "r726", "r727", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r747", "r863" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r880", "r890", "r900", "r932" ] }, "hrmy_StockAppreciationRightsMarketAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "StockAppreciationRightsMarketAdjustment", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Stock appreciation rights market adjustment.", "label": "Stock Appreciation Rights Market Adjustment", "terseLabel": "Stock appreciation rights market adjustment" } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "hrmy_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercised", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of share options and restricted stock units exercised during the current period.", "label": "Stock Issued During Period, Shares, Stock Options and Restricted Stock Units Exercised", "terseLabel": "Exercise of options and restricted stock units, Shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Number of Awards, Awards exercised", "terseLabel": "Exercise of stock options , Shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r61", "r62", "r96", "r429" ] }, "hrmy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options and restricted stock units.", "label": "Stock Issued During Period, Value, Stock Options and Restricted Stock Units Exercised", "terseLabel": "Exercise of options and restricted stock units" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r11", "r62", "r65", "r66", "r96" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Repurchase of shares of common stock approved", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1022" ] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining authorized repurchase amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased And Retired During Period Shares", "terseLabel": "Shares of common stock repurchased and retired", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r11", "r61", "r62", "r96" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r62", "r65", "r66", "r89", "r706", "r723", "r748", "r749", "r841", "r870", "r984", "r1006", "r1068", "r1125" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "STOCKHOLDERS' EQUITY:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r93", "r206", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r402", "r501", "r750", "r752", "r769" ] }, "hrmy_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]" } } }, "auth_ref": [] }, "hrmy_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosure of Cash Flow Information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r926" ] }, "hrmy_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "TermLoanMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Term Loans.", "label": "Term Loan [Member]", "terseLabel": "Term Loans" } } }, "auth_ref": [] }, "hrmy_ThreeCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ThreeCustomersMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Three customers.", "label": "Three Customers" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r918" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r925" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r945" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r947" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments", "terseLabel": "Financial Instruments", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r383", "r400", "r500", "r524", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r651", "r829", "r830", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r842", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r1002", "r1003", "r1004", "r1005", "r1061", "r1063", "r1064", "r1065", "r1066", "r1067" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r948" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r949" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r949" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r947" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r947" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r950" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r948" ] }, "hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen equity incentive plan and two thousand twenty incentive award plan.", "label": "2017 and 2020 Plans" } } }, "auth_ref": [] }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfCostGoodOrServiceExtensibleList", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Cost, Product and Service [Extensible Enumeration]", "documentation": "Indicates type of cost from product sold and service rendered." } } }, "auth_ref": [ "r1024" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "United States" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government securities", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r796", "r819", "r1086" ] }, "hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Unamortized debt discount associated with exit fee, debt financing costs and discount with warrant financing.", "label": "Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing", "negatedLabel": "Unamortized debt discount associated with debt financing costs" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r944" ] }, "hrmy_UponAchievementOfAggregateNetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "UponAchievementOfAggregateNetSalesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Upon achievement of aggregate net sales.", "label": "Attaining $500,000 Aggregate Net Sales" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use Of Estimates", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r30", "r31", "r32", "r128", "r129", "r131", "r132" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r914" ] }, "hrmy_WAKIXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "WAKIXMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "WAKIX.", "label": "Upon FDA Approval of WAKIX", "terseLabel": "WAKIX" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Weighted average number of shares of common stock - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r231", "r239" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Weighted average number of shares of common stock - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r230", "r239" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r912" ] }, "hrmy_ZynerbaAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240630", "localname": "ZynerbaAcquisitionMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Zynerba Acquisition.", "label": "Zynerba Acquisition [Member]", "terseLabel": "Zynerba Acquisition" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r957": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r958": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Subparagraph": "(a)", "Publisher": "SEC" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 93 0001558370-24-010956-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-010956-xbrl.zip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

S::X5B4(+O4"N&!#'O:5RY+U*O?R0 M&* *@N]4Q?^8X=)WM#62,@QQA?>L9C NFH^N'

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

^\YMB\H[[K_?@)7],'>!5 M@*2R3?H<_EGV_L--AOLUDM^[>:;FM/,#>;+MVYK\JD/P.SGE;V<@M>PY 'ZZ MH<\<$Z;['?D0R-]ES=8-Z_&=<>D2A0G?.O7X"E4&/WYEXP_N.G7A EL2:XD> M @^K/ZI+NV95=G>JLK?TP7";15=KF,B"__B%/:21J]0GOG:8((H[[-=4V+956-]ANWHP\$ MGOE^<8574)%FZ'(2)D%^BWA".$1*9@2E5QC3%I*D>HB9*3:J4O-VQRY'EGP" M2'JS?5*D6E9'8:=Z*2H28;)]6>#6/!Y0ANP#1KE,+TF1GZI8OJ31CK5N=KF@ MI2V5ODI#VSA8%%N6*P23(DRWKPLP7[4M^V5]52QW%1PA29DHM.>9#<,%[7#1 M!X0ZK[3QM<)L3[3C=)XK4_3RFZ

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end XML 94 hrmy-20240630x10q_htm.xml IDEA: XBRL DOCUMENT 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-06-30 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-01-01 2024-06-30 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-01-01 2024-03-31 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-01-01 2023-06-30 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-01-01 2023-03-31 0001802665 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001802665 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001802665 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001802665 us-gaap:RetainedEarningsMember 2024-06-30 0001802665 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001802665 us-gaap:RetainedEarningsMember 2024-03-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001802665 2024-03-31 0001802665 us-gaap:RetainedEarningsMember 2023-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001802665 us-gaap:RetainedEarningsMember 2023-06-30 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001802665 us-gaap:RetainedEarningsMember 2023-03-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001802665 2023-03-31 0001802665 us-gaap:RetainedEarningsMember 2022-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001802665 us-gaap:CommonStockMember 2024-06-30 0001802665 us-gaap:CommonStockMember 2024-03-31 0001802665 us-gaap:CommonStockMember 2023-12-31 0001802665 us-gaap:CommonStockMember 2023-06-30 0001802665 us-gaap:CommonStockMember 2023-03-31 0001802665 us-gaap:CommonStockMember 2022-12-31 0001802665 us-gaap:StockAppreciationRightsSARSMember 2024-01-01 2024-06-30 0001802665 srt:MinimumMember 2023-01-01 2023-12-31 0001802665 srt:MaximumMember 2023-01-01 2023-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember hrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember 2024-01-01 2024-06-30 0001802665 us-gaap:RestrictedStockUnitsRSUMember hrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember 2023-01-01 2023-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001802665 country:US hrmy:WAKIXMember 2022-02-01 2022-02-28 0001802665 hrmy:TermLoanMember 2024-01-01 2024-06-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001802665 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001802665 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001802665 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001802665 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001802665 hrmy:IncrementalTermLoanMember 2023-09-30 0001802665 hrmy:FiveYearSeniorSecuredTermLoanMember 2023-07-31 0001802665 srt:MinimumMember 2024-06-30 0001802665 srt:MaximumMember 2024-06-30 0001802665 us-gaap:RelatedPartyMember 2024-04-01 2024-06-30 0001802665 us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001802665 us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001802665 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001802665 hrmy:WAKIXMember 2022-03-31 0001802665 hrmy:CataplexyMember hrmy:NdaForWakixMember 2020-10-31 0001802665 hrmy:DaytimeSleepinessMember hrmy:WAKIXMember 2019-08-31 0001802665 hrmy:DaytimeSleepinessMember hrmy:WAKIXMember 2024-06-30 0001802665 hrmy:CataplexyMember hrmy:NdaForWakixMember 2024-06-30 0001802665 hrmy:WAKIXMember 2024-06-30 0001802665 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001802665 us-gaap:EmployeeStockOptionMember 2024-06-30 0001802665 hrmy:FiveYearSeniorSecuredTermLoanMember 2023-07-01 2023-07-31 0001802665 hrmy:RepaymentOfDebtDueOnMaturityDateMember hrmy:TermLoanMember 2024-01-01 2024-06-30 0001802665 hrmy:RepaymentOfDebtCommencingOnDecember312023Member hrmy:TermLoanMember 2024-01-01 2024-06-30 0001802665 hrmy:RepaymentOfDebtBeginningOnDecember312025Member hrmy:TermLoanMember 2024-01-01 2024-06-30 0001802665 hrmy:TermLoanMember 2024-06-30 0001802665 srt:MinimumMember hrmy:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-01 2024-06-30 0001802665 srt:MinimumMember hrmy:TermLoanMember us-gaap:BaseRateMember 2024-01-01 2024-06-30 0001802665 srt:MaximumMember hrmy:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-01 2024-06-30 0001802665 srt:MaximumMember hrmy:TermLoanMember us-gaap:BaseRateMember 2024-01-01 2024-06-30 0001802665 hrmy:BioprojetMember hrmy:SalesBasedTrademarkAndTieredRoyaltiesMember 2024-04-01 2024-06-30 0001802665 hrmy:BioprojetMember hrmy:SalesBasedTrademarkAndTieredRoyaltiesMember 2024-01-01 2024-06-30 0001802665 hrmy:BioprojetMember hrmy:SalesBasedTrademarkAndTieredRoyaltiesMember 2023-04-01 2023-06-30 0001802665 hrmy:BioprojetMember hrmy:SalesBasedTrademarkAndTieredRoyaltiesMember 2023-01-01 2023-06-30 0001802665 hrmy:PANTHERxSpecialtyPharmacyLLCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001802665 hrmy:PANTHERxSpecialtyPharmacyLLCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001802665 hrmy:CaremarkLLCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001802665 hrmy:CaremarkLLCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001802665 hrmy:AccredoHealthGroupIncMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001802665 hrmy:AccredoHealthGroupIncMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001802665 hrmy:PANTHERxSpecialtyPharmacyLLCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001802665 hrmy:CaremarkLLCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001802665 hrmy:AccredoHealthGroupIncMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001802665 hrmy:PANTHERxSpecialtyPharmacyLLCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001802665 hrmy:CaremarkLLCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001802665 hrmy:AccredoHealthGroupIncMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001802665 hrmy:IncentiveAwardPlanTwoThousandTwentyMember 2024-06-30 0001802665 hrmy:EmployeeStockPurchasePlanMember 2021-04-30 0001802665 2023-06-30 0001802665 2022-12-31 0001802665 hrmy:LongTermCommercialPaperMember 2023-12-31 0001802665 hrmy:LongTermUsGovernmentSecuritiesMember 2024-06-30 0001802665 hrmy:ShortTermUsGovernmentSecuritiesMember 2023-12-31 0001802665 us-gaap:ShortTermInvestmentsMember 2024-06-30 0001802665 hrmy:ShortTermCorporateDebtSecuritiesMember 2024-06-30 0001802665 hrmy:ShortTermCommercialPaperMember 2024-06-30 0001802665 hrmy:LongTermInvestmentsMember 2024-06-30 0001802665 hrmy:LongTermCorporateDebtSecuritiesMember 2024-06-30 0001802665 us-gaap:ShortTermInvestmentsMember 2023-12-31 0001802665 hrmy:ShortTermCorporateDebtSecuritiesMember 2023-12-31 0001802665 hrmy:ShortTermCommercialPaperMember 2023-12-31 0001802665 hrmy:LongTermUsGovernmentSecuritiesMember 2023-12-31 0001802665 hrmy:LongTermInvestmentsMember 2023-12-31 0001802665 hrmy:LongTermCorporateDebtSecuritiesMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2024-06-30 0001802665 us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2024-06-30 0001802665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001802665 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001802665 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001802665 us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001802665 us-gaap:CommercialPaperMember 2024-06-30 0001802665 us-gaap:CashAndCashEquivalentsMember 2024-06-30 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001802665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001802665 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001802665 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001802665 us-gaap:CommercialPaperMember 2023-12-31 0001802665 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001802665 2023-10-01 2023-10-31 0001802665 hrmy:Hbs102Member hrmy:AllCountriesExcludingChinaMember hrmy:AssetPurchaseAgreementWithConsynanceTherapeuticsMember 2021-08-01 2021-08-31 0001802665 us-gaap:SellingAndMarketingExpenseMember 2024-04-01 2024-06-30 0001802665 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001802665 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001802665 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-06-30 0001802665 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001802665 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001802665 us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001802665 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001802665 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001802665 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001802665 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001802665 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001802665 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001802665 2023-04-01 2023-06-30 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001802665 hrmy:BioprojetMember hrmy:SalesBasedTrademarkAndTieredRoyaltiesMember 2024-06-30 0001802665 hrmy:BioprojetMember hrmy:SalesBasedTrademarkAndTieredRoyaltiesMember 2023-12-31 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-10-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001802665 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001802665 hrmy:IncentiveAwardPlanTwoThousandTwentyMember 2024-01-01 2024-06-30 0001802665 hrmy:EmployeeStockPurchasePlanMember 2021-04-30 2021-04-30 0001802665 2023-12-31 2023-12-31 0001802665 us-gaap:StockAppreciationRightsSARSMember 2023-12-31 0001802665 us-gaap:StockAppreciationRightsSARSMember 2024-06-30 0001802665 2023-01-01 2023-12-31 0001802665 hrmy:EmployeeStockPurchasePlanMember 2024-04-01 2024-06-30 0001802665 hrmy:EmployeeStockPurchasePlanMember 2024-01-01 2024-06-30 0001802665 hrmy:EmployeeStockPurchasePlanMember 2023-04-01 2023-06-30 0001802665 hrmy:EmployeeStockPurchasePlanMember 2023-01-01 2023-06-30 0001802665 2018-06-01 2018-06-30 0001802665 hrmy:ThreeCustomersMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001802665 hrmy:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001802665 hrmy:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001802665 hrmy:ThreeCustomersMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001802665 srt:MinimumMember 2024-01-01 2024-06-30 0001802665 srt:MaximumMember 2024-01-01 2024-06-30 0001802665 hrmy:BioprojetMember hrmy:WAKIXMember 2019-08-01 2019-08-31 0001802665 hrmy:BioprojetMember hrmy:PitolisantsMember 2022-07-01 2022-07-31 0001802665 hrmy:BioprojetMember hrmy:Orexin2ReceptorAgonistOx2rMember 2024-04-01 2024-04-30 0001802665 hrmy:BioprojetMember hrmy:Orexin2ReceptorAgonistOx2rMember 2024-01-01 2024-06-30 0001802665 hrmy:Hbs102Member hrmy:AllCountriesExcludingChinaMember hrmy:AssetPurchaseAgreementWithConsynanceTherapeuticsMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-03-01 2023-03-31 0001802665 hrmy:BioprojetMember hrmy:WAKIXMember 2021-01-01 2021-01-31 0001802665 hrmy:CataplexyMember hrmy:NdaForWakixMember 2020-10-01 2020-10-31 0001802665 hrmy:BioprojetMember hrmy:WAKIXMember 2020-10-01 2020-10-31 0001802665 hrmy:BioprojetMember 2019-11-01 2019-11-30 0001802665 hrmy:DaytimeSleepinessMember hrmy:WAKIXMember 2019-08-01 2019-08-31 0001802665 hrmy:BioprojetMember 2019-08-01 2019-08-31 0001802665 hrmy:BioprojetMember hrmy:WAKIXMember 2019-08-31 0001802665 hrmy:BioprojetMember hrmy:PitolisantsMember 2019-02-28 0001802665 hrmy:BioprojetMember hrmy:Orexin2ReceptorAgonistOx2rMember 2024-04-30 0001802665 hrmy:BioprojetMember hrmy:PitolisantsMember 2022-07-31 0001802665 hrmy:BioprojetMember hrmy:WAKIXMember country:US hrmy:UponAchievementOfAggregateNetSalesMember 2022-03-01 2022-03-31 0001802665 hrmy:WAKIXMember 2022-03-01 2022-03-31 0001802665 hrmy:BioprojetMember 2019-08-31 0001802665 hrmy:Hbs102Member hrmy:AllCountriesExcludingChinaMember hrmy:AssetPurchaseAgreementWithConsynanceTherapeuticsMember 2021-08-31 0001802665 hrmy:EpygenixAcquisitionMember 2024-04-01 2024-06-30 0001802665 hrmy:EpygenixAcquisitionMember 2024-01-01 2024-06-30 0001802665 hrmy:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-01 2024-06-30 0001802665 hrmy:EpygenixAcquisitionMember 2024-04-30 2024-04-30 0001802665 hrmy:ZynerbaAcquisitionMember 2023-10-01 2023-10-31 0001802665 hrmy:BioprojetMember country:US 2022-03-01 2022-03-31 0001802665 2023-01-01 2023-06-30 0001802665 hrmy:EpygenixAcquisitionMember 2024-04-30 0001802665 2024-06-30 0001802665 2023-12-31 0001802665 2024-04-01 2024-06-30 0001802665 2024-08-02 0001802665 2024-01-01 2024-06-30 utr:sqft hrmy:segment shares iso4217:USD iso4217:USD shares hrmy:Right hrmy:Vote hrmy:Institution pure hrmy:product hrmy:customer http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember 0001802665 --12-31 Q2 false http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember 0 0 http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent 10-Q true 2024-06-30 2024 false 001-39450 HARMONY BIOSCIENCES HOLDINGS, INC. DE 82-2279923 630 W. Germantown Pike Suite 215 Plymouth Meeting PA 19462 484 539-9800 Common Stock, par value $0.00001 value per share HRMY NASDAQ Yes Yes Large Accelerated Filer false false false 56834745 317296000 311660000 29614000 41800000 83157000 74140000 5643000 5363000 16127000 12570000 6507000 5537000 458344000 451070000 754000 371000 270000 270000 87178000 72169000 125186000 137108000 180186000 144162000 6465000 6298000 400039000 360378000 858383000 811448000 22683000 17730000 9641000 23747000 91644000 99494000 15000000 15000000 7614000 7810000 146582000 163781000 171422000 178566000 1796000 2109000 173218000 180675000 319800000 344456000 0.00001 0.00001 500000000 500000000 56833771 56833771 56769081 56769081 1000 1000 632168000 610266000 -234000 2000 -93352000 -143277000 538583000 466992000 858383000 811448000 172814000 134216000 327429000 253342000 32144000 25008000 59628000 45788000 140670000 109208000 267801000 207554000 63583000 14969000 85772000 28258000 28507000 24528000 55740000 47100000 27224000 22809000 52900000 44871000 119314000 62306000 194412000 120229000 21356000 46902000 73389000 87325000 37000 -31000 -104000 -29000 4404000 6218000 8939000 11949000 4705000 3442000 9133000 6528000 21694000 44095000 73479000 81875000 10103000 9795000 23554000 18090000 11591000 34300000 49925000 63785000 -63000 -491000 -236000 -371000 11528000 33809000 49689000 63414000 0.20 0.57 0.88 1.07 0.20 0.56 0.87 1.05 56802357 59974123 56786873 59853808 57541696 60743953 57571570 60997410 56769081 1000 610266000 2000 -143277000 466992000 49925000 49925000 -236000 -236000 64690 420000 420000 21482000 21482000 56833771 1000 632168000 -234000 -93352000 538583000 56791214 1000 620507000 -171000 -104943000 515394000 11591000 11591000 -63000 -63000 42557 573000 573000 11088000 11088000 56833771 1000 632168000 -234000 -93352000 538583000 59615731 1000 675118000 -151000 -272130000 402838000 63785000 63785000 -371000 -371000 383927 4069000 4069000 14851000 14851000 59999658 1000 694038000 -522000 -208345000 485172000 59954618 1000 685716000 -31000 -242645000 443041000 34300000 34300000 -491000 -491000 45040 674000 674000 7648000 7648000 59999658 1000 694038000 -522000 -208345000 485172000 49925000 63785000 254000 206000 11922000 11922000 42595000 21482000 14851000 -85000 -497000 356000 840000 -17756000 -7635000 1220000 1312000 1126000 799000 9017000 9072000 280000 557000 4004000 -2227000 3555000 2777000 -25095000 1288000 73758000 79622000 46317000 72847000 44481000 63491000 637000 205000 33069000 25500000 -61042000 -9561000 7500000 1000000 269000 514000 689000 4584000 -7080000 3070000 5636000 73131000 311930000 244534000 317566000 317665000 8944000 10691000 42093000 19890000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. ORGANIZATION AND DESCRIPTION OF BUSINESS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">The Company</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Harmony Biosciences Holdings, Inc., and its consolidated subsidiaries (the “Company”), was founded in July 2017 as Harmony Biosciences II, LLC, a Delaware limited liability company. The Company converted to a Delaware corporation named Harmony Biosciences II, Inc. in September 2017 and, in February 2020, the Company changed its name to Harmony Biosciences Holdings, Inc. The Company’s operations are conducted in its wholly owned subsidiaries, Harmony Biosciences, LLC (“Harmony”), and Harmony Biosciences Management, Inc. The Company is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders as well as patients living with other neurological diseases who have unmet medical needs. The Company is headquartered in Plymouth Meeting, Pennsylvania.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 10, 2023, the Company completed a tender offer to acquire all of the outstanding shares of common stock of Zynerba Pharmaceuticals, Inc. (together with its subsidiary, Zynerba Pharmaceutical Pty, Ltd., “Zynerba”). Zynerba is a clinical-stage pharmaceutical company focused on innovative pharmaceutically produced transdermal cannabidiol therapies for orphan neurobehavioral disorders, including Fragile X Syndrome. As of July 1, 2024, Zynerba was renamed and is known as Harmony Biosciences Management, Inc.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2024, the Company acquired all of the issued and outstanding capital stock of Epygenix Therapeutics, Inc., a Wyoming corporation (“Epygenix”). As a result, the Company now has an exclusive license relating to the use of clemizole, initially for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome. </p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">2. </span>LIQUIDITY AND CAPITAL RESOURCES</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $93,352 and $143,277, as of June 30, 2024, and December 31, 2023, respectively. As of June 30, 2024, the Company had cash, cash equivalents and investments of $434,088.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company believes that its existing cash, cash equivalents and investments on hand as of June 30, 2024, as well as additional cash generated from operating and financing activities will meet its operational liquidity needs and fund its planned investing activities for the next twelve months from the date of issuance of these unaudited condensed consolidated financial statements.</p> -93352000 -143277000 434088000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.<span style="font-style:italic;"> </span>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated balance sheet as of June 30, 2024, the unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2024, and 2023, and the unaudited condensed consolidated statements of operations and comprehensive income and the unaudited condensed consolidated statements of shareholders’ equity for the three and six months ended June 30, 2024, and 2023, are unaudited. The </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">balance sheet as of December 31, 2023, was derived from audited financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2024, and the results of its operations and its cash flows for the three and six months ended June 30, 2024, and 2023. The unaudited condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reclassifications</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain prior period amounts within the unaudited condensed consolidated statements of operations and comprehensive income have been reclassified to conform to current period presentation. In particular, interest expense and interest income were previously classified together as interest expense, net and are now separately classified as interest expense and interest income, respectively. The reclassification of these items had no impact on net income, earnings per share or accumulated deficit in current or prior periods.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 38pt;"><b style="font-weight:bold;">Significant Risks and Uncertainties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, clinical trial results of the Company’s product candidates; the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products, if approved; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company’s research and development efforts will result in successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 39pt;"><b style="font-weight:bold;">Operating Segments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company holds all its tangible assets, conducts its operations, and generates its revenue in the United States. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair Value of Financial Instruments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s unaudited condensed consolidated financial statements include cash, cash equivalents, restricted cash, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is the Company’s policy to measure non-financial assets and liabilities at fair value on a nonrecurring basis. These non-financial assets and liabilities are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures certain assets and liabilities at fair value based on the fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three levels based on the source of inputs as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Money market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of June 30, 2024, or December 31, 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Cash and cash equivalents and restricted cash consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds and debt securities that approximate fair value. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 317,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 311,660</p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 270</p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total cash, cash equivalents, and restricted cash shown in the statements of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 317,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 311,930</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Investments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s investments consist of debt securities that are classified as available-for-sale. Short-term and long-term investments are carried at fair value and unrealized gains and losses are recorded as a </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">component of accumulated comprehensive income in stockholders’ equity. Interest income earned on cash and investment balances, accretion of the discount on investments in debt securities, amortization of premiums and realized gains and losses, if any, are recorded in interest income on the unaudited condensed consolidated statement of operations and comprehensive income. Realized gains and losses that result from the sale of investments are determined on a specific identification basis. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At each reporting period, the Company reviews any unrealized losses position to determine if the decline in the fair value of the underlying investments is a result of credit losses or other factors. If the assessment indicates that a credit loss exists, any impairment is recognized as an allowance for credit losses in our consolidated statement of operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of June 30, 2024, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 41% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 35% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 24% of gross accounts receivable. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 39% of gross accounts receivable, CVS Caremark, which accounted for 32% of gross accounts receivable; and Pantherx, which accounted for 29% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the six months ended June 30, 2024, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 40% of gross product revenue; Accredo accounted for 33% of gross product revenue; and Pantherx accounted for 27% of gross product revenue. For the six months ended June 30, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 35% of gross product revenue; Pantherx accounted for 33% of gross product revenue; and Accredo accounted for 32% of gross product revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single supplier for its product and a single supplier for its active pharmaceutical ingredient.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Share Repurchases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company accounts for share repurchases as constructive retirements, whereby it reduces common stock and additional paid-in capital by the amount of the original issuance, with any excess purchase price recorded as a reduction to retained earnings. Under this method, issued and outstanding shares of common stock are reduced by the amount of shares of common stock repurchased, and no treasury stock is recognized on the condensed consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Combinations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Business combinations and asset acquisitions are accounted for in accordance with FASB ASC 805 Business Combinations. Refer to Note 4, <i style="font-style:italic;">Acquisitions</i>, for a more detailed discussion of the Company’s acquisitions of Zynerba and Epygenix.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-07,<i style="font-style:italic;"> Improvements to Reportable Segment Disclosures</i> (“ASU 2023-07”). ASU 2023-07 is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This ASU is effective for annual reporting periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 is required to be applied retrospectively to all prior periods presented in the financial statements. The Company has one reportable segment and is currently evaluating the impact that ASU 2023-07 will have on its condensed consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In December 2023, the FASB issued Accounting Standards Update (“ASU”) No 2023-09, <i style="font-style:italic;">“Income Taxes (Topic 740): Improvements to Income Tax Disclosures”</i> (“ASU 2023-09”). ASU 2023-09 expands disclosures in the rate reconciliation and requires disclosure of income taxes paid by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its condensed consolidated financial statements.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated balance sheet as of June 30, 2024, the unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2024, and 2023, and the unaudited condensed consolidated statements of operations and comprehensive income and the unaudited condensed consolidated statements of shareholders’ equity for the three and six months ended June 30, 2024, and 2023, are unaudited. The </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">balance sheet as of December 31, 2023, was derived from audited financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2024, and the results of its operations and its cash flows for the three and six months ended June 30, 2024, and 2023. The unaudited condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. </p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reclassifications</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain prior period amounts within the unaudited condensed consolidated statements of operations and comprehensive income have been reclassified to conform to current period presentation. In particular, interest expense and interest income were previously classified together as interest expense, net and are now separately classified as interest expense and interest income, respectively. The reclassification of these items had no impact on net income, earnings per share or accumulated deficit in current or prior periods.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 38pt;"><b style="font-weight:bold;">Significant Risks and Uncertainties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, clinical trial results of the Company’s product candidates; the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products, if approved; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company’s research and development efforts will result in successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.</p> 1 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. </p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 39pt;"><b style="font-weight:bold;">Operating Segments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company holds all its tangible assets, conducts its operations, and generates its revenue in the United States. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.</p> 1 1 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair Value of Financial Instruments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s unaudited condensed consolidated financial statements include cash, cash equivalents, restricted cash, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is the Company’s policy to measure non-financial assets and liabilities at fair value on a nonrecurring basis. These non-financial assets and liabilities are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures certain assets and liabilities at fair value based on the fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three levels based on the source of inputs as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Money market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of June 30, 2024, or December 31, 2023.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Cash and cash equivalents and restricted cash consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds and debt securities that approximate fair value. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 317,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 311,660</p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 270</p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total cash, cash equivalents, and restricted cash shown in the statements of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 317,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 311,930</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program.</p> The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 317,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 311,660</p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 270</p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total cash, cash equivalents, and restricted cash shown in the statements of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 317,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 311,930</p></td></tr></table> 317296000 311660000 270000 270000 317566000 311930000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Investments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s investments consist of debt securities that are classified as available-for-sale. Short-term and long-term investments are carried at fair value and unrealized gains and losses are recorded as a </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">component of accumulated comprehensive income in stockholders’ equity. Interest income earned on cash and investment balances, accretion of the discount on investments in debt securities, amortization of premiums and realized gains and losses, if any, are recorded in interest income on the unaudited condensed consolidated statement of operations and comprehensive income. Realized gains and losses that result from the sale of investments are determined on a specific identification basis. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At each reporting period, the Company reviews any unrealized losses position to determine if the decline in the fair value of the underlying investments is a result of credit losses or other factors. If the assessment indicates that a credit loss exists, any impairment is recognized as an allowance for credit losses in our consolidated statement of operations. </p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of June 30, 2024, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 41% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 35% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 24% of gross accounts receivable. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 39% of gross accounts receivable, CVS Caremark, which accounted for 32% of gross accounts receivable; and Pantherx, which accounted for 29% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the six months ended June 30, 2024, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 40% of gross product revenue; Accredo accounted for 33% of gross product revenue; and Pantherx accounted for 27% of gross product revenue. For the six months ended June 30, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 35% of gross product revenue; Pantherx accounted for 33% of gross product revenue; and Accredo accounted for 32% of gross product revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single supplier for its product and a single supplier for its active pharmaceutical ingredient.</p> 5 3 1 0.41 0.35 0.24 3 1 0.39 0.32 0.29 3 1 0.40 0.33 0.27 3 1 0.35 0.33 0.32 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Share Repurchases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company accounts for share repurchases as constructive retirements, whereby it reduces common stock and additional paid-in capital by the amount of the original issuance, with any excess purchase price recorded as a reduction to retained earnings. Under this method, issued and outstanding shares of common stock are reduced by the amount of shares of common stock repurchased, and no treasury stock is recognized on the condensed consolidated financial statements.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Combinations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Business combinations and asset acquisitions are accounted for in accordance with FASB ASC 805 Business Combinations. Refer to Note 4, <i style="font-style:italic;">Acquisitions</i>, for a more detailed discussion of the Company’s acquisitions of Zynerba and Epygenix.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-07,<i style="font-style:italic;"> Improvements to Reportable Segment Disclosures</i> (“ASU 2023-07”). ASU 2023-07 is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This ASU is effective for annual reporting periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 is required to be applied retrospectively to all prior periods presented in the financial statements. The Company has one reportable segment and is currently evaluating the impact that ASU 2023-07 will have on its condensed consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In December 2023, the FASB issued Accounting Standards Update (“ASU”) No 2023-09, <i style="font-style:italic;">“Income Taxes (Topic 740): Improvements to Income Tax Disclosures”</i> (“ASU 2023-09”). ASU 2023-09 expands disclosures in the rate reconciliation and requires disclosure of income taxes paid by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its condensed consolidated financial statements.</p> 1 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. ACQUISITIONS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acquisition of Zynerba</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the Company completed a tender offer to purchase the outstanding common stock of Zynerba (“Zynerba Common Stock”) for (i) $1.1059 per share of Zynerba Common Stock (the “Common Cash Amount”), the aggregate amount of which was $60,000 and was paid at closing, plus (ii) one contingent value right (each, a “CVR”) per share of Zynerba Common Stock (the “Common CVR Amount”), which represents the right to receive up to approximately $2.5444 per share of Zynerba Common Stock, subject to the achievement of certain clinical, regulatory and sales-based milestones. The Common CVR Amounts are to be paid in cash, subject to any applicable withholding of taxes and without interest. The aggregate amount of consideration to acquire Zynerba Common Stock was $60,000, excluding transaction related fees of $2,645 and was paid by the Company using cash on hand. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Zynerba Acquisition was accounted for as an asset acquisition under ASC Topic 805, Business Combinations, because substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable IPR&amp;D asset, ZYN002, Zynerba’s lead asset. ZYN002 is the first and only pharmaceutically manufactured, synthetic cannabidiol, devoid of THC, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system and is currently in Phase III clinical trial for the potential treatment of Fragile X Syndrome. The Company recognized the acquired assets and assumed liabilities based on the consideration paid, including transaction costs, on a relative fair value basis, and after first allocating the preliminary excess of the fair value of net assets acquired over the purchase price consideration to certain qualifying assets, principally, the IPR&amp;D asset.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acquisition of Epygenix</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On April 30, 2024, the Company acquired all of the issued and outstanding capital stock of Epygenix pursuant to the terms of a stock purchase agreement. In connection with the closing of the transaction, the Company paid the former stockholders of Epygenix up front consideration of $35,000 less a working capital </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">adjustment. In addition, the Company will be obligated to pay up to $130,000 upon the achievement of development and regulatory milestones and up to $515,000 upon the achievement of certain sales-based milestones, in each case to Epygenix’s former stockholders. As a result, the Company now has an exclusive license relating to the use of clemizole, initially for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The total purchase consideration for Epygenix was as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash consideration paid to selling shareholders and to settle restricted stock units ("RSUs")</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32,686</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 450</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total purchase consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,136</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The acquisition of Epygenix was accounted for as an asset acquisition under ASC Topic 805, Business Combinations. The Company did not acquire any outputs and there was not an acquired substantive process in place to create outputs. <span style="background:#ffffff;">The Company recognized the acquired assets and assumed liabilities based on the consideration paid, including transaction costs, on a relative fair value basis, and after first allocating the preliminary excess of the fair value of net assets acquired over the purchase price consideration to certain qualifying assets, principally, the IPR&amp;D asset. In accordance with the accounting for asset acquisitions, an entity that acquires IPR&amp;D assets in an asset acquisition follows the guidance in ASC Topic 730, Research and Development, which requires that both tangible and intangible identifiable research and development assets with no alternative future use be allocated a portion of the consideration transferred and recorded as research and development expense at the acquisition date. As a result, the Company recorded a charge of </span><span style="background:#ffffff;">$17,095</span><span style="background:#ffffff;"> related to acquired in-process research and development expense during the three and six months ended June 30, 2024.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>The following table shows the allocation of the purchase consideration based on the relative fair value of assets acquired and liabilities assumed by the Company, after reducing the excess fair value of the IPR&amp;D asset as described above:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,095</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,268</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 590</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35,953</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities assumed</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,817</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,136</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 1.1059 60000000 1 2.5444 60000000 2645000 35000000 130000000 515000000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash consideration paid to selling shareholders and to settle restricted stock units ("RSUs")</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32,686</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 450</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total purchase consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,136</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,095</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,268</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 590</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35,953</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities assumed</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,817</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,136</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 32686000 450000 33136000 17095000 17095000 17095000 18268000 590000 35953000 2817000 33136000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. INVESTMENTS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The carrying value and amortized cost of the Company’s available-for-sale debt securities, summarized by type of security, consisted of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,171</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,443</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,614</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 59,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 59,743</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,435</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total long-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 87,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (267)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 87,178</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,865</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,996</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,939</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 41,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 41,800</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 744</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 42,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 42,741</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 28,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (118)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 28,684</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total long-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 72,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 72,169</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies investments with an original maturity of less than one year as current and investments with an original maturity date of greater than one year as noncurrent on its unaudited condensed consolidated balance sheet. The investments classified as noncurrent have original maturity dates ranging from 1-2 years. The Company did not have any available-for-sale debt security investments in a continuous unrealized loss position of greater than 12 months as of June 30, 2024, and December 31, 2023, respectively. </p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The carrying value and amortized cost of the Company’s available-for-sale debt securities, summarized by type of security, consisted of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,171</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,443</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,614</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 59,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 59,743</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,435</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total long-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 87,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (267)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 87,178</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,865</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,996</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,939</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 41,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 41,800</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 744</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 42,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 42,741</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 28,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (118)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 28,684</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total long-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 72,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 72,169</p></td></tr></table> 16175000 1000 5000 16171000 13443000 4000 4000 13443000 29618000 5000 9000 29614000 59793000 37000 87000 59743000 27615000 180000 27435000 87408000 37000 267000 87178000 23832000 36000 3000 23865000 15968000 28000 15996000 1940000 1000 1939000 41740000 64000 4000 41800000 744000 744000 42688000 81000 28000 42741000 28795000 7000 118000 28684000 72227000 88000 146000 72169000 P1Y P2Y <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. FAIR VALUE MEASUREMENTS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Money market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of June 30, 2024, or December 31, 2023. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s assets measured at fair value consisted of the following: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:33.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="6" style="vertical-align:bottom;width:31.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="6" style="vertical-align:bottom;width:31.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 270,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 270,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 244,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 243,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 884</p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,609</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,609</p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 73,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 73,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 58,737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 58,737</p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,623</p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 387,781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 270,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 116,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 358,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 243,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 114,853</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s assets measured at fair value consisted of the following: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:33.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="6" style="vertical-align:bottom;width:31.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="6" style="vertical-align:bottom;width:31.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 270,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 270,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 244,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 243,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 884</p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,609</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,609</p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 73,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 73,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 58,737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 58,737</p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,623</p></td></tr><tr><td style="vertical-align:bottom;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 387,781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 270,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 116,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 358,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 243,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 114,853</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 270989000 270989000 244569000 243685000 884000 16171000 16171000 24609000 24609000 73186000 73186000 58737000 58737000 27435000 27435000 30623000 30623000 387781000 270989000 116792000 358538000 243685000 114853000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. INVENTORY</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">Inventory, net consisted of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,060</p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,020</p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,283</p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,363</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">Inventory, net consisted of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,060</p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,020</p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,283</p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,363</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 1135000 1060000 1744000 2020000 2764000 2283000 5643000 5363000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. INTANGIBLE ASSETS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2019, the Company received FDA approval of WAKIX<span style="font-size:7pt;">®</span> (pitolisant) for the treatment of excessive daytime sleepiness (“EDS”) in adult patients with narcolepsy. This event triggered a milestone payment of $75,000 under the provisions of the 2017 LCA (defined below) which the Company capitalized as an intangible asset. The Company determined a useful life of 10 years for such intangible asset, and, as of June 30, 2024, the remaining useful life was 5.3 years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company received FDA approval for the New Drug Application (“NDA”) for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. This event triggered a milestone payment of $100,000 under the provisions of the 2017 LCA which the Company capitalized as an intangible asset and paid in January of 2021. The Company determined a useful life of 9 years for such intangible asset, and, as of June 30, 2024, the remaining useful life was 5.3 years. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2022, the Company attained $500,000 in life-to-date aggregate net sales of WAKIX in the United States. This event triggered a final $40,000 payment under the provisions of the 2017 LCA which the Company capitalized as an intangible asset and paid in March of 2022. The Company determined a useful life of 7.6 years for such intangible asset, and, as of June 30, 2024, the remaining useful life was 5.3 years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amortization expense was $5,961 for each of the three months ended June 30, 2024, and 2023, respectively, and $11,922 for each of the six months ended June 30, 2024, and 2023, respectively, and is recorded in general and administrative on the unaudited condensed consolidated statements of operations and comprehensive income.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years ending December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 (excluding the six months ended June 30, 2024)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,923</p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,845</p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,845</p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,845</p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,845</p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,883</p></td></tr><tr><td style="vertical-align:middle;width:84.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 125,186</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The gross carrying amount and net book value of the intangible asset is as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross Carrying Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 215,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 215,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89,814)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (77,892)</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Book Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 125,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 137,108</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 75000000 P10Y P5Y3M18D 100000000 P9Y P5Y3M18D 500000000 40000000 P7Y7M6D P5Y3M18D 5961000 5961000 11922000 11922000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years ending December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 (excluding the six months ended June 30, 2024)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,923</p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,845</p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,845</p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,845</p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,845</p></td></tr><tr><td style="vertical-align:bottom;width:84.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,883</p></td></tr><tr><td style="vertical-align:middle;width:84.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 125,186</p></td></tr></table> 11923000 23845000 23845000 23845000 23845000 17883000 125186000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The gross carrying amount and net book value of the intangible asset is as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross Carrying Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 215,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 215,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89,814)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (77,892)</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Book Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 125,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 137,108</p></td></tr></table> 215000000 215000000 89814000 77892000 125186000 137108000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">License Agreements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2017, Harmony entered into a License Agreement (the “2017 LCA”) with Bioprojet Société Civile de Recherche (“Bioprojet”) whereby Harmony acquired the exclusive right to commercialize the pharmaceutical compound pitolisant for the treatment, and/or prevention, of narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, and Parkinson’s disease as well as any other indications unanimously agreed by the parties in the United States and its territories. A milestone payment of $50,000 was due upon acceptance by the FDA of pitolisant’s NDA, which was achieved in February 2019 and was expensed within research and development for the year ended December 31, 2019. A milestone payment of $77,000, which included a $2,000 fee that is described below, was due upon FDA approval of WAKIX (pitolisant) for treatment of EDS in adult patients with narcolepsy, which was achieved in August 2019. The $2,000 payment and $75,000 milestone payment were paid in August and November 2019, respectively. In addition, a milestone payment of $102,000, which included a $2,000 fee was due upon the FDA approval of the NDA for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. The $2,000 payment was paid in October 2020 and a $100,000 milestone payment was paid in January 2021. A final $40,000 milestone payment was paid to Bioprojet in March 2022 upon WAKIX attaining $500,000 in aggregate net sales in the United States. The 2017 LCA also requires a fixed trademark royalty and a tiered royalty based on net sales, which is payable to Bioprojet on a quarterly basis. The Company incurred $30,199 and $22,542 for the three months ended June 30, 2024, and 2023, respectively, and $54,937 and $41,602 for the six months ended June 30, 2024, and 2023, respectively, for sales-based, trademark and tiered royalties recognized as cost of product sold. As of June 30, 2024, and December 31, 2023, the Company had accrued $30,199 and $40,419, respectively, for sales-based, trademark and tiered royalties.  </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2022, Harmony entered into a License and Commercialization Agreement (the “2022 LCA”) with Bioprojet whereby Harmony obtained exclusive rights to manufacture, use and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon agreement of both parties. Harmony paid an initial, non-refundable $30,000 licensing fee in October 2022 and additional payments of up to $155,000 are potentially due under the 2022 LCA upon the achievement of certain future development and sales-based milestones. In addition, there are other payments due upon achievement of development milestones for new indications and formulations as agreed upon by both parties. The 2022 LCA also requires a fixed trademark royalty and a tiered royalty based on net sales upon commercialization, which will be payable to Bioprojet on a quarterly basis. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In April 2024, the Company announced that it entered into a sublicense agreement with Bioprojet for an orexin-2 receptor agonist (OX2R) (the “Licensed Compound”) to be evaluated for the treatment of narcolepsy and other potential indications (the “Sublicense”). Under the Sublicense, the Company obtained the exclusive right to develop, manufacture and commercialize the Licensed Compound in the United States and Latin American territories (the “Licensed Territories”), which are rights that Bioprojet originally licensed from Teijin Pharma, the innovator of the Licensed Compound. The Licensed Compound is currently in pre-clinical development with a Clinical Trial Application currently anticipated in mid-2025. Under the Sublicense, the Company paid Bioprojet an upfront license fee of $25,500, which the Company recognized as an IPR&amp;D charge recorded in research and development within the unaudited condensed consolidated statements of operations and comprehensive income for the three and six months ended June 30, 2024, and will also be obligated to pay up to $127,500 upon achievement of development and regulatory milestones and up to $240,000 upon </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">achievement of sales-based milestones, as well as royalty rates in the mid-teens on any sales of product using the Licensed Compound in the Licensed Territories. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Agreement Related to Intellectual Property</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company entered into an asset purchase agreement with ConSynance Therapeutics, Inc. (the “APA”) to acquire HBS-102 (formerly referred to as “CSTI-100”), a potential first-in-class molecule with a novel mechanism of action. Under the terms of the APA, the Company acquired full development and commercialization rights globally, with the exception of Greater China, for $3,500. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identified asset. In March 2023, the Company achieved a preclinical milestone, which triggered a $750 payment under the provisions of the APA, which the Company recognized as an IPR&amp;D charge recorded in research and development within the unaudited condensed consolidated statement of operations and comprehensive income for the six months ended June 30, 2023. There are additional payments due under the APA upon the achievement of certain milestones including $1,000 for preclinical milestones, $19,000 for development milestones, $44,000 for regulatory milestones and $110,000 for sales milestones.</p> 50000000 77000000 2000000 2000000 75000000 102000000 2000000 2000000 100000000 40000000 500000000 30199000 22542000 54937000 41602000 30199000 40419000 30000000 155000000 25500000 25500000 127500000 240000000 3500000 750000000 1000000 19000000 44000000 110000000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. ACCRUED EXPENSES</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consist of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Royalties due to Bioprojet</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 40,419</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Rebates and other sales deductions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 43,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 38,842</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,354</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,354</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,835</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Professional fees, consulting, and other services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,195</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,495</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 91,644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 99,494</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consist of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Royalties due to Bioprojet</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 40,419</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Rebates and other sales deductions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 43,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 38,842</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,354</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,354</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,835</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Professional fees, consulting, and other services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,195</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,495</p></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 91,644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 99,494</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 30199000 40419000 43570000 38842000 2993000 3354000 3343000 2354000 7201000 9835000 2053000 2195000 2285000 2495000 91644000 99494000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. DEBT</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Term Loan A Credit Agreement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2023, the Company entered into a Credit Agreement (the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as “Administrative Agent”, and certain lenders. The TLA Credit Agreement provides for a five-year senior secured term loan (the “TLA Term Loan”) in an aggregate principal amount of $185,000. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2023, the Company entered into the First Incremental Amendment (the “First Incremental Amendment”) with the Administrative Agent and Bank of America, N.A., as incremental lender. The First Incremental Amendment provides for an incremental senior secured term loan (the “Incremental Term Loan”) in an aggregate principal amount of $15,000. The First Incremental Amendment amends the TLA Credit Agreement and provides that the Incremental Term Loan will have identical terms as the TLA Term Loan. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The repayment schedule for both the TLA Term Loan and the Incremental Term Loan (together, the “Term Loans”) consists of quarterly $3,750 principal payments, which commence on December 31, 2023, increasing to quarterly $5,000 principal payments beginning on December 31, 2025, with a $115,000 payment due on the maturity date of July 26, 2028. The Term Loans bear interest at a per annum rate equal to, at the Company’s option, (i) a base rate plus a specified margin ranging from 2.50% to 3.00%, based on the </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Company’s senior secured net leverage ratio (as defined in the TLA Credit Agreement) or (ii) Term SOFR plus a credit spread adjustment of 0.10% plus a specified margin ranging from 3.50% to 4.00%, based on the Company’s senior secured net leverage ratio.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The net cash received related to the Term Loans as a result of the transactions, less debt issuance costs of $2,997, was $197,003. The debt issuance costs related to the Term Loans will be amortized as additional interest expense over the loan term of the TLA Credit Agreement. The fair value of the Term Loans as of June 30, 2024, was $187,863.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">Long-term debt, net consists of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 188,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 196,250</p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Unamortized debt discount associated with debt financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,684)</p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total debt, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 186,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 193,566</p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less current portion </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (15,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (15,000)</p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 171,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 178,566</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Future minimum payments relating to total debt, net as of June 30, 2024, for the periods indicated below consists of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years ending December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 (excluding the six months ended June 30, 2024)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,500</p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,250</p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 125,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:middle;width:83.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 188,750</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Interest expense related to the Company’s long-term debt, net, is included in interest expense within the unaudited condensed consolidated statements of operations and comprehensive income and consists of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.108181%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest on principal balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,109</p></td></tr><tr><td style="vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 840</p></td></tr><tr><td style="vertical-align:bottom;width:59.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total term loan interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,949</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> P5Y 185000000 15000000 3750000 5000000 115000000 0.0250 0.0300 0.0010 0.0350 0.0400 2997000 197003000 187863000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">Long-term debt, net consists of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 188,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 196,250</p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Unamortized debt discount associated with debt financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,684)</p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total debt, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 186,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 193,566</p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less current portion </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (15,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (15,000)</p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 171,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 178,566</p></td></tr></table> 188750000 196250000 2328000 2684000 186422000 193566000 15000000 15000000 171422000 178566000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Future minimum payments relating to total debt, net as of June 30, 2024, for the periods indicated below consists of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years ending December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 (excluding the six months ended June 30, 2024)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,500</p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,250</p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 125,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:middle;width:83.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 188,750</p></td></tr></table> 7500000 16250000 20000000 20000000 125000000 188750000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Interest expense related to the Company’s long-term debt, net, is included in interest expense within the unaudited condensed consolidated statements of operations and comprehensive income and consists of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.108181%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest on principal balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,109</p></td></tr><tr><td style="vertical-align:bottom;width:59.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 840</p></td></tr><tr><td style="vertical-align:bottom;width:59.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total term loan interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,949</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 4228000 5794000 8583000 11109000 176000 424000 356000 840000 4404000 6218000 8939000 11949000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. LEASES</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2018, the Company entered into an operating lease for approximately fifteen thousand square feet of office space in Plymouth Meeting, PA, which expires in May 2024. The Company subsequently entered into two separate operating leases for additional office space in Plymouth Meeting, PA, which include approximately thirteen thousand square feet and seven thousand square feet of additional office space, respectively, and expire in May 2024. In March 2024, the Company amended its existing operating leases for office space in Plymouth Meeting to extend their terms through June 2025. The terms of the lease payments provide for rental payments on a monthly basis and on a graduated scale. The Company also leases a fleet of automobiles that are used by its sales representatives and are classified as operating leases.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future lease payments using our incremental borrowing rate. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Our leases have remaining lease terms of less than 1 year to 3 years, some of which may include the option to extend or terminate the leases.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded operating lease costs of $622 and $444 for the three months ended June 30, 2024, and 2023, respectively and $1,131 and $822 for the six months ended June 30, 2024, and 2023, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the weighted-average remaining lease term for operating leases was 1.7 years and the weighted-average discount rate for operating leases was 7.56%. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental balance sheet information related to operating leases was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ZWzq0CzwCEKuPCVgZxTtlg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Other noncurrent assets</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,344</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liability, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_yidNsz5DyEiA8Joa48K1Dw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,437</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liability, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-7diSDYAs0-8S0r7FMJfNg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Other long-term liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,082</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Total operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,519</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information related to operating leases was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 922</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets obtained in exchange for operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 615</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future payments under noncancelable operating leases with initial terms of one year or more as of June 30, 2024, consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years ending December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 (excluding the six months ended June 30, 2024)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,047</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,250</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 495</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,804</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (164)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,640</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 15000 13000 7000 P1Y P3Y true true 622000 444000 1131000 822000 P1Y8M12D 0.0756 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental balance sheet information related to operating leases was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ZWzq0CzwCEKuPCVgZxTtlg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Other noncurrent assets</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,344</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liability, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_yidNsz5DyEiA8Joa48K1Dw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,437</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liability, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-7diSDYAs0-8S0r7FMJfNg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Other long-term liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,082</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Total operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,519</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information related to operating leases was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 922</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets obtained in exchange for operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 615</p></td></tr></table> 2508000 2344000 1786000 1437000 854000 1082000 2640000 2519000 1075000 922000 1254000 615000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future payments under noncancelable operating leases with initial terms of one year or more as of June 30, 2024, consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years ending December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 (excluding the six months ended June 30, 2024)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,047</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,250</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 495</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,804</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (164)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,640</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 1047000 1250000 495000 12000 2804000 164000 2640000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Litigation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company is subject to claims and suits arising in the ordinary course of business. The Company accrues such liabilities when they are known, if they are deemed probable and can be reasonably estimated. As of June 30, 2024, there were no material claims or suits outstanding. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. STOCKHOLDERS’ EQUITY</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Common Stock</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the Company’s stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive any dividends declared by the Company’s board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. The Company’s common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Share Repurchase Program </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the Company’s Board of Directors approved a share repurchase program (the “October 2023 Repurchase Program”) providing for the repurchase of shares of common stock in an aggregate amount of up to $200,000, excluding commissions and transaction fees. The October 2023 Repurchase Program may be suspended, terminated, or modified at any time for any reason. During the three and six months ended June 30, 2024, and 2023, no shares of common stock were repurchased and cancelled by the Company. As of June 30, 2024, the remaining amount of common stock authorized for repurchases was $150,000. </p> 1 200000000 0 0 0 0 150000000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">2020 Stock Incentive Plan</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the Company adopted, and its stockholders approved, the 2020 Incentive Award Plan (the “2020 Plan”), in order to facilitate the grant of cash and equity incentives to directors, employees (including the Company’s named executive officers) and consultants of the Company and its subsidiaries. The 2020 Plan provides for the grant of stock options, including incentive stock options (“ISOs”) and non-qualified stock options (“NSOs”), SARs, restricted stock, dividend equivalents, restricted stock units (“RSUs”) and other stock or cash-based awards.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options and stock appreciation rights under the 2020 Plan have a 10-year contractual term and vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). RSUs vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). As of June 30, 2024, there were 7,654,586 shares of common stock available for issuance under the 2020 Plan. The number of shares that may be issued under the 2020 Plan automatically increases on January 1 of each year in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">2017 Stock Incentive Plan</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2017, the Company adopted an equity incentive plan (the “2017 Plan”). Under the 2017 Plan, directors, officers, employees, consultants, and advisors of the Company can be paid incentive compensation measured by the value of the Company’s shares of common stock through grants of stock options, stock appreciation rights (“SARs”), or restricted stock. Following the adoption of the 2020 Plan, no further grants have been, or will be, made under the 2017 Plan. However, the 2017 Plan will continue to govern the terms and conditions of outstanding awards granted under it.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Stock Options</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes stock option activity for the six months ended June 30, 2024:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value ($000's)</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards outstanding—December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,316,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,307,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,996)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,791)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards outstanding—June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,549,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,893</p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards exercisable—June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,772,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,050</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Stock Appreciation Rights</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes SARs activity for the six months ended June 30, 2024:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value ($000's)</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards outstanding—December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 43,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards outstanding—June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 43,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 887</p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards exercisable—June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 827</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 36pt;"><span style="font-style:normal;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Restricted Stock Units</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes RSU activity for the six months ended June 30, 2024:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Awards outstanding—December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 330,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31.53</p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Awards issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 464,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30.62</p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Awards vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (15,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29.03</p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Awards forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (3,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30.69</p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Awards outstanding—June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 776,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31.03</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Value of Stock Options and SARs</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company values options and SARs using the Black-Scholes option-pricing model. The Company lacks sufficient historical company-specific volatility information. Therefore, the Company estimates expected stock volatility based on historical volatility of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. For SARs, the expected term is based </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">upon the weighting of certain future events. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for the time periods approximately equal to the expected term of the award. An expected dividend yield of 0% is based on the fact that the Company has never paid cash dividends and does not expect to do so in the foreseeable future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The assumptions used to value the awards are summarized in the following table.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">69.84 - 72.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">74.87 - 80.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">4.06 - 4.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3.42 - 4.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lack of marketability discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">2.04 - 6.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">2.26 - 10.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><span style="font-style:normal;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Value of RSUs</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of RSUs is equal to the value of the Company’s common stock on the grant date.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted average per share fair value of awards issued under the 2017 Plan and 2020 Plan was $21.24 and $20.64 on June 30, 2024, and December 31, 2023, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Stock-Based Compensation Expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock-based compensation expense for the three and six months ended June 30, 2024, and 2023, was recorded in the unaudited condensed consolidated statements of operations and comprehensive income in the following line items:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,932</p></td></tr><tr><td style="vertical-align:bottom;width:49.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,094</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,219</p></td></tr><tr><td style="vertical-align:bottom;width:49.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,691</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,203</p></td></tr><tr><td style="vertical-align:bottom;width:49.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,354</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock-based compensation expense related to options and RSUs issued under the 2017 Plan and 2020 Plan is included in stockholder’s equity, and a liability for SARs is included in other non-current liabilities, in the Company’s unaudited condensed consolidated balance sheet. As of June 30, 2024, the total unrecognized stock-based compensation expense was $68,926 and $19,749 for stock options and RSUs, respectively. This amount will be recognized in the Company’s consolidated statement of operations over a weighted average period of 2.6 years. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Employee Stock Purchase Plan</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The 2020 Employee Stock Purchase Plan (“ESPP”) was adopted by the Company’s Board of Directors on April 30, 2021. The ESPP permits eligible employees to purchase shares of the Company’s common stock at a 15% discount from the lesser of the fair market value per share of the Company’s common stock on the first day of the offering period or the fair market value of the Company’s common stock on the purchase date. Funds are collected from employees through after-tax payroll deductions. The total number of shares reserved for issuance under the ESPP was initially 629,805, which automatically increases on January 1 of each year in an amount equal to the lesser of (i) 1.0% of the shares of the Company’s common stock outstanding on </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors. It is intended that the ESPP meet the requirements for an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. There were 10,707 and 14,043 shares issued under the ESPP for each of the three and six months ended June 30, 2024, and 2023, respectively. The discount on the ESPP was $78 and $103 for the three months ended June 30, 2024, and 2023, respectively, and $158 and $208 for the six months ended June 30, 2024, and 2023, respectively, and is recorded within stock-based compensation expense.</p> P10Y 7654586 0.040 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes stock option activity for the six months ended June 30, 2024:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value ($000's)</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards outstanding—December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,316,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,307,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,996)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,791)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards outstanding—June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,549,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,893</p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards exercisable—June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,772,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,050</p></td></tr></table> 6316422 32.47 P7Y2M1D 1307396 30.51 46996 8.97 27791 37.14 7549031 32.26 P7Y2M12D 27893000 3772766 30.50 P6Y3M18D 21050000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes SARs activity for the six months ended June 30, 2024:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value ($000's)</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards outstanding—December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 43,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards outstanding—June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 43,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 887</p></td></tr><tr><td style="vertical-align:bottom;width:55.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Awards exercisable—June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 827</p></td></tr></table> 43208 9.38 P5Y3M25D 0 0 43208 9.38 P4Y9M29D 887000 39556 8.98 P4Y8M19D 827000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes RSU activity for the six months ended June 30, 2024:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Awards outstanding—December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 330,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31.53</p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Awards issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 464,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30.62</p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Awards vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (15,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29.03</p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Awards forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (3,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30.69</p></td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Awards outstanding—June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 776,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31.03</p></td></tr></table> 330000 31.53 464600 30.62 15000 29.03 3250 30.69 776350 31.03 0 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">69.84 - 72.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">74.87 - 80.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">4.06 - 4.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3.42 - 4.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lack of marketability discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">2.04 - 6.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">2.26 - 10.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 0.0000 0.0000 0.6984 0.7298 0.7487 0.8078 0.0406 0.0465 0.0342 0.0462 0.0000 0.0000 P2Y14D P6Y1M9D P2Y3M3D P10Y9M7D 21.24 20.64 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,932</p></td></tr><tr><td style="vertical-align:bottom;width:49.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,094</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,219</p></td></tr><tr><td style="vertical-align:bottom;width:49.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,691</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,203</p></td></tr><tr><td style="vertical-align:bottom;width:49.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,354</p></td></tr></table> 1683000 956000 3054000 1932000 2100000 1146000 4094000 2219000 7180000 5691000 14249000 10203000 10963000 7793000 21397000 14354000 68926000 19749000 P2Y7M6D 0.15 629805 0.010 10707 10707 14043 14043 78000 103000 158000 208000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16. EARNINGS PER SHARE</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic earnings per share is calculated by dividing net income by the weighted average number of shares of common stock outstanding. Diluted net income per share of common is computed under the treasury stock method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income, the potential dilutive effects of stock options, stock appreciation rights and restricted stock units.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net income per share:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 49,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 63,785</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net income per share of common stock - basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.07</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net income per share of common stock- diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.05</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average number of shares of common stock - basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 56,802,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 59,974,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 56,786,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 59,853,808</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average number of shares of common stock - diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 57,541,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 60,743,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 57,571,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 60,997,410</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Securities outstanding that were included in the computation above, utilizing the treasury stock method are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:47.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock options, SARs, and RSUs to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 739,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 769,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 784,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,143,602</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Potential shares of common stock issuable that were excluded from the computation of diluted weighted-average shares outstanding excluded from the numerator, are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:103.82%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options, SARs, and RSUs to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,629,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,520,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,583,892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,146,464</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net income per share:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 49,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 63,785</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net income per share of common stock - basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.07</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net income per share of common stock- diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.05</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average number of shares of common stock - basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 56,802,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 59,974,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 56,786,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 59,853,808</p></td></tr><tr><td style="vertical-align:bottom;width:41.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average number of shares of common stock - diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 57,541,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 60,743,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 57,571,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 60,997,410</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Securities outstanding that were included in the computation above, utilizing the treasury stock method are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:47.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock options, SARs, and RSUs to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 739,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 769,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 784,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,143,602</p></td></tr></table> 11591000 34300000 49925000 63785000 0.20 0.57 0.88 1.07 0.20 0.56 0.87 1.05 56802357 59974123 56786873 59853808 57541696 60743953 57571570 60997410 739339 769830 784697 1143602 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Potential shares of common stock issuable that were excluded from the computation of diluted weighted-average shares outstanding excluded from the numerator, are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:103.82%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options, SARs, and RSUs to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,629,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,520,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,583,892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,146,464</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 7629250 5520235 7583892 5146464 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17. INCOME TAXES</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A reconciliation between the statutory federal income tax rate and the Company’s effective income tax rate for the three and six months ended June 30, 2024, and 2023 is as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nondeductible IPR&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 46.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 32.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-style:italic;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nondeductible IPR&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 46.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 32.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-style:italic;margin-bottom:12pt;visibility:hidden;">​</span></p> 0.210 0.210 0.210 0.210 -0.007 -0.005 -0.002 -0.015 0.112 0.040 0.074 0.051 0.026 0.029 0.016 0.029 0.165 0.049 0.006 0.003 0.006 0.006 0.003 0.004 0.466 0.222 0.321 0.221 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">18. RELATED-PARTY TRANSACTIONS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was party to a management agreement for professional services provided by a related party, Paragon Biosciences, LLC (“Paragon”). Paragon is an entity that shares common ownership with the Company. In addition, the Chairman of the Company’s board of directors is the Founder, Chairman and CEO of Paragon. The Company is also party to a right of use agreement with Paragon whereby it has access to and the right to use certain office space leased by Paragon in Chicago, IL. The Company incurred $72 and $74 for the three months ended June 30, 2024, and 2023, respectively, and incurred $145 and $145 for the six months ended June 30, 2024, and 2023, respectively, in expenses to Paragon, which are included in general and administrative in the unaudited condensed consolidated statements of operations and comprehensive loss. As of June 30, 2024, and December 31, 2023, there were no amounts due to or due from related parties included in the unaudited condensed consolidated balance sheets. </p> 72000 74000 145000 145000 0 0 false false false false